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Glucose homeostasis 
The monosaccharide glucose is an important energy source of all mammalian cells. 
It is obtained from the diet, mainly through starch from consumed plants. When 
cellular energy reserves run low, glucose is degraded by the glycolysis pathway to 
generate energy. When glucose is not required for immediate energy production it 
can be stored in the form of glycogen in animal cells (1).  
 
In healthy individuals, glucose levels are tightly regulated by the body. Normal 
fasting blood glucose levels range between 4 – 8 mM, with fluctuations throughout 
the day (2). Glucose homeostasis requires a balance between glucose use, uptake, 
storage and excretion and is therefore a multi-organ process. Regulation of blood 
glucose levels depends primarily on two hormones secreted by the endocrine cells 
of the pancreas: insulin and glucagon (figure 1). In a fed state (i.e. after a meal), 
insulin dominates and it stimulates glucose uptake from the blood by target organs 
(e.g. muscle) and glycogen formation by the liver to store excess glucose. In a 
fasted state, glucagon dominates and this hormone stimulates the liver to 
breakdown glycogen to synthesize glucose for release into the blood to prevent 
hypoglycemia (too low plasma glucose concentration) (3). Disruption of glucose 
metabolism can lead to low blood glucose levels (hypoglycemia) or high blood 
glucose levels (hyperglycemia). 
 
 
Figure 1: Regulation of blood glucose levels by two pancreatic hormones: insulin and 
glucose. After a meal glucose levels rise, this stimulates the pancreas to secrete insulin into 
the blood. Insulin than stimulates the uptake of glucose from the blood by tissue cells and it 
also stimulates the liver to store the glucose in the form of glycogen. When glucose levels 
are low, the pancreas secretes glucagon, which has the opposite effects of insulin. Glucagon 
promotes the breakdown of glycogen and the release of glucose in the blood. Adapted from 
(4). 
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Diabetes mellitus 
Diabetes mellitus represents a heterogeneous group of disorders that have 
hyperglycemia as a common feature. Diabetes is one of the most prevailing chronic 
diseases. Worldwide, there are 382 million people with diabetes, and this number 
is expected to rise to 592 million by 2035 due to the rapid increase in the incidence 
of the disease caused by population growth, aging, urbanization and increasing 
prevalence of obesity and physical inactivity (4).  
 
Non-diabetic hyperglycemia which does not meet the criteria set for diabetes is 
known as prediabetes (5). Metabolic abnormalities that precede diabetes are 
impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) (table 1). 
Progression of this prediabetic state to diabetes can take many years, but up to 
70% of patients with these symptoms eventually develops diabetes (6).  
 
Table 1: Diagnostic criteria for diabetes and intermediate hyperglycemia according to the 
2006 WHO recommendations (7). 2 hour glucose: venous plasma glucose 2–h after ingestion 
of 75g oral glucose load 
Diabetes 
Fasting plasma glucose  
 
2 hour plasma glucose 
≥ 7.0 mmol/l 
or 
≥ 11.1 mmol/l 
Impaired glucose tolerance (IGT) 
Fasting plasma glucose  
 
2 hour plasma glucose  
< 7.0 mmol/l 
and 
≥ 7.8 and < 11.1 mmol/l 
Impaired fasting glucose (IFG) 
Fasting plasma glucose  
 
2 hour plasma glucose  
6.1 to 6.9 mmol/l 
and (if measured) 
<7.8 mmol/l 
 
The main types of diabetes are type 1 and type 2. Type 1 is caused by an 
autoimmune destruction of beta cells, the insulin producing cells in the pancreas 
(4). Generally, 90-95% of diabetes is type 2, which is historically regarded as a 
disease of the elderly. Although this age group still has a high risk of developing 
diabetes, onset of the disease in persons under 30 years of age and even in children 
and adolescents is increasing (8; 9). While type 1 is characterized by an absolute 
deficiency of insulin secretion, type 2 is characterized by an inability of peripheral 
tissues to respond to insulin (insulin resistance) and/or defects in insulin secretion 
(beta cell dysfunction) (4). Other specific types of diabetes can be caused by 
genetic defects of the beta cell or in insulin action. Also diseases of the pancreas, 
Chapter 1 
10 
 
drugs, chemicals and infections can induce diabetes (e.g. by impairing insulin 
secretion) (10).  
 
Beta cells 
Beta cells reside in the pancreas in clusters known as the islets of Langerhans. They 
are adapted to sense blood glucose levels and can adjust insulin secretion 
accordingly (11). Their main function is to release insulin in response to increased 
blood glucose levels.  
 
 
Figure 2: K
+
ATP –dependent (triggering) and K
+
ATP-independent (augmentation) pathways 
involved in glucose induced insulin secretion. Glucose metabolism leads to ATP production 
which triggers closure of the K
+
ATP (potassium) channel. The cell depolarizes which opens 
voltage gated calcium channels and the increase in calcium concentration stimulates insulin 
release. The rate of calcium-stimulated insulin release is augmented by the K
+
ATP-
independent pathway. Adapted from (14) and (16). 
 
Insulin release occurs as a biphasic process involving different pools of insulin 
granules. In the first phase glucose enters the beta cell through GLUT-2 
transporters. When more glucose is available as a substrate, ATP production 
increases leading to an elevated cytosolic ATP/ADP ratio. This triggers closure of 
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ATP-gated K
+
 channels, causing plasma membrane depolarization, and opening of 
voltage-gated Ca
2+
 channels, followed by a rise in cytosolic Ca
2+
 signals which 
initiates insulin granule exocytosis (3). The second phase of glucose-stimulated 
insulin release does not involve a further increase in Ca
2+
 concentration. Instead it 
to increase the effect of Ca
2+
 on exocytosis of insulin granules through biochemical 
mechanisms that are not yet fully uncovered (12).  
 
The amount of insulin granules present in beta cells is much higher than the 
number required to be released after a meal.  The granules are present in the 
cytosol (reserve granules) or docked at the plasma membrane. The docked 
granules are either primed (ready for release) or unprimed (incapable of being 
released). Primed granules can be further subdivided into readily releasable and 
immediately releasable, with the latter having the lowest threshold for release. 
Granules in the immediately releasable pool will undergo exocytosis in response to 
glucose stimulation (13; 14). The remaining granules are responsible for the second 
phase of insulin release. The conversion of the readily releasable granules to the 
immediately releasable state is therefore the rate-limiting step of the second phase 
(15). Pathways and granule pool involved in glucose induced insulin secretion are 
shown in figure 2.  
 
When the need for insulin secretion is higher than normal (e.g. during 
hyperglycemia), an increased beta cell glucose sensitivity occurs as a compensatory 
mechanism (figure 3). This leads to hypersecretion of insulin (i.e. more insulin is 
secreted than normally would be expected for the level of glycemia). Continuous 
overstimulation of the beta cells will eventually lead to a depletion of insulin stores, 
subsequently leading to a reduced insulin secretion and a deterioration of beta cell 
function (13; 17). In diabetic patients this can be seen as a blunted first phase 
response (18; 19). Supraphysiological glucose concentrations (10 – 30 mM) can 
cause potentially irreversible beta cell damage and can be deleterious for beta cell 
function and survival. This concept is called glucotoxicity (20). Glucotoxicity leads to 
a vicious cycle in which hyperglycemia is worsened by beta cell failure. Persisting 
hyperglycemia can ultimately lead to serious diabetic complications. 
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Figure 3: Hyperglycemia leads to beta cell failure which perpetuates hyperglycemia in a 
vicious cycle. Adapted from (13). 
 
Diabetic complications 
Diabetic patients are at risk of developing a number of disabling and life-
threatening health problems. Several epidemiological studies have shown a 
relationship between hyperglycemia and an increased risk of cardiovascular 
diseases, including microvascular pathologies in the eye, kidney and peripheral 
nerves. As a consequence, diabetes is a leading cause of blindness, renal disease 
and a variety of debilitating neuropathies (e.g. diabetic foot) (4; 21).  
 
Most of these diabetic complications find their origin in damaging of the 
endothelium, a thin layer of cells lining the cardiovascular system (22-24). Though 
the endothelium was regarded as a passive barrier for years, it is now known that 
endothelial cells plays an important role in numerous physiological functions 
including regulation of blood pressure, blood vessel growth and regulation of 
permeability. An important endothelium-derived mediator is nitric oxide (NO). NO 
is a soluble gaseous radical continuously produced by the enzyme nitric oxide 
synthase (NOS) from L-arginine. NO can then diffuse into vascular smooth muscle 
cells that line small blood vessels. Here it can bind to and activate the enzyme 
guanylyl cyclase which results in the formation of cyclic guanosine monophosphate 
(cGMP). cGMP then activates kinases responsible for vascular relaxation (25; 26). 
Endothelium dependent vasorelaxation is shown in figure 4. Endothelial 
dysfunction (ED) occurs when the endothelium loses its physiological properties. 
ED has been linked to diabetes through demonstration of impaired endothelial-
dependent vasodilation (26).  
Introduction 
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Figure 4: Endothelium dependent vascular relaxation. Increased intracellular calcium (e.g. by 
stimulation of muscarinic receptors) activates nitric oxide synthase (NOS) through 
calmodulin (by displacement of its inhibitor caveolin). NO is then produced from L-arginine, 
which requires a number of cofactors, including tetrahydrobiopterin (BH4) and nicotinamide 
adenine dinucleotide phosphate (NADPH). NO diffuses to the smooth muscle cells where it 
initiates relaxation through activation of guanylyl cyclase. L-NMMA and L-NAME are 
inhibitors of NOS. Adapted from (27) and (28). 
 
Molecular mechanisms of diabetic complications 
The initiation of diabetic tissue damage can be influenced by genetic predisposition 
of individual susceptibility and by independent accelerating factors (e.g. 
hypertension). Moreover, various mechanisms that explain how hyperglycemia 
directly causes vascular complications have been described (29). These include 
activation of the protein kinase C (PKC) pathway, increased hexosamine pathway 
flux, increased flux through the polyol pathway and increased formation of 
advanced glycation end products (AGEs). The latter two pathways will be described 
in more detail as they are subject of this thesis.  
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Polyol pathway 
In tissues that do not require insulin for glucose transport (e.g. nerves, lens, 
kidney), hyperglycemia can lead to an increase in the intracellular glucose. This 
activates the polyol pathway (figure 5) (30). During normoglycemia only ~ 3% of all 
glucose will enter the polyol pathway. Most of the glucose will be phosphorylated 
to glucose-6-phosphate by hexokinase. However, under hyperglycemic conditions 
this increases to 30%, mainly due to a saturation of hexokinase (31; 32). Aldose 
reductase, the first and rate-limiting enzyme in the pathway, reduces glucose to 
sorbitol using NADPH as a cofactor. Then, sorbitol is reduced to fructose by sorbitol 
dehydrogenase which uses NAD
+
 as a cofactor. The accumulated sorbitol and 
fructose lead to increased intracellular osmolarity and influx of water, which will 
eventually lead to osmotic cell injury. For example, in the lens this can lead to 
swelling and opacity, resulting in cataractogenesis. Redox imbalance following the 
depletion of NADPH and NAD
+
 further contributes to cell damage and organ injury 
(33-35). A decrease in NADPH levels can lead to a deficiency in reduced glutathione 
(GSH), which could induce or worsen intracellular oxidative stress. Additionally, 
NAD
+
 depletion limits the activity of the enzyme glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), which results in increased amounts of triose phosphates. 
As a result, triose phosphate can increase the formation of methylglyoxal 
(precursor of AGEs) and diacylglycerol (DAG; a potent PKC activator) (29). 
 
 
Figure 5: Hyperglycemia increases glucose flux through the polyol pathway. This pathway 
can lead to diabetic complications via accumulation of sorbitol, redox imbalance and 
depletion of NADPH and NAD
+
. Adapted from (35). 
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Increased intracellular formation of advanced glycation end-products 
Formation of advanced glycation end products (AGEs) leads to increased formation 
of oxygen radicals. AGEs constitute a heterogeneous group of macromolecules 
formed by the nonenzymatic glycation of proteins, lipids and nucleic acids. AGEs 
can be ingested with food and are also formed in small amounts endogenously in 
the body as a consequence of normal metabolism (36). AGEs have a number of 
chemical and biological properties that are potentially pathogenic. AGEs can 
contribute to diabetic complication by the formation of crosslinks in the basal 
membrane and accumulation of glycated proteins which alter cellular structure and 
protein function. For example, AGEs can affect the structure and function of 
capillaries which then develop thickened basement membranes and become leaky. 
In addition, AGEs can interact with the receptor for AGEs (RAGE). This interaction 
induces oxidative stress and subsequently the release of pro-inflammatory 
cytokines and growth factors that contribute towards the pathology of diabetic 
complications (29; 37; 38). 
 
Oxidative stress 
When there is an imbalance between the cellular antioxidant capacity and the 
production of reactive oxygen species (ROS), oxidative stress occurs (39). Oxidative 
stress also plays a pivotal role in the development of diabetic complications (40).  
 
ROS such as superoxide anion (O2
•–
), hydrogen peroxide (H2O2) and hydroxyl radical 
(HO•) are molecules derived from oxygen. They are generated endogenously 
through multiple mechanisms (e.g. during mitochondrial oxidative 
phosphorylation). Additionally, they can be formed from interactions with 
exogenous sources such as smoke, xenobiotics or radiation (39). ROS have an 
important role in cellular signalling and in a variety of cellular processes. They can 
interact with critical signalling molecules (i.e. cause post-translational protein 
modification such as oxidizing thiol groups), and thereby change the activity and 
alter the function of the target protein (41). For example, hydrogen peroxide is 
known to be one of the metabolic signals for insulin secretion (42).  
 
Physiological levels of ROS are tightly controlled by enzymatic and non-enzymatic 
antioxidants. Enzymatic oxidants include superoxide dismutase (SOD) is the first 
line of defense against superoxide. Three distinct forms are present in eukaryotes 
which all contain metals required for their enzyme activity. The cytosolic form 
contains copper or zinc ions (Cu/Zn-SOD or SOD1), the mitochondrial form contains 
manganese ions (Mn-SOD or SOD2) and the extracellular form also contains copper 
and zinc ions (EC-SOD or SOD3) (43). SODs catalyze the dismutation of superoxide 
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to H2O2 and oxygen. H2O2 can subsequently be degraded by catalase into water and 
oxygen (44) or into water by glutathione peroxidase by oxidizing reduced 
glutathione (GSH) to GSSG (45). Non-enzymatic endogenous antioxidants are 
amongst others alpha-lipoic acid, ascorbic acid (vitamin C) and vitamin E (46; 47)  
 
 
Figure 6: Molecular mechanisms underlying hyperglycemia-induced damage. Mitochondrial 
superoxide overproduction activates PARP which in turn leads to a decrease in GAPDH 
activity. Subsequently four pathways of hyperglycemia-induced damage are activated due to 
accumulation of glycolytic intermediates upstream of GAPDH: the polyol pathway, the 
hexosamine pathway, the PKC pathway and the AGE pathway.  Adapted from (49). 
 
During disease or infection, antioxidant systems can get overwhelmed with ROS. 
This can result in damage of nucleic acids (e.g. 8-Oxoguanine), proteins (e.g. protein 
carbonylation) and lipids (e.g. lipid peroxidation) (39). Activation of the previously 
mentioned pathways arises from hyperglycemia-induced overproduction of 
superoxide by the mitochondrial electron transport chain (29). Electron transport 
occurs in the inner mitochondrial membrane via coupled redox reactions. It is 
responsible for generation of ATP by oxidizing reduced co-enzymes generated in 
the tricarboxylic acid (TCA) cycle, fatty acid oxidation and amino acid oxidation. 
Under normal circumstances a small percentage of electrons leak out (mainly at 
complex I and III) and react with oxygen to form superoxide (48). During 
hyperglycemia, more glucose is being oxidized in the glycolysis and TCA cycle which 
increases the flux of electron donors (NADH and FADH2) into the electron transport 
chain, ultimately leading to an increase in superoxide generation (49). The 
overproduction of superoxide induces DNA strand breaks, by which the enzyme 
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poly(ADP-ribose) polymerase (PARP) is activated. PARP can detect and signal DNA 
strand breaks. Upon detection, PARP binds to the DNA and synthesizes a poly(ADP-
ribose) (PAR) chain as a signal for DNA repair enzymes. NAD
+
 is required as a 
substrate for the synthesis of these PAR monomers (50). PAR polymers can 
accumulate on GAPDH, thereby decreasing its activity and subsequently cause an 
accumulation of glycolytic intermediates upstream of GAPDH (40; 49). Decreased 
GAPDH activity can than lead to an activation of the polyol (because of high 
intracellular levels of glucose), PKC (due to an increase of DAG) and hexosamine (by 
an increase of fructose-6 phosphate) pathway and an increase in the formation of 
intracellular AGEs (by increased formation of the AGE precursor methylglyoxal) 
(49). An overview of the molecular mechanisms of hyperglycemia induced diabetic 
complications is shown in figure 6. 
 
Current treatment of diabetes 
Treatment goals for patients with diabetes are focused on control of hyperglycemia 
(51). This can be achieved through lifestyle changes (e.g. increase in physical 
activity) and pharmacological intervention. Control of blood glucose levels can 
delay the progression to type 2 diabetes in people with IGT (52). The main 
pharmacological treatments are focused on elevating insulin levels, improvement 
of insulin sensitivity and reducing the rate at which glucose is absorbed from the 
gastrointestinal tract (53). The mechanisms of action of all classes will be briefly 
discussed below and are summarized in figure 7. 
 
 
 
Figure 7: Overview of the working mechanisms of the most used pharmacological diabetic 
treatments.  
 
Chapter 1 
18 
 
Drugs that increase insulin levels – Secretagogues 
This group includes insulin, sulfonylureas, incretin mimetics and dipeptidyl 
peptidase 4 (DPP-4) inhibitors. Since its first use as a treatment in 1922 by the 
Canadians Frederick Banting and Charles Best, exogenous insulin remains an 
important part of diabetes treatment and is indeed lifesaving for type 1 patients 
(54). Chronic insulin therapy in type 2 diabetes is mostly used in the later stages 
when other medications have failed to control blood glucose levels (55). 
Sulfonylureas act on beta cells to increase insulin release. They close the K
+
ATP 
channel by binding to the SUR subunit. This ultimately triggers a rise in intracellular 
Ca
2+
 concentration, which stimulates insulin release (56). Incretin mimetics and 
DPP-4 inhibitors are relatively new therapies, which use the properties of the 
incretin hormones glucagon-like peptide 1 (GLP-1) and  gastric inhibitory peptide 
(GIP). These are gut-derived hormones that bind to specific G-protein–coupled 
receptors present on beta cells. Upon activation of the receptor, adenylate cyclase 
is activated, inducing the production of AMP which ultimately triggers insulin 
synthesis and secretion and inhibits glucagon release. In addition to their 
insulinotropic effect, incretins also slow down gastric emptying (GLP-1) and 
regulate appetite by enhancing satiety (57). Incretin mimetics are GLP-1 receptor 
agonists. DPP-4 inhibitors (also called incretin enhancers) prolong the activity of 
incretins by inhibiting their proteolytic degradation and inactivation by DPP-4 (58). 
 
Drugs that increase insulin sensitivity – Sensitizers 
This group includes thiazolidinediones (TZDs) and biguanides. TZDs are also known 
as glitazones. They improve insulin action by activating peroxisome proliferator–
activated receptor-γ (PPAR-γ) nuclear receptors in tissues such as adipose, skeletal 
muscle and liver. Activation of these receptors modulates transcription genes 
involved in the control of glucose and lipid metabolism (59). Biguanides decrease 
hepatic glucose output. Metformin is the only biguanide currently used in the 
treatment of diabetes. The molecular mechanisms by which metformin decreases 
hepatic gluconeogenesis are debated. Metformin appears to accumulate in the 
mitochondria where it induces a mild and specific inhibition of the respiratory-
chain complex 1. This results in a decrease of ATP production, which in turn 
activates the proposed molecular target of metformin, AMP-activated protein 
kinase (AMPK). AMPK inhibits energy consuming processes (e.g. glucose, lipid and 
protein synthesis) and switches the metabolism of the cell toward energy 
production (60; 61).  
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Drugs that reduce postpranial glucose absorption 
This group includes alpha-glucosidase inhibitors and amylin analogues. Alpha-
glucosidases break down starch and disaccharides to glucose. By inhibiting these 
enzymes the absorption of glucose from the gut is delayed (62). Amylin is a peptide 
hormone that is co-secreted with insulin from the beta cell. Amylin analogues 
mimic the functions of amylin by inhibiting glucagon release and slow down gastric 
emptying (63). 
 
Natural compounds as treatments against diabetes 
Besides the conventional pharmacological treatments, natural compounds are also 
being studied as treatments against diabetes. More than 400 proven medicinal 
plants exhibit antidiabetic properties, but from only about 25% the mechanism of 
action is known (64). An example of a medicinal plant with hypoglycemic activities 
is ginseng. Ginseng is known to increase insulin sensitivity although the efficacy and 
potency depends on the species that is used (65). Furthermore, the dietary spice 
cinnamon reduced serum glucose in people with type 2 diabetes (66). The 
mechanism of action is not yet known, although cinnamon extracts inhibit alpha-
glucosidase activity (67). Also herbs used as traditional medicine possess 
antidiabetic properties (68). Another well studied natural compound which has 
been reported to have beneficial effects in diabetes is alpha-lipoic acid. Due to its 
role as an antioxidant it can decelerate the development of diabetic complications. 
Furthermore, it has been shown to increase insulin sensitivity by increasing glucose 
uptake and utilization (69).  
 
Polyphenols and diabetes 
Since oxidative stress plays a central role in the pathogenesis of diabetic 
complications, therapies focusing on antioxidant effects might be of interest. 
Polyphenols are the most abundant antioxidants in the diet. They are compounds 
found in plant-based foods (fruits, vegetables, whole grains, cereals, legumes) and 
plant-derived beverages (fruit juices, tea, coffee and red wine) (70). Beneficial 
effects of polyphenols on blood glucose management, based on in vitro studies, 
animal models and some clinical trials, are shown in figure 8. These effects are 
mainly attributed to a reduction of intestinal glucose uptake, improvement of beta 
cell function and insulin action, regulation of carbohydrate metabolism and 
improvement of insulin uptake (71).  
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Figure 8: Mechanisms by which polyphenols can improve glucose homeostasis. Adapted 
from (71). 
 
Of the polyphenols, flavonoids are the most abundant in the human diet, with 
more than 4000 types identified in a wide range of dietary sources like berries, 
soybeans and onions (71). The total consumption of dietary flavonoids is estimated 
at several hundred milligrams per day with Mediterranean populations (e.g. 
Spanish) showing a higher intake than non-Mediterranean populations (72). 
Flavonoids intake has been linked to a reduced risk for various diseases, including 
diabetes (73). The antioxidant and anti-inflammatory activity of flavonoids along 
with their other properties (e.g. inhibition of alpha- glucosidase) make them 
promising candidates for the management of hyperglycemia, alone or in 
combination with established antidiabetic treatments. 
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Aim and outline of the thesis 
The overall aim of this thesis was to investigate the potential mechanisms by which 
natural compounds could help to attenuate or delay the onset of diabetic 
complications. The first chapters focus on mechanisms of protection by 
polyphenols. However since it is known that polyphenols can also exert pro-oxidant 
activities, we also studied the protective mechanism of a polyol compound. This is 
discussed in chapters 5 – 8. 
 
In chapter 2 the role of PARP is investigated in a chronic oxidative stress model. In 
this model we use the polyphenol fisetin and the antibiotic minocycline to inhibit 
PARP activity.  
 
In chapter 3 the effects on redox state of endothelial cells under hyperglycemic 
conditions is investigated. In this study we used the polyphenols flavone, rutin and 
quercetin to investigate their protective role on NAD
+
 levels. 
 
In chapter 4 the effects of the AGE N
ε
-carboxymethyllysine on the glutathione 
system of a human beta cell line is investigated. 
 
In chapter 5 a review about the health effects of the polyol erythritol is given 
 
In chapter 6 the  endothelial protective effects of erythritol are investigated in an 
endothelial cell line using targeted and transcriptomic approaches. 
 
In chapter 7 the effects of erythritol on endothelial cells is further investigated with 
a focus on anti-angiogenic mechanisms.  
 
In chapter 8 the possible influence of erythritol on beta cell dysfunction is 
investigated in a hamster beta cell line 
 
In chapter 9 antioxidant and inflammatory markers are measured in a pilot study 
on the effects of erythritol in patients with type 2 diabetes 
 
In chapter 10 the most important findings are discussed and the future 
perspectives are given. 
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Abstract 
Oxidative stress plays a major role in the pathophysiology of chronic inflammatory 
disease and it has also been linked to accelerated telomere shortening. Telomeres 
are specialized structures at the ends of linear chromosomes that protect these 
ends from degradation and fusion. Telomeres shorten with each cell division 
eventually leading to cellular senescence. Research has shown that poly(ADP-
ribose)-polymerase-1 (PARP-1) and subtelomeric methylation play a role in 
telomere stability. We hypothesized that PARP-1 plays a role in accelerated aging in 
chronic inflammatory diseases due to its role as co-activator of NF-κb and AP-1. 
Therefore we evaluated the effect of chronic PARP-1 inhibition (by fisetin and 
minocycline) in human fibroblasts (HF) cultured under normal conditions and under 
conditions of chronic oxidative stress, induced by tert-butyl hydroperoxide (t-BHP). 
Results showed that PARP-1 inhibition under normal culturing conditions 
accelerated the rate of telomere shortening. However, under conditions of chronic 
oxidative stress, PARP-1 inhibition did not show accelerated telomere shortening. 
We also observed a strong correlation between telomere length and subtelomeric 
methylation status of HF cells. We conclude that chronic PARP-1 inhibition appears 
to be beneficial in conditions of chronic oxidative stress, but may be detrimental 
under relatively normal conditions. 
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Introduction 
Chronic inflammatory diseases afflict millions of people across the world leading to 
a substantial social and economic burden. From diabetes alone, 366 million people 
worldwide were suffering in 2011 (1). It is estimated that by the year 2030 this 
number will be almost doubled due to the rapid increase in the incidence of the 
disease caused by population growth, aging, urbanization and increasing 
prevalence of obesity and physical inactivity (2). Chronic inflammatory conditions in 
diabetes may lead to many serious complications, e.g. retinal damage, renal failure 
and cardiovascular diseases. Chronic inflammation and chronic oxidative stress, 
which occur in many chronic diseases, can contribute to the progress of these 
diseases by accelerating the rate of biological aging (3). 
 
Accelerated biological aging has been associated with telomere shortening (4). 
Telomeres are nucleoprotein structures at the end of chromosomes consisting of 
stretches of a repetitive DNA sequence, TTAGGG in humans. They prevent 
chromosomal ends from being recognized as double strand breaks and protect 
them from end-to-end fusions and degradation. In somatic human cells, telomeres 
shorten with every round of replication (i.e. end replication problem) and cells are 
triggered into replicative senescence once telomeres shorten to a critical length (3; 
5; 6). However, the end replication problem is not the only factor that contributes 
to the loss of telomeric DNA. Oxidative stress also appears to play a role in 
telomere shortening because of the high presence of GGG repeats, which are more 
readily oxidized compared to a lone guanine in the DNA (7; 8). Recently, it has been 
shown that telomeric regions are favoured targets of a persistent DNA damage 
response induced by genotoxic and oxidative stress, both in vitro and in vivo (9). 
Oxidative stress induces single-strand breaks both directly and indirectly. These are 
less efficiently repaired in telomeric DNA as compared to genomic DNA and as a 
result increase the rate of telomere shortening due to incomplete replication (10).  
 
Since oxidative stress plays a major role in chronic inflammatory diseases, telomere 
attrition may be involved in the pathophysiology of these diseases. Several studies 
have linked telomere shortening to various chronic metabolic and inflammatory 
diseases such as atherosclerosis, diabetes type 2, inflammatory bowel disease and 
chronic obstructive pulmonary disease, conditions that are all characterized by the 
presence of systemic oxidative stress (11-18). However, the exact underlying 
mechanisms of telomere shortening under conditions of chronic oxidative stress 
still have to be elucidated. 
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Recent evidence indicates that epigenetic regulation may be important in telomere 
stability. Telomeres lack CpG dinucleotides which are susceptible to methylation, 
but the immediately adjacent subtelomeric regions have a high density of CpG 
sequences (19). In cells deficient of DNA methyltransferases (DNMTs) an induction 
of telomere elongation was observed which was associated with subtelomeric DNA 
hypomethylation (20). Also other studies have found a link between epigenetic 
status of subtelomeres and telomere length (21), which suggests a role for 
subtelomeric DNA methylation in telomere stability.  
 
 
Figure 1: PARP-1 can influence telomere length regulation in two different ways. First, it can 
enhance DNA repair and protect the telomeres and contribute to a decrease in the rate of 
telomere shortening. Second, it can enhance the inflammatory response by activating NF-κB 
or AP-1, which will lead to more oxidative DNA damage which in turn could accelerate 
telomere shortening.   
 
The activity of the nuclear enzyme Poly(ADP-ribose) polymerase-1 (PARP-1) has 
also been reported to play a role in this process of telomere stability. It has been 
shown that PARP-1 associates with telomere repeat binding factor 2 (TRF2), a 
telomere-specific DNA binding protein that protects chromosome ends by 
promoting the formation of the ‘capped’ state (22). Furthermore, PARP-1 has been 
implicated in the regulation of multiple physiological cellular functions like DNA 
repair, gene transcription, cell cycle progression, cell death, chromatin function and 
genomic stability (23; 24). PARP-1 may influence telomere stability under 
conditions of chronic oxidative stress in two different ways (figure 1). First, through 
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its function in repair of oxidative stress induced DNA damage. It can enhance 
repair, protect the telomeres and contribute to a decrease in the rate of telomere 
shortening. On the other hand, PARP-1 is also a co-activator of the stress-response 
related transcription factors Nuclear Factor-Kappa B (NF-κB) and Activator Protein-
1 (AP-1) and as a co-activator it can mediate the inflammatory response (25; 26). In 
this role it may have a negative effect on telomere shortening, since inflammation 
will lead to more oxidative stress and oxidative DNA damage which could 
accelerate telomere shortening. Therefore, it is hypothesized that PARP-1 activity 
will contribute to accelerated telomere shortening and accelerated aging in chronic 
inflammatory diseases, through its function as a co-activator of inflammatory 
responses. The aim of this study was to investigate the effect of chronic PARP-1 
inhibition on telomere stability under normal culturing conditions and under 
conditions of chronic oxidative stress in an in vitro model using human fibroblasts 
(HF). Additionally, the effect of prolonged culturing of HF cells under these 
conditions on subtelomeric methylation status was studied.  
 
Material and methods 
Chemicals 
 inimum Essential  edium ( E ), Hank’s Buffered  alt  olution (HB  ), fetal 
bovine serum (FCS), trypsin, essential amino acids, non-essential amino acids, 
vitamins, penicillin/streptomycin were all obtained from Invitrogen (Breda, The 
Netherlands). Bovine Serum Albumin (BSA), Minocycline, 4',6-diamidino-2-
phenylindole (DAPI), tert-butyl hydroperoxide (t-BHP) and dimethyl sulfoxide 
(DMSO) were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). The 
cell supernatant containing mouse monoclonal 10H anti-PAR polymer antibody was 
produced by Prof. W. Buurman (Maastricht University, Maastricht, The 
Netherlands). FITC-conjugated goat anti-mouse immunoglobin and fluorescent 
mounting medium were obtained from DAKO (Glostrup, Denmark). Hydrogen 
peroxide (H2O2) was purchased from Merck (Darmstadt, Germany). Fisetin was 
obtained from Fit Ingredients (Haibach, Germany). Primary human fibroblast cells 
(normal non-fetal skin tissue) were acquired from Coriell (Coriell Institute for 
Medical Research, Camden, USA). Hela cell lines were kindly provided by Prof. 
Alexander Bürkle (University of Konstanz, Germany).  
 
Cell culture 
HF cells were cultured in minimum essential medium (MEM) + glutamax 
supplemented with 20% non-heat inactivated FCS, 1% penicillin/streptomycin, 
0.5% non-essential amino acids, 0.5% essential amino acids and 0.03% vitamins. 
Cells were maintained at 37 °C in a 5% CO2 atmosphere. All cells were passaged at 
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approximately 80% confluency. To induce oxidative stress, parallel cultures were 
grown with or without exposure to t-BHP. To determine the concentration to be 
used, a concentration series was made from 5 nM to 100 nM t-BHP. Cell viability 
was tested by the trypan blue exclusion test. Cells were viable at concentrations 
<10 nM. At 5 nM a viability of >80% was found and we used this concentration for 
our experiments. Additionally, in a separate experiment the effect of PARP-1 
inhibition was investigated by supplementation of fisetin (10 mM dissolved in 
DMSO, further diluted in culture medium to final concentration of 1 µM) or 
minocyline (10 mM dissolved in DMSO, further diluted in culture medium to final 
concentration of 100 nM) to the medium of HF cells in the presence or absence of 
t-BHP. All compounds were added to the culture medium every 2-3 days during 
passaging or medium renewal. The passage at which the experiment was started is 
called P0. 
 
Immunohistochemical staining of PAR-polymers 
To verify the PARP-1 inhibiting effects of the selected PARP-inhibitors, HF cells were 
seeded at a density of 15 x 10
4
 cells per well in a six well plate. The next day, cells 
were treated with  00 μ  H2O2 to induce PARP-1 overactivation and PAR-polymer 
formation. Treatment was done for 10 minutes in the presence or absence of 
fisetin (1 μ ) or minocycline (100 n ), which were added 30 minutes before the 
H2O2 treatment. After incubation, the cells were trypsinized, washed with PBS and 
fixed in methanol. Fixed cells were put on microscope slides, washed with 0.1% BSA 
in PB  and incubated with 100 μl mouse monoclonal 10H anti-PAR polymer 
antibody for one hour at room temperature. After washing with 0.1% BSA in PBS, 
cells were incubated with 100 μl polyclonal goat anti-mouse immunoglobin/FITC 
for one hour at room temperature. Next, cells were washed again with 0.1% BSA in 
PB  and incubated for 10 minutes with 100 μl DAP  solution.  ubsequently, cells 
were mounted with fluorescent mounting medium and evaluated using a 
fluorescence microscope with Lucia GF 4.80 software. At least 100 cells per slide 
were studied for the presence of PAR polymers in the nucleus. 
 
DNA isolation 
DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Venlo, The 
Netherlands) according to the manufacturer’s protocol and quantified using a 
nanodrop (Isogen Life Science, Belgium). 
 
Telomere length measurement 
Telomere length was determined by quantitative PCR as previously described (11; 
27). Two master mixes were prepared, one with telomere primers and one with 
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Human β globin (HBG) primers (1x  Q  YBRgreen supermix from Biorad).  equences 
and concentrations of the primers are shown in table 1. Sample DNA was pipetted 
in a 96-well plate at a final concentration of 10 ng/µl. 20µl of the mastermix was 
added and the plate was shortly centrifuged. Each sample was run in triplicate. For 
the standard curve a reference DNA sample was diluted serially to produce three 
concentrations of 1.25, 5 and 10 ng/µl. In every run, negative controls (MQ + 
mastermix) and reference samples were included. The references were derived 
from two different Hela cell lines, one with relatively short telomeres (Hela S3: 5.5 
kb) and one with long telomeres (Hela 229: 14–15 kb). By adding reference DNA of 
controls to each qPCR, a standard curve could be created and the absolute 
telomere length of the samples could be calculated as kilo-base pairs (kbp).  Hela 
cell lines were kindly provided by Prof. Alexander Bürkle, University of Konstanz, 
Germany. The PCR was performed using a BioRad MyiQ iCycler Single Color RT-PCR 
detection system using iQTM SYBR® Green Supermix, containing iTaq Polymerase, 
dNTPs, SYBRGreen I and buffers (BioRad, CA, USA). 
 
Table 1: Primer sequences and concentrations for telomere length PCR 
Primer Sequence (5’ to 3’) Concentration 
(nM) 
Telomere 1 CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT 100 
Telomere 2 GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT 900 
HBG Forward GCTTCTGACACAACTGTGTTCACTAGC 300 
HBG Reverse CACCAACTTCATCCACGTTCACC 700 
 
Telomerase activity 
Telomerase activity was evaluated by Telomeric Repeat Amplification Protocol 
(TRAP) assay using the TeloTAGGG Telomerase PCR ELISAPLUS (Roche Diagnostics, 
Milan, Italy) which is an extension of the original method described by Kim et al. 
(28). Cell extracts (1–3 × 10
5
 cell equivalents) were employed in the first step, in 
which telomerase adds telomeric repeats (TTAGGG) to the  ′-end of the biotin-
labeled synthetic P1-TS primer. These elongation products, as well as the internal 
standard (IS), were amplified by PCR. In the second step the PCR products were 
split into two aliquots, denatured and hybridized separately to digoxigenin-(DIG)-
labeled detection probes, specific for the telomeric repeats and for the IS, 
respectively. Results obtained by densitometric analysis were normalized upon the 
data of IS and expressed as relative telomerase activities (RTA). 
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Subtelomere methylation 
Bisulfite treatment of genomic DNA was performed with an EZ DNA methylation kit 
(Zymo Research, CA, USA). The bisulfite-treated DNA was subjected to a 
polymerase chain reaction (PCR) to amplify the subtelomere region with the 
primers specific for chromosome arm 2p. Primer sequences were obtained from 
Lee et al (29). Methylation specific primers were: forward: 
ATGATTAGCGAGTTCGGTTTTAAC and reverse: GAATCGCGCCAAATATATACG and 
primers specific for unmethylated DNA were: forward: 
GATGATTAGTGAGTTTGGTTTTAATG and reverse: ACAAATCACACCAAATATATACAAA. 
PCR reactions were performed in a total volume of 25 µl containing 1x Taq 
polymerase buffer, 2 mM MgCl2, 0.2 mM dNTPs, 0.6 µM of each primer, 1U Taq 
polymerase and 500 ng bisulfite-treated DNA. PCR amplification was conducted as 
follows: Initial denaturation at 95°C for 10 minutes, followed by 40 cycles of 94°C 
for 30 seconds, 58°C for 30 seconds and 72°C for 30 seconds and ending with an 
extension at 72°C for 10 minutes. Amplified products were run on an ethidium 
bromide stained 2% agarose gel. Quantification was done by measuring grey values 
with the program ImageJ (http://rsbweb.nih.gov/ij/). 
 
Statistical analysis 
Differences between groups for telomere length and PAR polymer staining were 
tested using the Mann-Whitney U test. Effects of PARP-1 inhibition were tested 
using a Wilcoxon signed-rank test. The association between telomere length and 
subtelomeric methylation status was evaluated using the non-parametric 
 pearman’s rank correlation coefficient. P-values <0.05 were considered 
statistically significant and p-values <0.1 were considered statistical trends. 
Statistical analyses were analyzed with SPSS for Windows (version 20.0; SPSS Inc., 
Chicago, IL, USA). 
 
Results 
To determine whether chronic exposure of HF cells to oxidative stress induces a 
faster rate of telomere shortening we determined telomere length of HF cells 
exposed to 5 nM t-BHP. HF cells exposed to t-BHP showed significantly shorter 
telomeres than non-exposed cells of the same passage number (p<0.01) (figure 
2A). It was also observed that the telomere length significantly decreased over time 
in non-exposed cells as well as in exposed cells (p<0.001) (Figure 2A). In addition, 
the population doubling time was increased in the exposed cells compared to non-
exposed cells. Telomere length decreased with approximately 1490 bp after 45 
population doublings in the non-exposed cells and with 1938 bp after 45 
population doublings in the exposed cells. In the non-exposed cells, at several time-
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points the telomere length appeared to increase instead of decrease. To be able to 
explain this phenomenon we measured the telomerase activity in the cells. As 
expected (as we used a primary cell line), no detectable telomerase activity was 
measured (figure 2B). 
 
 
Figure 2: Telomere length (A) and telomerase activity (B) in human fibroblasts during 
culturing in absence (black line) or presence (grey line) of 5 nM tert-butyl hydroperoxide (t-
BHP). HF cells exposed to t-BHP showed significantly shorter telomeres than non-exposed 
cells of the same passage number. Telomere length significantly decreased over time in non-
exposed cells as well as in exposed cells. ** = p < 0.001 compared to p0 (start of the 
experiment); * = p < 0.01 compared to non-exposed cells of the same passage number. 
Mean ± SD of telomere length is shown. If telomerase activity was present, the relative 
telomerase activity value would be higher than 100. The values are lower than 10, which 
indicates that there is no telomerase activity in these cells.  
 
To confirm the PARP-1 inhibiting effect of fisetin and minocycline, HF cells were 
treated with H2O2 to induce PARP activity. The formation of PAR-polymers in these 
cells was evaluated using immunohistochemical staining. In non-treated cells, no 
PAR-polymer formation was observed. Treatment with H2O2 induced an increase in 
the number of PAR polymer positive cells (p<0.01). Preincubation with fisetin 
decreased the number of PAR-polymer positive cells with 40% indicating that 1 µM 
fisetin mildly inhibits PARP-1. Preincubation with 100 nM minocycline resulted in a 
90% reduction in the number of PAR-polymer positive cells (p<0.001), indicating 
that minocycline is a strong inhibitor of PARP-1 (figure 3). 
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Figure 3: A) PAR polymer formation in human fibroblasts treated with 300 μM H2O2 for 10 
minutes in the presence or absence of 1 µM fisetin or 100 nM minocycline which were 
added 30 minutes before the H2O2 treatment. ** = p<0.05 compared to cells treated with 
300 µM H2O2. B) Representative photographs of PAR polymer staining. Arrows indicate 
examples of PAR polymer positive cells. Magnification: 400x. 
 
To investigate the effect of chronic PARP-1 inhibition on telomere length regulation 
under conditions of chronic oxidative stress, HF cells were cultured with 1 µM 
fisetin or 100 nM minocycline in the presence or absence of t-BHP. After 10 
passages, telomeres in all culturing conditions were shorter compared to telomere 
length at the start of the experiment (figure 4). In addition, culturing the cells in 
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presence of t-BHP, fisetin and minocycline (p<0.1) resulted in shorter telomeres 
compared to untreated cells. However, culturing them in presence of minocycline 
or fisetin in combination with t-BHP did not result in accelerated telomere 
shortening when compared to untreated cells (figure 4).  
 
 
Figure 4: Effect of PARP inhibition by 1 µM fisetin (A) and 100 nM minocycline (B) on 
telomere length of human fibroblast cells at the start (p0-p2) and end (p9-p11) of the 
experiment cultured under normal conditions or under conditions of chronic oxidative stress 
induced by tert-butyl hydroperoxide (t-BHP).  # = p<0.1 compared to control. 
 
Additionally, at the end of the experiment cells treated with t-BHP, minocyline and 
t-BHP and fisetin showed a senescence-like phenotype (flattened, contracted and 
detached cells (30)). Cells cultured under the other conditions had a normal 
appearance. Also, cells cultured with t-BHP, t-BHP and fisetin and minocycline 
alone showed a decreased growth rate, resulting in a longer period before 
passaging (table 2). 
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Table 2: Average time span to reach 80% confluency in HF cultures (moment of passage). 
Mean ± SD are shown.  
Condition Days between passage (average P0-P11) 
Control 5.5 ± 1.0 
t-BHP 6.1 ± 1.2 
Fisetin 5.6 ± 1.0 
Fisetin + t-BHP 6.7 ± 2.4 
Minocycline 6.2 ± 2.2 
Minocycline + t-BHP 6.1 ± 1.0 
 
To examine the effect of subtelomeric methylation on telomere stability, the 
methylation status of chromosome 2p was evaluated at the start and end of the 
experiment (figure 5). At the start of the experiment HF cells showed an 
unmethylated pattern of the subtelomere region of chromosome 2p. At the end of 
the experiment differences between the conditions were observed. Cells cultured 
under normal conditions showed a methylation pattern that was similar to the 
pattern at the start of the experiment, while cells treated with t-BHP or 
minocycline showed an increase in methylation of almost 30%. For cells treated 
with fisetin this increase was only half (~15%). A  pearman’s correlation was run to 
determine the relationship between the level of methylation and telomere length, 
which revealed a statistically significant correlation (rs = 0.668; p = 0.018).   
 
Figure 5: A: Methylation specific PCR (MSP) result for chromosome 2p at passage 1 (start) 
and passage 10 (end). M and U indicate amplification from methylation and unmethylation 
sequence-specific primers. Water indicates MSP result with no template DNA (negative 
control). Densitometry of the photographs is shown in B. C:  pearman’s correlation revealed 
a statistically significant correlation (rs = 0.668; p = 0.018) between telomere length and the 
level of methylation.  
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Discussion 
In this study we investigated the effect of chronic PARP-1 inhibition on telomere 
stability under conditions of chronic oxidative stress. We used prolonged culturing 
of HF as a model for development of cellular senescence. To induce oxidative 
stress, we cultured HF in presence of t-BHP, which is a short-chain organic 
hydroperoxide that produces free radicals after metabolic activation (31).  
 
Chronic oxidative stress induces telomere shortening 
Prolonged culturing of HF resulted in telomeres shortening, indicating biological 
aging of HF. In addition, exposure to chronic oxidative stress significantly increased 
the rate of telomere shortening. Because the observed telomere shortening might 
be caused by an increased rate of cell division, the population doubling times were 
calculated. We found that the population doubling time was increased in the cells 
exposed to t-BHP, which could be caused by an increased level of apoptosis, 
leading to a decreased cell proliferation capacity. Unexpectedly, at several time 
points in the non-exposed cells telomere length was increased. This appeared not 
to be caused by increased telomerase activity, since telomerase activity was absent 
or very low in this primary cell line. An alternative mechanism may be involved 
which can be adopted by yeast and human telomerase-deficient cell lines, the 
alternative lengthening of telomeres (ALT) for telomere maintenance. ALT appears 
to be mechanistically related to survival in cells and to involve a homologous 
recombination based mechanism in which one telomere can be extended using the 
telomere from a non-homologous chromosome arm or extrachromosomal 
telomeric DNA (32-34). This mechanism has been demonstrated to exist in HF (35; 
36). Other processes may contribute to the observed increase in telomere length as 
well, such as survival and selection of cells with longer telomeres and with a better 
adaptation to the culturing conditions.  
 
Inhibition of PARP-1 by fisetin and minocycline 
Fisetin and minocycline were used to inhibit PARP-1. Fisetin is a flavonoid that is 
normally present in dietary sources like fruits and vegetables (37). Fisetin has been 
described to have many beneficial health effects, like memory-enhancement (38). 
It was found to possess anti-inflammatory effects via inhibition of the activation of 
NF-κB (39) and it has been shown previously that fisetin inhibited PARP-1 in 
pulmonary epithelial cells (40).  
 
At a concentration of 1 μ  fisetin caused a mild inhibition of PARP-1 activity when 
cells were exposed to H2O2. Chronic treatment of HF cells with fisetin resulted in 
shorter telomeres compared to control cells. In cells cultured in the presence of 
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both fisetin and t-BHP average telomere length was not significantly different 
compared to control cells. This finding appeared to support our hypothesis of the 
involvement of PARP-1 activity in telomere stability.  
 
A recent study by Sengupta et al.  showed fisetin to be a promising ligand for the 
formation of a four-stranded structure known as a G-quadruplex (41). Formation of 
quadruplexes has been shown to decrease the activity of telomerase, but it is also 
inhibits the ALT mechanism (42; 43). Since this mechanism might play a role in our 
model, it is possible that quadruplex formation by fisetin under normal situations 
causes a faster rate of telomere shortening due to impairment of ALT. G-
quadruplex formation is beneficial in anti-cancer therapy, as it impedes telomere 
elongation, a mechanism most tumor cells use for unlimited proliferation (44).  
 
Minocycline, also known as minocycline hydrochloride, is a member of the broad 
spectrum tetracyclines antibiotics. It is primarily used to treat acne and other skin 
infections and exerts anti-inflammatory effects that are completely separate from 
its antimicrobial actions (45). We showed that nanomolar concentrations of 
minocycline significantly inhibited PARP-1 activity, as was previously reported by 
Alano et al. (46). Culturing of cells in the presence of 100 nM minocycline resulted 
in shorter average telomere length as compared to control cells. On the other 
hand, when cells were cultured in the presence of minocycline in combination with 
t-BHP, average telomere length was not significantly decreased when compared to 
control. These findings, together with the findings of inhibition by fisetin, appeared 
to support our hypothesis that PARP-1 activity contributes to telomere stability and 
that inhibition of PARP-1 activity increases the rate of telomere shortening. 
However, under conditions of chronic oxidative stress inhibition of PARP-1 
appeared to results in a decreased rate of telomere shortening. The anti-
inflammatory activity of fisetin and minocycline may also contribute to the 
stabilizing effect on telomere length under chronic oxidative stress conditions. 
 
The effects of chronic minocycline treatment on mammalian cells are still largely 
unknown. Research mainly focused on examining the possible neuroprotective and 
anti-inflammatory effects of minocycline on progression of neurodegenerative 
disorders like multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). It has 
been described that minocycline is effective in various experimental models of ALS, 
Parkinson and Huntington disease (47-51). In a study of patients with acute stroke 
it was found that treatment with minocycline significantly improved the outcome 
compared to patients treated with placebo (52). Since oxidative stress is known to 
play a role in neuronal cell death in these diseases (53), PARP-1 inhibition might be 
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an underlying mechanism by which minocycline exerts these neuroprotective 
effects. However, minocycline has also been shown to be effective in other disease 
models. It was already found that minocycline may prevent blindness in a rat model 
of diabetic retinopathy (45). Several studies have suggested an important role of 
PARP activation in the pathogenesis of diabetic complications like nephropathy, 
neuropathy and retinopathy (54-56). Furthermore, minocycline has been shown to 
exert in vivo cardioprotective effects by suppressing oxidative stress and therefore 
preventing fetal cardiac myocyte death after prenatal cocaine exposure (57).  
 
A selective PARP-1 inhibitor was not tested in our experiments. However, Beneke 
et al described an experiment in which they exposed cells to the well-known PARP-
1 inhibitor 3-aminobenzamide (3-AB) and measured telomere length (58). They 
found in two mammalian cell systems (hamster and human) that pharmacological 
inhibition of PARP1 led to a fast, dose-dependent decrease of telomere length. 
These results are comparable with the results we obtained in our experiment in 
which fisetin and minocycline were applied as PARP inhibitors. 
 
The effects on telomere length were observed to be similar with both inhibitors. 
However, minocycline treated cells showed morphological changes at an earlier 
passage than untreated cells or cells treated with fisetin. This might be explained 
by the fact that minocycline is known to have strong PARP-1 inhibiting capacity 
only, whereas fisetin has been reported to exert other effects that may enhance 
cellular function (37). Fisetin is an activator of sirtuin 1 (SIRT1), a histone 
deacetylase (59). An increased activity of SIRT1 is associated with enhanced survival 
and longevity. Fisetin has already been shown to increase the lifespan of the yeast 
Saccharomyces cerevisiae (59). Additionally, fisetin is able to inhibit COX2 
expression (60). It has been shown that selective COX2 inhibitors can modulate 
cellular senescence in human dermal fibroblasts (61). Activation of SIRT1 and/or 
inhibition of COX2 by fisetin could explain why cells treated with fisetin had a 
normal appearance and cells treated with minocycline, which is not known as a 
SIRT1 activator, were in a senescence state at passage 11, although they had similar 
telomere length.  
 
Subtelomeric methylation 
Mouse models and in vitro studies suggest a role for subtelomeric methylation in 
telomere length regulation (20; 21). Normally, telomeres have a “closed” 
conformation which is established by epigenetic markers, including methylation of 
the subtelomeric region. When telomeres become shorter, the epigenetic markers 
decrease, which leads to a more “open” confirmation that allows a greater 
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accessibility for telomere-elongating activities (62). It has been shown that the 
subtelomeric region of Alzheimer patients with short telomeres was 
hypermethylated (63).  n contrast, in patients with Parkinson’s disease an increase 
in short telomeres with subtelomeric hypomethylation was found (64). PARP-1 is 
also known to be able to influence DNA methylation by regulation the expression 
and activity of DNMT1 or by direct interaction with DNMT1 (65-67). We observed a 
correlation between methylation status and telomere length. We found a change 
from unmethylated status at the beginning of the experiment to 50% methylated in 
conditions with the shortest telomeres at the end of the experiment of the 
subtelomeric region of chromosome 2p. Cells that were chronically treated with 
fisetin showed less increase in methylation, which could be caused by the ability of 
fisetin to inhibit SssI DNMT- and DNMT1-mediated DNA methylation (68).  
 
Conclusion 
Chronic fisetin treatment of HF at physiological concentrations resulted in shorter 
telomeres compared to control cells, indicating reduced telomere stability and 
enhanced biological aging of these cells. Under the assumption that it is healthy, 
fisetin is often added to nutritional supplements at relatively high concentrations. 
Since the biological effects of regular consumption of high doses fisetin (and also 
flavonoids in general) are not known, thorough safety evaluation is warranted with 
respect to these nutritional supplements. Chronic minocycline treatment also 
enhanced telomere shortening. This implies that precaution should be taken when 
minocycline is subscribed as a chronic treatment.  
 
However, under conditions of chronic oxidative stress, both fisetin and minocycline 
appeared to reduce the rate of telomere shortening. Since our study was limited to 
testing the effects of fisetin and minocycline in an in vitro model with HF cells that 
were chronically exposed to oxidative stress, more research is needed to evaluate 
possible positive effects of fisetin and minocycline in chronic inflammatory 
diseases. It can be concluded that chronic administration of pharmaceuticals or 
nutraceuticals with PARP inhibiting activity appears to be beneficial in conditions of 
chronic oxidative stress, but may be detrimental under relatively normal 
conditions.  
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Abstract 
Background: NAD
+
 is important for oxidative metabolism by serving as an electron 
transporter. Hyperglycemia decreases NAD
+
 levels by activation of the polyol 
pathway and by overactivation of poly(ADP-ribose)-polymerase (PARP).  
Methods: We examined the protective role of three structurally related flavonoids 
(rutin, quercetin and flavone) during high glucose conditions in an in vitro model 
using human umbilical vein endothelial cells (HUVECs). Additionally we assessed 
the ability of these flavonoids to inhibit aldose reductase enzyme activity.   
Results: We have previously shown that flavonoids can inhibit PARP activation. 
Extending these studies, we here provide evidence that flavonoids are also able to 
protect endothelial cells against a high glucose induced decrease in NAD
+
. In 
addition, we established that flavonoids are able to inhibit aldose reductase, the 
key enzyme in the polyol pathway. 
Conclusions: We conclude that this protective effect of flavonoids on NAD
+
 levels is 
a combination of the flavonoids ability to inhibit both PARP activation as well as 
aldose reductase enzyme activity. 
General significance: This study shows that flavonoids, by a combination of effects, 
maintain the redox state of the cell during hyperglycemia. This mode of action 
enables flavonoids to ameliorate diabetic complications. 
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Introduction 
Worldwide more almost 400 million people suffer from diabetes. This number will 
only grow due to the rapid increase in the incidence of the disease caused by 
population growth, aging, urbanization and increasing prevalence of obesity and 
physical inactivity (1). A hallmark of diabetes is hyperglycemia (2). A number of 
epidemiological studies have shown a relationship between hyperglycemia and an 
increased risk of cardiovascular diseases, including microvascular pathologies in the 
eye, kidney and peripheral nerves. As a consequence, diabetes is a leading cause of 
blindness, renal disease and a variety of debilitating neuropathies (e.g. diabetic 
foot) (3; 4). 
 
Nicotinamide adenine dinucleotide (NAD) is found in all living cells in an oxidized 
form (NAD
+
) and a reduced form (NADH). The main function of NAD in cells is 
modulating cellular redox status by carrying electrons from one reaction to 
another. Additionally, it is also involved in other cellular processes (e.g. acting as a 
substrate for enzymes involved in posttranslational modification) (5). 
Hyperglycemia decreases NAD
+ 
levels by an increased flux of glucose through the 
polyol pathway. This pathway becomes active when intracellular glucose levels are 
elevated (6). During normoglycemia only ~ 3% of all glucose will enter the polyol 
pathway. Most of the glucose will be phosphorylated to glucose-6-phosphate by 
hexokinase. However, under hyperglycemic conditions ten times more glucose 
enters the polyol pathway (7), mainly due to a saturation of hexokinase (8). Aldose 
reductase, the first and rate-limiting enzyme in the pathway, reduces glucose to 
sorbitol using NADPH as a cofactor. Then, sorbitol is reduced to fructose by sorbitol 
dehydrogenase which uses NAD
+
 as a cofactor. The osmotic stress that 
accompanies sorbitol accumulation and the redox imbalance following the 
depletion of NADPH and NAD
+
 contributes to cell damage and organ injury, 
ultimately leading to cataract genesis, neuropathy and other diabetic complications 
(9-11). 
 
Poly(ADP-ribose)-polymerase (PARP) activation can also lead to NAD
+
 depletion. 
The nuclear enzyme PARP has been implicated in the regulation of many important 
cellular functions like DNA repair, gene transcription, cell cycle progression, cell 
death, chromatin function and genomic stability (12). PARP detects and signals 
single-strand DNA breaks (SSB), which can be induced by hyperglycemia. Upon 
detection of a SSB, PARP binds to the DNA and synthesizes a poly(ADP-ribose) 
(PAR) chain as a signal for DNA repair enzymes. NAD
+
 is required as a substrate for 
the synthesis of these PAR monomers. Overactivation of PARP therefore depletes 
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cellular NAD
+
 stores (13). Several studies have suggested an important role of PARP 
activation in the pathogenesis of diabetic complications like nephropathy, 
neuropathy and retinopathy (14-16). 
 
Previously we have established that dietary flavonoids inhibit PARP both in vitro as 
well as in vivo (17-19). Flavonoids are polyphenolic compounds which are found in 
fruits, vegetables and plant-derived products like red wine and tea (18). Flavonoids 
have been shown to display positive health effects, e.g. reduced risks for 
cardiovascular and chronic inflammatory diseases (20-23), which have been 
ascribed to their antioxidant and anti-inflammatory properties (22; 24). We now 
studied the effect of high glucose with or without flavonoids on NAD
+
 levels in 
endothelial cells. In addition we determined whether three structurally related 
flavonoids are also able to inhibit aldose reductase, the most important enzyme of 
the polyol pathway. 
 
Material and methods 
Chemicals 
All chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) unless 
stated otherwise. F1 K medium, Hank’s Balanced  alt  olution (HB  ), trypsin-
EDTA, non-heat inactivated fetal calf serum (FCS), and penicillin/streptomycin were 
obtained from Gibco (Breda, The Netherlands). Endothelial cell growth supplement 
(ECGS) was obtained from BD Bioscience (Breda, The Netherlands). Heparin was 
purchased from Leo Pharmaceuticals (Amsterdam, The Netherlands). 
 
Cell culture 
Human Umbilical Vein Endothelial (HUVEC) cells (CRL-1730) were obtained from 
ATCC. HUVECs were cultured in F12K medium with 10% FCS, 1% 
penicillin/streptomycin, 0.05 mg/ml endothelial cell growth supplement (ECGS) and 
0.1 mg/ml heparin. Cells were maintained in collagen coated flasks at 37°C in a 5% 
CO2 atmosphere. For experiments, cells were seeded in 6 or 96 well plates and 
allowed to attach overnight. Next, medium was removed and cells were washed 
with HBSS. Additionally, fresh medium was added containing glucose (30 mM final 
concentration) or vehicle (medium) and flavonoids (5 µM final concentration), 
sorbinil (0.5 µM final concentration) or its vehicle (DMSO).  
 
Gene expression analysis 
RNA was isolated from Qiazol suspended cells according to the manufacturer’s 
protocol and quantified spectrophotometrically with a Nanodrop. RNA (500 ng) 
was reverse transcribed using iScript
TM
 cDNA synthesis kit (Biorad, Veenendaal, The 
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Netherlands). Next, real time PCR was performed with a Biorad MyIQ iCycler Single 
Color RT-PCR detection system using Sensimix
TM
Plus SYBR and Fluorescein 
(Quantace-Bioline, Alphen a/d Rijn, The Netherlands), 5 µl diluted (10x) cDNA and 
0.3 µM primers in a total volume of 25 µl. PCR was conducted as follows: 
denaturation at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds 
and 60°C for 45 seconds. After PCR, a melt curve (60-95°C) was produced for 
product identification and purity. β-actin was included as internal control. Primer 
sequences are shown in table 1. Data were analysed using the MyIQ software 
system (BioRad) and were expressed as relative gene expression (fold change) 
using the 2
ΔΔCt
 method. 
 
Table 1: Primer sequences for genes used for gene expression analysis 
Gene Forward (5’ to 3’) Reverse (5’ to 3’) 
Beta-actin (β-actin) CCTGGCACCCAGCACAAT GCCGATCCACACGGAGTACT 
Aldose reductase TACACATGGGCACAGTCGAT GGGGTTGGGTACCTGGAA 
PARP-1 GCCAGTTCAGGACCTCATCAA CGGCCTGGATCTGCCTTT 
 
Determination of NAD
+
 levels 
Cell were lysed with 1% dodecyltrimethylammonium bromide (DTAB) in 0.2 N 
NaOH. To ensure only NAD
+ 
levels were measured 0.4 M HCl was added and 
samples were incubated at 60°C for 15 minutes. Afterwards, cells were incubated 
at room temperature for 10 minutes and 0.5 M Trizma base was added to the cells 
after which NAD
+
 levels were determined with the NAD
+
/NADH cell based assay kit 
from Cayman Chemical (Ann Arbor, MI, USA). 
 
Preperation of lens aldose reductase 
Porcine lenses were used as a source of aldose reductase enzyme. Porcine eyes 
were obtained from a local slaughterhouse. Lenses were removed and stored at -
20°C until use. Lens homogenate was prepared fresh for every experiment. Lenses 
were homogenized in 1.25 ml homogenization buffer (20 mM potassium phosphate 
buffer, pH 7.5 containing 0.5 mM EDTA and 5 mM 2-mercaptoethanol). The 
homogenate was centrifuged at 10.000 x g for 10 minutes at 4°C. 
 
Aldose reductase assay 
Aldose reductase activity was determined spectrophotometrically. The reaction 
mixture (0.7 ml) contained 30 mM potassium phosphate buffer (pH 6.2), 0.2 mM 
NADPH, 0.2 M lithium sulphate, the substrate DL-glyceraldehyde (0-2 mM). 
Flavonoids (flavone, quercetin and rutin) were added to the reaction mixture (final 
concentration 0.5 or 5 µM). As a positive control, the known aldose reductase 
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inhibitor sorbinil was used in a concentration of 0.5 µM. Reaction was initiated by 
addition of NADPH. The consumption of NADPH was followed by the decrease in 
absorbance at 340 nm for 5 minutes at 37 °C. 
 
Statistical analysis 
The effect of HG incubation and effects of flavonoids were tested using Student’s t-
test for independent samples or the Mann-Whitney U test when not normally 
distributed. P-values <0.05 were considered statistically significant and p-values 
<0.1 were considered statistical trends. Statistical analyses were analyzed with SPSS 
for Windows (version 20.0; SPSS Inc., Chicago, IL, USA). 
 
Results 
In figure 1, the effect of incubating HUVECs with 30 mM of glucose on gene 
expression of aldose reductase and PARP-1 is presented. It is visible that both 
aldose reductase and PARP-1 have a significant higher expression after 24 hours 
incubation compared to normal glucose. When flavonoids are coincubated during 
these 24 hours, there is no effect on aldose reductase expression compared to only 
high glucose incubation. Only quercetin seems to lower PARP-1 expression 
compared to high glucose incubation.  
 
 
Figure 1: Effect of incubation with 30 mM glucose on the expression of aldose reductase (A) 
and PARP-1 (B) after several incubation times. Effect of addition of flavonoids (compared to 
high glucose incubation) after 24 hours incubation is shown in C (Aldose Reductase) and D 
(PARP-1). Data are expressed as mean ± standard error from three independent 
experiments.  *: p<0.05 compared to normal glucose incubation; ** p<0.05 compared to 
incubation with high glucose alone. 
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Figure 2: Effect of 24 hour incubation with 7 (control) or 30 mM (HG) glucose on the NAD+ 
level of HUVECs with or without coincubation with flavonoids. Data are expressed as mean ± 
standard error from four independent experiments. *: p<0.05 compared to control; ** 
p<0.05 compared to incubation with high glucose alone; ## p<0.1 compared to incubation 
with high glucose alone.  
 
The effect of incubation with 30 mM glucose on the NAD
+
 status of HUVECs is 
depicted in figure 2. High glucose incubation leads to a significant decrease in NAD
+
 
levels after 24 hours. This decrease is attenuated when the cells are coincubated 
with flavone or quercetin (trend) but not with rutin. Incubation with the known 
aldose reductase inhibitor sorbinil led to an even larger decrease in NAD
+ 
levels.  
 
Quercetin, rutin and flavone at a concentration of 5 µM decreased the Vmax of the 
aldose reductase catalysed conversion of DL-glyceraldehyde to glycerol. Sorbinil 
was used as a control and decreased both the Vmax and Km at a concentration of 0.5 
µM. Rutin also showed a small but significant decrease of Km compared to the 
control (table 2 and figure 3).  
 
Table 2: Kinetics of porcine aldose reductase in the absence and presence of flavonoids. 
Data are expressed as mean ± standard deviation of at least three separate experiments. *: 
p<0.05 compared to control. 
 Km (mM) 
Vmax 
(µM NADPH oxidized/min/mg protein) 
Control 0.065 ± 0.02 1.68 ± 0.31 
0.5 µM Sorbinil 0.038 ± 0.003
* 
0.67 ± 0.06
* 
0.5 µM Flavone 0.071 ± 0.04 1.61 ± 0.18 
5 µM Flavone 0.058 ± 0.02 1.25 ± 0.04
* 
0.5 µM Quercetin 0.084 ± 0.01 1.78 ± 0.33 
5 µM Quercetin 0.062 ± 0.02 1.02 ± 0.18
* 
0.5 µM Rutin 0.056 ± 0.02 1.53 ± 0.29 
5 µM Rutin 0.034 ± 0.01
* 
0.81 ± 0.10
* 
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Figure 3: An example of a Michaelis Menten plot of aldose reductase in absence (filled 
circles) and presence of 5 µM quercetin (filled squares), 5 µM rutin (open triangles), 5 µM 
flavone (filled triangles) or 0.5 µM sorbinil (open circles). Data are expressed as mean ± 
standard error of at least three experiments.  
 
Discussion 
In epidemiological studies, the intake of flavonoids has been related to a reduced 
risk for various diseases, including diabetes (23; 25; 26). Many complications that 
arise from diabetes are attributed to a redox imbalance. In previous studies we 
established that flavonoids were able to attenuate NAD
+
 depletion by inhibiting 
PARP overactivation both in vitro as well as in vivo (17-19). Extending these studies, 
we here provide evidence that flavonoids are also able to protect endothelial cells 
against a decrease in NAD
+
 due to high glucose. In addition we show that flavonoids 
are able to inhibit the key enzyme of the polyol pathway, aldose reductase.  
 
In this study three structurally related flavonoids were studied. Flavone, the core 
structure of the flavonoid subgroup flavones, a compound that is present in many 
cereal grains as well as in dill weed (27). Quercetin, one of the most prominent 
dietary flavonoids present in many foods including citrus fruit and berries (28) and 
rutin, a glycoside of quercetin which is found in buckwheat (29). 
 
Gene expression of aldose reductase and PARP was investigated in endothelial cells 
exposed to 30 mM glucose. A higher expression of aldose reductase in peripheral 
blood mononuclear cells has been linked to an increased risk for kidney disease in 
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diabetic patients (30). Furthermore, in transgenic mice, it was found that human 
aldose reductase expression increased atherosclerosis lesion size which could be 
attenuated by aldose reductase inhibitors (31; 32). An increase in PARP mRNA 
expression was found in patients with type 2 diabetes and microangiopathy (33). 
We found an increase in the expression of both genes when endothelial cells were 
exposed to 30 mM glucose for 24 hours. Coincubation with flavonoids or sorbinil 
did not affect this increase.  
 
NAD
+
 is a co-factor in numerous critical oxidation reactions. Because of the 
involvement in redox signalling, NAD
+
:NADH is regarded as one of the most 
important redox couples of the cells and therefore an important determinant of 
redox status of cells. We found a slight decrease in NAD
+ 
levels after incubating 
HUVECs with 30 mM glucose for 24 hours. This change is most likely a combination 
of the two previously described pathways; a decrease in NAD
+
 due to activation of 
the polyol pathway and overactivation of PARP-1. Therefore we also investigated 
the potential of flavonoids to inhibit aldose reductase.  
 
The flavonoids’ ability to inhibit aldose reductase has been described previously 
(34). In our study, it was found that all tested flavonoids were able to inhibit aldose 
reductase enzyme activity at a concentration of 5 µM. Quercetin and flavone 
appear to be non-competitive inhibitors because only the Vmax of the reaction is 
decreased. Conversely, rutin not only decreased the Vmax, it also decreased the KM 
slightly. This would indicate a slightly higher reaction rate at very low substrate 
concentrations but a much lower rate at higher substrate concentrations. Rutin 
contains rutinose, which is a disaccharide composed of rhamnose and glucose. The 
latter is a substrate of aldose reductase, however the affinity of aldose reductase 
for DL-glyceraldehyde is higher (7). Rutin as a competitive inhibitor is further 
supported by the results of sorbinil, which is a known competitive inhibitor of 
aldose reductase (35). Sorbinil was tested at a lower concentration (0.5 µM) but 
shows the same results as rutin, a decrease in both the Vmax as well as KM. Of the 
tested flavonoids, rutin showed the strongest inhibition, while flavone had the least 
effect. This is contrary to their capacity to inhibit PARP overactivation, where 
flavone is the most potent inhibitor and rutin is not able to inhibit PARP (Table 3). 
In both reactions quercetin is an intermediate inhibitor compared to rutin and 
flavone.  
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Table 3: Overview of structure and PARP inhibiting capacity of flavonoids used in this study 
(17; 18). 
Name Flavone Quercetin Rutin 
Structure 
  
 
PARP 
inhibiting 
capacity 
Strong, also at low 
concentrations 
Strong, less at low 
concentrations 
No inhibiting capacity 
 
 
These findings indicate that the overactivation of PARP-1 plays a larger role than 
the polyol pathway in the decrease of NAD
+
 levels in HUVECs. When cells were 
coincubated with flavonoids, we observed that flavone was able to attenuate the 
decrease in NAD
+
 concentration. Flavone is the most potent PARP-1 inhibitor but 
did not have a big effect on aldose reductase activity. This finding is also supported 
by the observation that rutin, the most potent aldose reductase activity inhibitor, 
did not show an effect on NAD
+
 levels. Quercetin, an average inhibitor of both 
pathways, showed a trend towards increasing NAD
+
 levels to normal. The influence 
of the polyol pathway on the lower NAD
+ 
level seems to be small. Most likely the 
activation of this pathway has a more pronounced effect on the levels of NADPH. 
By lowering the levels of this essential cofactor for glutathione, the cells get more 
susceptible to oxidative stress (36). This in turn can lead to more reactive oxygen 
species that can damage DNA, inducing activation of PARP-1, which subsequently 
can lead to a decrease in NAD
+
 levels as we observed in HUVECs. This might also be 
the reason why coincubation with sorbinil leads to an extra decrease in  NAD
+
 
levels in HUVECs. By inhibiting the aldose reductase almost completely, unlike the 
flavonoids which show a mild inhibition, other pathways involved in the 
pathogenesis of diabetic complications may become more activated (e.g. activation 
PKC), this then can lead to more oxidative stress and activation of PARP-1 (36).  
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Conclusion 
We conclude that flavonoids are able to exert pleiotropic protective effects under 
high glucose conditions (figure 4).  
 
 
Figure 4: Flavonoids can protect cells under hyperglycemic stress in several ways. First, 
flavonoids are able to inhibit overactivation of PARP-1, preventing a decrease in NAD
+
 levels. 
Furthermore, flavonoids are able to inhibit aldose reductase activity, preventing an 
additional decrease in NAD
+
  and NADH levels. Also, because of their antioxidant properties, 
flavonoids are able to prevent damaging effects of oxidative stress. By a combination of all 
these effects flavonoids are able to protect cells against high glucose induced damage. 
 
We observed that flavonoids were able to inhibit overactivation of PARP-1, thereby 
preventing a fall in NAD
+
 levels. Furthermore we observed that flavonoids are able 
to inhibit aldose reductase activity, preventing an additional decrease in NAD
+
 
levels. Moreover, because of the known antioxidant properties of flavonoids they 
are also able to prevent the deleterious effects of reactive oxygen species which 
can be formed when a redox imbalance is present. In conclusion, the combination 
of all these effects is most likely the reason why flavonoids were able to protect 
endothelial cells against a high glucose induced drop in NAD
+
 levels in an in vitro 
system. 
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Abstract 
One of the pathways involved in the pathogenesis of diabetic complications is the 
formation of excessive levels of advanced glycation end (AGE) products. N
ε
-
carboxymethyllysine (CML) is one of the best-characterized AGEs. Because little is 
known about the effects of AGEs on pancreatic beta cells, we investigated the 
effect of CML on human pancreatic cells and determined the activity and gene 
expression of glutathione system components. CML at a concentration of 0.5 mM 
induced cell death in human pancreatic beta cells, which was accompanied by 
increased intracellular oxidative stress. No changes in the gene expression of the 
receptor for AGEs (RAGE) were found, although an increase in the level of a target 
cytokine of RAGE after CML exposure was observed. Additionally we found that 
CML lowered the levels of GSH and affected the activity and expression of other 
components of the glutathione system. These changes indicate that the cells are 
even more vulnerable for oxidative stress after exposure to CML. Since beta cells 
are low in antioxidant enzymes and repair for oxidized DNA, CML, but most likely 
also other AGEs, accelerates beta cell dysfunction and increases beta cell death 
during chronic hyperglycemia.  
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Introduction 
Hyperglycemia, which occurs during type 2 diabetes, is associated with oxidative 
stress (1). Formation of advanced glycation end products (AGEs) is one of the 
mechanisms that results in the increased formation of oxygen radicals. AGEs 
constitute a heterogeneous group of macromolecules formed by the nonenzymatic 
glycation of proteins, lipids and nucleic acids. AGEs can be ingested with food and 
are also formed in small amounts endogenously in the body as a consequence of 
normal metabolism (2). During prolonged hyperglycemia AGEs can contribute to 
diabetic complications by the formation of crosslinks in the basal membrane and 
accumulation of glycated proteins which alters cellular structure and protein 
functions. Furthermore, interaction with the receptor for AGE (RAGE) leads to the 
expression of pro-inflammatory genes like interleukin-8 (IL-8) and monocyte 
chemoattractant protein-1 (MCP-1) (3; 4). N
ε
-carboxymethyllysine (CML) is one of 
the best-characterized AGEs. Elevated levels of serum CML have been associated 
with arterial stiffness and pose a higher risk of cardiovascular and all-cause 
mortality (5-7). 
 
Pancreatic beta cells appear to be particularly vulnerable for oxidative stress. 
Expression and activity of the key antioxidant enzymes superoxide dismutase 
(SOD), catalase (CAT) and glutathione peroxidase (GPx) is low in beta cells 
compared to other cell types (8). Moreover, beta cells were found incapable to 
adapt their antioxidant enzyme activity in response to oxidative stress (9). In 
addition, it was shown that pancreatic islets possess low repair machinery for 
oxidized DNA (10). Although a lot of research has focused on the amount of 
antioxidant enzymes in pancreatic islets and the effect of overexpression of GPx, 
little is known about the levels and role of other components of the glutathione 
system in the beta cell.  
 
Glutathione, a tripeptide (γ-glutamylcysteinylglycine), is the major free thiol in 
most living cells and is involved in many biological processes. Within cells, GSH is 
found in both the reduced sulfhydryl form (GSH) and the glutathione disulfide 
oxidized form (GSSG). Under normal conditions, more than 90% of the glutathione 
pool is present in the reduced form. The balance between GSH and GSSG is tightly 
regulated in the cell, as a decrease in GSH can put the cell at risk for oxidative 
damage. An increased GSSG to GSH ratio is therefore often considered as an 
indicator of oxidative stress (11). 
 
Glutathione has a diversity of crucial physiological roles, but it principally serves as 
an endogenous antioxidant. It functions as a cofactor for GPx, the major defense 
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mechanism against potential toxic hydrogen peroxide and other peroxides (12). 
During the detoxification process of peroxides, GSSG is formed. GSH is regenerated 
from GSSG by the NADPH-dependent enzyme glutathione reductase (GR) (13). 
Additionally, glutathione S-transferase (GST) uses GSH as a substrate to form 
conjugates with electrophiles, resulting in more water soluble metabolites which 
are more readily excreted. Glutaredoxin (Grx) utilizes the reducing power of 
glutathione to catalyze disulfide reductions in the presence of NADPH and GR. Grx 
is involved in regulation of various cellular functions, including electron transport 
and protein folding (14).  
 
Because little is known about the effects of AGEs on pancreatic beta cells, we 
investigated the effect of CML on pancreatic cell viability and determined the 
activity and expression of components belonging to the glutathione system.  
 
Material and Methods 
Chemicals 
All chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) unless 
stated otherwise. CML was obtained from SyMO-Chem BV (Eindhoven, 
Netherlands). Roswell Park  emorial  nstitute (RP  ) 16 0 medium, Hank’s 
Balanced Salt Solution (HBSS), trypsin-EDTA (1x), non-heat inactivated fetal calf 
serum (FCS), and L-Glutamine were obtained from Gibco (Breda, The Netherlands).  
 
Cell culture 
The human pancreatic beta cell line 1.1E7 (15) was obtained from HPA Culture 
Collections. Cells were cultured in RPMI 1640 medium with 10% non-heat 
inactivated FCS and 2 mM L-glutamine. Cells were maintained in T75 flasks at 37 °C 
in a 5% CO2 atmosphere.  
 
MTT assay 
Cells were seeded at a density of 5000 cells per well in a 96-well plate and after 
overnight attaching, medium was removed and cells were washed with HBSS. CML 
was added to the plate in different concentrations (0 – 1 mM). Subsequently, cells 
were incubated for 24 hours. After treatment, supernatant was removed and cells 
were washed with PBS. Next, 100 µl of MTT solution (0.5 mg/ml in culture medium) 
was added and cells were incubated for 1 hour at 37 °C. After incubation, the plate 
was washed with PBS and the formazan crystals were dissolved in 200 µl DMSO. 
Cells were incubated for 30 minutes after which the absorbance at 540 nm was 
measured spectrophotometrically using a microplate reader. Relative viability is 
expressed as a percentage relative to untreated cells. 
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Measurement of intracellular oxidative stress 
The production of intracellular reactive oxygen species was measured using 2,7-
dichlorofluorescein diacetate (DCFH-DA) as described previously (16; 17). Cells 
were seeded at a density of 5000 cells per well in a 96 well plate and after 
overnight attaching, medium was removed and cells were washed with HBSS. Cells 
were then incubated with 0.5 mM CML in the presence of 10 µM DCFH-DA. After 
24 hours, cells were washed with PBS to remove any DCFH-DA that was not taken 
up by the cells. Fluorescence (excitation 485 nm; emission 535 nm) was measured 
with the use of a microplate reader. 
 
Gene expression analysis 
RNA was isolated from Qiazol suspended cells according to the manufacturer's 
protocol and quantified spectrophotometrically. Reverse transcription reaction was 
performed using 500 ng of RNA, which was reverse-transcribed into cDNA using 
i cript™ cDNA synthesis kit (Biorad, Veenendaal, The Netherlands). Next, real time 
PCR was performed with a BioRad MyiQ iCycler Single Color RT-PCR detection 
system using  ensimix™Plus  YBR and Fluorescein (Quantace-Bioline, Alphen a/d 
Rijn, The Netherlands), 5 μl diluted (10×) cDNA, and 0.  μ  primers in a total 
volume of  5 μl. PCR was conducted as follows: denaturation at 95 °C for 10 
minutes, followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 45 seconds. 
After PCR, a melt curve (60–95 °C) was produced for product identification and 
purity. β-actin was included as internal control. Primer sequences are shown in 
table 1. Data were analyzed using the MyIQ software system (BioRad) and were 
expressed as relative gene expression (fold change) using the 2
ΔΔCt
 method. 
 
Table 1: Sequences of the primers used in gene expression analysis 
Gene Forward (5’ to 3’) Reverse (5’ to 3’) 
Beta-actin (β-actin) CCTGGCACCCAGCACAAT GCCGATCCACACGGAGTACT 
Receptor for AGE (RAGE) GGCCAGGGCTAGAGTTCC GCTGTCAGCATCAGCATCAT 
Gamma-glutamylcystein 
synthetase (γ-GCS) (catalytic 
subunit) 
GCACATCTACCACGCCGTC 
 
CCACCTCATCGCCCCAC 
 
Glutathione reductase CAAGCTGGGTGGCACTTG TTGGAAAGCCATAATCAGCA 
Glutathione S-transferase pi 
(GSTP1) 
GCTCTATGGGAAGGACCAG CTCAAAAGGCTTCAGTTGC 
Glutaredoxin-2 CCGTCGCTAAATTCTCCAAA TGGCACTCGCTGGAATC 
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Cytokine release 
1.1E7 cells were incubated with 0.5 mM CML for 24 hours. After incubation, culture 
medium was collected. Cytokines released in the supernatant of the cells were 
measured using the Bio-plex pro assay according to manufacturer’s instructions. 
This assay uses antibodies coupled to magnetic beads which react with 50 µl 
supernatant. After a series of washes to remove unbound protein, acytokine-
specific biotinylated detection antibody was added to the reaction. After 30 
minutes incubation and several washes, a streptavidin-phycoerythrin (streptavidin-
PE) reporter complex was added to bind biotinylated detection antibodies. The 
plate was then read using the Luminex system and data was analyzed using the Bio-
Plex Manager software
TM
.  
 
GSH/GSSG levels 
1.1E7 cells were incubated with 0.5 mM CML for 24 hours. After incubation, cells 
were washed with PBS, harvested with trypsin-EDTA and centrifuged (1000xg, 5 
minutes, 4 °C). Next, cells were washed with ice-cold PBS and centrifuged again. 
Cell pellets were then resuspended in ice-cold extraction buffer (0.1% Triton X-100 
and 1.3% SSA in a 0.1 M potassium phosphate buffer with 5 mM EDTA, pH 7.5) and 
sonicated in icy water for 10 minutes. The extracts were used for determination of 
intracellular GSH and GSSG content using an enzymatic recycle method described 
by Rahman et al. (18). 
 
Glutathione reductase activity 
1.1E7 cells were incubated with 0.5 mM CML for 24 hours. After incubation, cells 
were washed with HBSS, harvested with trypsin-EDTA and centrifuged (1000xg, 5 
minutes, 4 °C). Cell pellets were then resuspended in 145 mM sodium phosphate 
buffer pH 7.4 containing 1 mM EDTA. Next, cells were sonicated in icy water for 10 
minutes and centrifuged (15 minutes, 10.000xg, 4ºC). Final reaction mixture (1 ml) 
contained 0.06 mM NADPH (in 1% Na2CO3) and 50 µl sample in buffer. The reaction 
was started by the addition of 0.225 mM GSSG (in 0.01 M NaOH). The consumption 
of NADPH was followed by the decrease in absorbance at 340 nm for 3 minutes at 
37 °C. Activity was corrected for protein content of the samples and expressed in 
nmol/mg protein per minute.  
 
Glutathione transferase activity 
1.1E7 cells were incubated with 0.5 mM CML for 24 hours. After incubation, cells 
were washed with HBSS, harvested with trypsin-EDTA and centrifuged (1000xg, 5 
minutes, 4 °C). Cell pellets were then resuspended in 100 mM potassium 
phosphate buffer pH 6.5 containing 6.3 mM EDTA. Next, cells were sonicated in icy 
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water for 10 minutes and centrifuged (15 minutes, 10.000xg, 4 ºC). Final reaction 
mixture (1 ml) contained 1 mM GSH and 50 µl sample in buffer. The reaction was 
started by the addition of 1 mM CDNB (in ethanol).  The production of GS 
dinitrobenzene was followed by the increase in absorbance at 340 nm for 3 
minutes at 37 °C. With each run a spontaneous reaction was included that 
contained buffer instead of a sample. Activity was corrected for spontaneous 
reaction and for protein content of the samples and expressed in µmol/mg protein 
per minute.  
 
Glutaredoxin activity 
1.1E7 cells were incubated with 0.5 mM CML for 24 hours. After incubation, cells 
were washed with HBSS, harvested with trypsin-EDTA and centrifuged (1000xg, 5 
minutes, 4 °C). Cell pellets were then resuspended in 100 mM potassium 
phosphate buffer pH 7.0 containing 1 mM EDTA. Next, cells were sonicated in icy 
water for 10 minutes and centrifuged (15 minutes, 10.000xg, 4 ºC). Final reaction 
mixture (1 ml) contained 0.5 mM GSH, 0.2 mM NADPH, 1 unit glutathione 
reductase  and 50 µl sample in buffer. The reaction was started by the addition of 
0.35 mM 2-hydroxyethyl disulfide (HED).  The decrease in absorbance at 340 nm, 
which accompanies the oxidation of NADPH, was monitored for 3 minutes at 37 °C. 
Activity was corrected for protein content of the samples and expressed in 
µmol/mg protein per minute.  
 
Protein determination 
Protein concentrations were determined spectrophotometrically using the DC 
protein assay kit (Biorad, Veenendaal, The Netherlands) according to 
manufacturer’s protocol.  
 
Statistical analysis 
The effect of C L incubation was tested using  tudent’s t-test for independent 
samples or the Mann-Whitney U test when not normally distributed. P-values <0.05 
were considered statistically significant and P-values <0.1 were considered 
statistical trends. We also include statistical trends because for bioactive molecules 
like GSH, even a small percentage change in the amount can be of biological 
relevance. Statistical analyses were analyzed with SPSS for Windows (version 20.0; 
SPSS Inc., Chicago, IL, USA). 
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Results 
CML exposure causes a decrease in viability in beta cells 
The effect of CML exposure on 1.1E7 cell viability was determined by MTT assay 
(figure 1A). At concentrations up to 0.125 mM a dose-dependent decrease in 
viability of 100% to 87% was observed, albeit with a high degree of variation 
between the different experiments. Above 0.125 mM the additional decrease in 
viability was only 4%. CML concentrations higher than 0.25 mM show a lower 
degree of variation between the experiments and concentrations higher than 0.5 
mM  did not show an additional decrease in viability, therefore a CML 
concentration of 0.5 mM was chosen as the exposure condition.  
 
CML exposure causes an increase in intracellular oxidative stress 
To determine intracellular levels of reactive oxygen species we used the fluorogenic 
dye DCFH-DA. After diffusion into the cell, DCFH-DA is enzymatically hydrolyzed by 
esterases to the non-fluorescent compound DCFH. When ROS are present, DCFH 
can be oxidized to the highly fluorescent compound DCF. After 24 hour exposure to 
CML we found a 23% increase in DCF fluorescence (figure 1B). This indicates that 
CML causes a significant increase in intracellular oxidative stress in the beta cell.  
 
Figure 1: The effect of exposure to different concentrations N
ε
-carboxymethyllysine (CML)  
(0 – 2 mM) for 24 hours on cell viability of human beta cells (A). Incubation with 0.5 mM CML 
for 24 hours increases intracellular oxidative stress (B). Data are expressed as mean ± 
standard error of the mean (SEM) of three (MTT) or four (DCFH) independent experiments. * 
= p < 0.05 compared to non-exposed cells. 
CML exposure increases the levels of MCP-1 in the culture medium 
Because AGEs bind to RAGE, we measured the gene expression of this receptor in 
the beta cells. We did not observe an effect on gene expression after exposure to 
CML (figure 2A). Since RAGE activation is associated with an increase in pro-
inflammatory genes, the levels of IL-8 and MCP-1, cytokines which are known to be 
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upregulated by RAGE were investigated in the supernatant of cells exposed to CML 
(19-21). No effects on the levels of IL-8 were observed (figure 2B). MCP-1 levels 
were increased by almost 40% (figure 2C). Other RAGE associated cytokines were 
also measured with the Luminex system, but these data are not included because 
the concentrations were below detection limit. 
 
Figure 2: The effect of exposure to 0.5 mM CML for 24 hours on gene expression of RAGE (A) 
and the levels of two cytokines which are elevated by RAGE signaling, IL-8 (B) and MCP-1 (C). 
Data are expressed as mean ± standard error of the mean (SEM) of three (RAGE expression) 
or four (IL-8 and MCP-1) independent experiments. # = p < 0.1 compared to non-exposed 
cells. 
 
Effect on components of the glutathione system 
We determined the activity and gene expression of several components of the 
glutathione system. We observed a trend to a lower GSH concentration of the cells 
after CML exposure (figure 3A). The GSSG concentration did not change, but was 
very low and below the detection limit in some samples (figure 3B). The expression 
of the enzyme gamma-glutamylcystein synthetase (γ-GCS), involved in the 
biosynthesis of GSH, was not affected by exposure to CML (figure 3C).  
Figure 3: The effect of exposure to 0.5 mM CML for 24 hours on GSH content (A), GSSG 
content (B) and gene expression of gamma-glutamylcystein synthetase (γ-GCS) (C).  Data are 
expressed as mean ± standard error of the mean (SEM) of three independent experiments. # 
= p < 0.1 compared to non-exposed cells. 
A trend toward decreased activity of GR after CML exposure was detected, which 
was not accompanied by a change in gene expression of this enzyme (figure 4A and 
4B). We also measured GST activity, which did not show any change after CML 
exposure (figure 4C). Because GST are a large family of genes, the expression of one 
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specific class was determined. Glutathione S-transferase pi (GSTP1) was chosen 
because its overexpression has been linked to the prevention of oxidative stress 
(22; 23). We found an upregulation in the expression of GSTP1 when cells were 
exposed to CML for 24 hours (figure 4D). We did not find any significant changes in 
glutaredoxin activity or gene expression (figure 4E and 4F). 
 
Figure 4: The effect of exposure to 0.5 mM CML for 24 hours on activity (A) and gene 
expression (B) of glutathione reductase; activity of glutathione transferase (C) expression of 
GSTP1 (D); activity of glutaredoxin (E) and expression of glutaredoxin-2 (F). Data are 
expressed as mean ± standard error of the mean (SEM) of three (gene expression, GR 
activity) or four (GST and Grx activity) independent experiments. * = p < 0.05 compared to 
non-exposed cells; # = p < 0.1 compared to non-exposed cells. 
 
Discussion 
AGE formation is one of the major pathways by which hyperglycemia can cause 
diabetic complications, therefore AGEs contribute to the pathogenesis of diabetes 
(24). Beta cell dysfunction and death is involved in the progression of diabetes. 
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(25). In this study we investigated the effect of exposure with the AGE CML on a 
human pancreatic beta cell line.  
 
In this study we used a concentration of 0.5 mM CML to induce changes in 
glutathione components. This concentration is higher than usually found in the 
plasma of diabetic patients, typically reported in the nanomolar or low micromolar 
range (26-28). This high concentration was chosen to determine the effects of CML 
in a relatively short incubation time of 24 hours.  Since we also use FCS in this 
model, it is possible that CML binds to FCS and that the actual amount of free CML 
reacting with the cells is much lower than 0.5 mM and might even be in the in vivo 
range. 
 
Only a limited number of studies about the effect of AGE on beta cell viability and 
function have been published. A study in a mouse beta cell line found that 
exposure to AGEs increased superoxide production in the mitochondria, which led 
to an impairment of insulin secretion (29). Increased oxidative stress via the 
mitochondria due to exposure to AGEs was also found in rat beta cells (30). 
Exposure of different rodent beta cell lines to AGEs induced both proliferation and 
apoptosis in these cells (31). In line with these studies, we also observed a decrease 
in beta cell viability after exposure to the AGE CML. This decreased viability was 
accompanied by an increase in oxidative stress which probably results from the 
interaction of CML with RAGE.  
 
RAGE is a multiligand transmembrane receptor which belongs to the 
immunoglobulin gene superfamily (32). Activation of RAGE by AGEs transduces 
multiple signals resulting in activation and translocation of nuclear transcription 
factors like NF-κB (4). This leads to the expression of proinflammatory cytokines, 
including IL-8 and MCP-1 (19-21). It has been shown that CML adducts are signal-
transducing ligands for RAGE, both in vitro and in vivo (33). However, another study 
found that CML-modified proteins were unable to bind to RAGE and activate 
proinflammatory signaling (34). No changes in the gene expression of RAGE after 
exposure to CML were found, but this may be due to the relatively short incubation 
time of 24 hours. However, increased concentrations of the proinflammatory 
cytokine MCP-1 were detected, which could be caused by RAGE signaling, as MCP-1 
is known to be regulated by RAGE. MCP-1 is involved in the pathogenesis of 
diabetic nephropathy (35) and is also implicated in the destruction of beta cells in 
type 1 diabetes (36).  The rise in MCP-1 levels could explain the observed increase 
in intracellular oxidative stress in these cells since MCP-1 has been associated with 
the induction of oxidative stress in previous studies. MCP-1 enhanced ROS 
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generation in monocytes from unstable angina patients (37). Additionally, MCP-1-
deficiency impaired ROS generation and attenuated oxidative stress in an 
ovariectomy rodent model (as a model for menopause) (38).  
 
Previous research has shown that AGEs can increase GSSG levels in human 
neuroblastoma cells (39). Also in vivo an association between AGEs and a 
decreased glutathione redox ratio in patients undergoing continuous ambulatory 
peritoneal dialysis was found (40). We found a trend toward a decrease in GSH 
content in beta cells exposed to CML. The amount of GSSG was already very low 
and no further change could be detected after CML exposure. A decrease in GSH 
content has been associated with diabetes in previous studies, e.g. levels of GSH 
were lower in erythrocytes of type 2 diabetes patients (41). This decrease was 
associated with a lower activity of the enzyme γ-GCS which is involved in the 
biosynthesis of GSH (41). We did not find a change in gene expression of γ-GCS 
after exposing the cells to CML. Replenishment of the GSH pool by GR is dependent 
on the GSSG pool and the availability of NADPH. Since we do not see changes in the 
GSSG concentration, the amount of available NADPH limits the glutathione 
reductase activity after CML exposure.  
 
CML increased the expression of GST in both cell culture and animal models (42). 
However, they also found increased GSH concentrations with a higher expression 
of GST. This seemed to be associated with activation of the transcription factor AP-
1 by RAGE, which in turn might be involved in the induction of G T and γ-GCS (42). 
We did find an increase in GSTP1 expression, however we did not find an increase 
in expression of RAGE and γ-GCS, which could explain why we did not find an 
increase in GSH. It is known that expression of Grx is high in beta cells and that Grx 
might play a regulatory role in insulin exocytosis (43). Glutaredoxin-1 expression 
has been linked to diabetic retinopathy, by inducing NF-κB translocation and 
expression of intercellular adhesion molecule-1 (ICAM-1) in rat retinal Müller cells 
(44). A recent study in patients with abnormal glucose levels found a higher Grx 
activity in plasma and serum of these patients compared to healthy subjects (45). 
We did not find any significant changes after 24 hour exposure to CML in activity 
levels of Grx or expression of glutaredoxin-2. 
 
In conclusion, we found that CML was able to induce cell death in human 
pancreatic beta cells, which was accompanied by an increase in intracellular 
oxidative stress. We did not find changes in the expression of RAGE, but we found 
an increase in the level of a target cytokine of RAGE after CML exposure. 
Additionally we found that CML exposure lowered the levels of GSH. Also other 
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components of the glutathione system were affected, we found a decrease in 
glutathione reductase activity and an increase in the expression of GSTP1 (figure 5). 
These changes in GSH levels and activities of components of the glutathione system 
indicate that the cells are even more vulnerable for oxidative stress after exposure 
to CML. Since beta cells are low in antioxidant enzymes and repair for oxidized 
DNA, it might be that AGEs like CML can accelerate beta cell dysfunction and beta 
cell death during hyperglycemia.  
 
 
Figure 5: Overview of the glutathione system and the effects of 24 hour incubation with 0.5 
mM N
ε
-carboxymethyllysine (CML) on this system in pancreatic beta cells. GSH = glutathione 
(reduced form); GSSG = glutathione (oxidized form); GR = glutathione reductase; GPx = 
glutathione peroxidase; GST = glutathione-S-transferase; NADP = nicotinamide adenine 
dinucleotide phosphate (oxidized form); NADPH = nicotinamide adenine dinucleotide 
phosphate (reduced form); H2O2 = hydrogen peroxide; H2O = water; SSG = glutathione 
adduct to protein; SH = thiol group; Grx = glutaredoxin. 
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Abstract 
Erythritol (1,2,3,4-butanetetrol) is a non-caloric C4 polyol made by fermentation 
that has a sweetness of 60-70% that of sucrose. The safety of erythritol has been 
consistently demonstrated in animal and human studies. Erythritol has a higher 
digestive tolerance compared to all other polyols because about 90% of the 
ingested erythritol is readily absorbed and excreted unchanged in urine. Erythritol 
is used in a wide range of applications for sweetening and other functionalities, e,g, 
in beverages, chewing gum and candies. In this review we summarize the health 
effects of erythritol described in literature. We focus on studies involving the anti-
cariogenic and the endothelial protective effects of erythritol. We conclude that 
erythritol can be of great importance and considered to be the preferred sugar 
replacer for a rapidly growing population of people with diabetes or prediabetes to 
reduce their risk of developing diabetic complications. 
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General characteristics 
Erythritol (1,2,3,4-butanetetrol) is a 4-carbon sugar alcohol or polyol, it has the 
unique property that it is a meso butanetetrol (figure 1). It occurs naturally in some 
mushrooms, some fruits (e.g. watermelon, grapes and pears) and in fermented 
foods including wine, cheese, sake and soy sauce [1,2]. Consumption of erythritol 
from its natural occurrence in foods has been estimated to be 80 mg per day (~1.3 
mg/kg body weight per day) in the United States [2]. Erythritol is also found 
endogenously in human and animal tissues and body fluids including blood, urine 
and cerebrospinal fluid [2]. 
 
Figure 1: Two possible stereoisomers of 1,2,3,4-butanetetrol are shown. On the left: 
erythritol, the 2R,3S isomer. Although this compound contains 2 asymmetric carbon atoms, 
the overall molecule is achiral because it contains a intramolecular plane of symmetry. This 
plane of symmetry is absent in the compound on the right, D-threitol, which is therefore 
chiral: It has a enantiomer (mirror image) L-threitol (not shown). 
 
Erythritol is a white, anhydrous, non-hydroscopic and crystalline substance. It is 60-
70% as sweet as sucrose [3]. Although erythritol was first isolated in 1852, it took 
until 1990 for it to be marketed as a new natural sweetener in Japan. Currently, the 
use of erythritol in foods has been approved in more than 60 countries. The range 
of applications include table top sweeteners, beverages, chewing gum, chocolate, 
candies and bakery products [3]. 
 
Manufacturing process 
Large scale production of erythritol uses fermentation, a natural process. As a 
starting material pure glucose, sucrose or glucose from maize (as a source of 
starch) is used. Starch is extracted from the maize and through hydrolysis the 
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starch chains are broken down into glucose molecules which are fermented into 
erythritol using an osmophilic yeast, like Moniliella pollinis. After fermentation, 
yeast cells and other impurities are removed by filtering. Once the fermentation 
broth is filtered, erythritol is purified by ion exchange resin, activated charcoal, and 
ultrafiltration. In the last step, crystallization, the broth is cooled down and 
erythritol precipitates from the solution yielding crystals with over 99% purity [4,3]. 
 
Safety 
A number of toxicological studies have been performed to evaluate the safety of 
erythritol. These have been extensively discussed in reviews by Bernt et al. and 
Munro et al. [2,5].  
 
In summary, based on acute toxicity studies, erythritol is classified as essentially 
non-toxic after oral administration. Subchronic studies further support the safety of 
erythritol. Chronic studies (up to 2 years) revealed no effect on survival or 
carcinogenicity by erythritol [2,5]. Even at high doses (up to 16 g/kg body weight), 
erythritol does not affect reproductive performance or fertility of parental rats. In 
addition, no adverse effects on the developing foetus were observed [6,7,2,5]. 
Erythritol does not possess mutagenic potential as observed in the Ames test and 
chromosomal aberration test [5,2,8,9].  
 
 In summary, animal toxicological studies and clinical studies have consistently 
demonstrated the safety of erythritol. Therefore it is not expected that erythritol 
will cause adverse effects under the conditions of its intended use in food. 
 
Metabolic fate 
The metabolic profile of erythritol is not like any other polyol which gives rise to 
some of erythritols’ unique properties. Erythritol is readily and virtually completely 
absorbed from the small intestine via passive diffusion similar to fructose. Fructose 
transport can also occur via GLUT2 transport with absorption enhanced in the 
presence of glucose due to greater GLUT2 insertion in the apical membrane as 
SGLT1 transports glucose. This explains the enhanced absorption of fructose in the 
presence of glucose. In addition, the presence of glucose has been shown to 
enhance paracellular flow due to the opening of tight junctions resulting in 
increased absorption of small solutes [10]. Enhanced GLUT2 insertion and 
enhanced paracellular flow in the presence of glucose has been hypothesized to be 
the same pathway with altered functions in the absence/presence of glucose. 
However, this hypothesis does not support the differences noted for minor 
increases in small solute transport compared to the greatly enhanced transport of 
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fructose when glucose is present [11,12]. As erythritol is readily absorbed on its 
own, the impact of the presence of glucose on erythritol absorption would be 
minimal and has not been investigated to date. After absorption, erythritol is 
distributed throughout the body, with maximum plasma concentrations occurring 
within the first 2 hours of digestion. Up to 90% is excreted unchanged in the urine. 
[13,14,5].  
 
Unabsorbed erythritol may be subjected to microbial fermentation in the colon. 
However, studies with 13C-erythritol showed no increase in breath 13CO2 and H2, 
which indicated that erythritol was not metabolized by the host [15]. Inability of 
faecal flora to metabolise erythritol was confirmed in in vitro studies with 
fermentation times up to 24 hours [15,16]. The potential for erythritol 
fermentation exists with exceedingly high doses, much greater than are 
represented with current intake [17]. 
 
Erythritol has a digestive tolerance that is much higher compared to other polyols. 
This can mainly be attributed to the fact that it is readily absorbed and only a small 
fraction reaches the colon. Other polyols are poorly absorbed, which can provoke 
undesirable intestinal effects when they are consumed in excessive quantities. 
These effects can occur due to gas formation by fermentation (leading to 
flatulence) or they are the result of osmotic effects (leading to laxative effects). 
Gastrointestinal responses of persons ingesting erythritol at up to 0.8 g/kg body 
weight were comparable to those of sucrose [13]. Also repeated ingestion of 
erythritol at daily doses of 1 g/kg body weight did not show more frequent 
gastrointestinal effects than sucrose, indicating that erythritol was well tolerated 
[18]. When 35 g erythritol was consumed in a drink it was well tolerated, while at a 
dose of 50 g only significant increases in borborygmi and nausea where observed. 
The consumption of 35 and 50 g xylitol in the same study induced significant 
gastrointestinal distress [19]. The maximum dose of erythritol not causing laxation 
was calculated to be 0.80 g/kg body weight for females and 0.66 g/kg for males 
[20]. However, the maximum dose is also dependent on the delivery method. 
Consumption of erythritol with solid foods is tolerated at a higher intake level than 
with beverages, because digestion of food products is slower providing a longer 
period for absorption to occur [19]. 
 
Because of its metabolic profile, erythritol does not provide energy to the body and 
therefore has a caloric value of 0 calories per gram [3]. In addition, erythritol does 
not raise plasma glucose or insulin levels and can therefore be regarded as safe for 
diabetic patients. No effect on plasma glucose or insulin levels was observed within 
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3 hours after ingestion of 1 g/kg body weight erythritol [14]. Ingestion of 0.3 g/kg 
body weight erythritol did not influence serum glucose or insulin levels, whereas 
the same dose of glucose rapidly increased these levels [21]. 
 
Health effects 
Dental health 
Mutans streptococci play an important role in the development of dental plaque. 
They attach to the biofilm on teeth and produce glucosyltransferase. This enzyme is 
responsible for the synthesis of insoluble glucan plaque material. Glucans and the 
bacteria accumulate on the teeth and are known as dental plaque. When large 
amounts of plaque form on teeth in presence of sugar, the mutans streptococci 
produce lactic acid. The acid weakens tooth enamel through demineralization, 
ultimately causing dental caries [3,22]. 
 
When erythritol was incubated with a range of mutans streptococci species no 
lactic acid production was observed. Furthermore, it was not used for growth or 
plaque formation by the mutans streptococci [23]. Another study showed that 
erythritol inhibited the growth of several strains of mutans streptococci strains [24]. 
A study by Hashino et al. showed that erythritol has inhibitory effects on 
Porphyromonas gingivalis and Streptococcus gordonii heterotypic biofilm 
development via several pathways, including a decrease in DNA/RNA synthesis, 
decreased extracellular matrix production and alterations of dipeptide acquisition 
and amino acid metabolism [25]. 
 
This was also supported by an in vivo study into the effects of 6-month use of 
erythritol, xylitol and glucose (in the form of chewable tablets and toothpaste). 
Erythritol and xylitol led to a significant reduction in the amount of plaque and 
saliva levels of mutans streptococci. In addition, a reduction in the amount of 
dental plaque was observed in subjects that had received erythritol and xylitol [24]. 
A 3 year clinical trial also found that erythritol promotes dental health [26]. In this 
study initially 7-8 year old children were given erythritol, xylitol or sorbitol candies 
containing 7.5 g of the polyol daily for three years. Erythritol consistently reduced 
the amount of dental plaque during the follow up period. In addition, the plaque of 
erythritol receiving subjects showed a reduction in the levels of acetic acid, 
propionic acid and lactic acid. Furthermore, erythritol consumption led to a lower 
salivary and plaque mutans streptococci counts compared with other groups. This 
longterm study also investigated the impact of polyol consumption on dental caries 
development [27]. It was found that a lower number of children in the erythritol 
group developed enamel or dentin caries over the three years (4.6% versus 5.5% in 
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the sorbitol and 5.8% in the xylitol group). In addition, in the erythritol group a 
lower number of enamel caries tooth surfaces developed to dentin caries (1.3% 
versus 1.7% in the sorbitol and 2.0% in the xylitol group). Furthermore, the time to 
development of enamel/dentin and dentin caries lesions (surfaces) was statistically 
significantly longer in the erythritol group compared to the sorbitol or xylitol group. 
These studies demonstrate that erythritol can reduce the risk of dental caries 
development. 
 
Antioxidant properties 
It is well known that the polyol mannitol is a hydroxyl radical scavenger [28,29]. 
Since erythritol closely resembles the structure of mannitol, den Hartog et al. 
investigated the hydroxyl radical scavenging capacity of erythritol and several other 
polyols. A correlation between the number of hydroxyl groups in the investigated 
compound and its rate constant for the reaction with hydroxyl radicals was found. 
Erythritol proved to be an excellent hydroxyl radical scavenger with a rate constant 
of 1.18 x 109 M-1s-1[30].  
 
In the same study the ability of erythritol to scavenge superoxide radicals was 
investigated. Erythritol proved to be inert towards superoxide radicals, probably 
because it lacks a major structural requirement for superoxide scavengers. The 
ability of erythritol to scavenge radicals in a cellular system was tested with a 
hemolysis assay. Erythritol delayed radical-induced hemolysis in red blood cells in a 
concentration dependent manner [30].  
 
The reaction of erythritol with hydroxyl radicals was also demonstrated in an in 
vivo model using diabetic rats. The rats were fed 1000 mg/kg per day for a period 
of 3 weeks after diabetes was induced by streptozotocin. The urine of the rats was 
investigated for the presence of two oxidative metabolites of erythritol: erythrose 
and erythrulose. The amount of erythrose in the urine was highest in the diabetic 
group fed with erythritol, indicating that erythritol scavenged hydroxyl radicals 
produced during hyperglycemia in these rats [30].   
 
In another in vivo study by Yokozawa et al. antioxidant properties of erythritol were 
also investigated [31]. Several doses of erythritol (100, 200 and 400 mg/kg body 
weight) were orally administrated to streptozotocin induced diabetic rats for 10 
days. The highest dose resulted in a decrease of 5-hydroxymethylfurfural (5-HMF) 
levels, a marker for the extent of glycosylation of serum protein. In addition, 
thiobarbituric acid reactive substances levels of serum, liver and kidney were lower 
in the groups that received erythritol, indicating a reduction of lipid peroxidation (a 
Chapter 5 
84 
 
marker of oxidative stress). This study also found a reduction in serum, liver and 
kidney glucose levels and a reduction in serum creatinine when rats were given 
erythritol. They conclude that erythritol is able to affect glucose metabolism and 
reduce lipid peroxidation and kidney damage caused by hyperglycemia [31]. 
 
Endothelial protective effects 
Most of the complications that arise from chronic hyperglycemia find their origin in 
damaging the endothelium, a thin layer of cells lining the cardiovascular system 
[32-34]. The endothelium plays an important role in numerous physiological 
functions with one of the most important endothelium-derived mediator being the 
soluble gaseous radical nitric oxide (NO), responsible for vascular relaxation. 
Endothelial dysfunction occurs when the endothelium loses its physiological 
properties. This has been linked to diabetes through demonstration of impaired 
endothelial-dependent vasodilatation [35].  
 
The study of den Hartog et al. also focused on the effect of erythritol on endothelial 
function. This was investigated in rings prepared from the thoracic aorta. Carbachol 
concentration response curves were recorded for the different groups (figure 2). In 
diabetic rats the ex vivo carbachol response is smaller and requires higher 
concentrations than in control rats. This indicates that the endothelium of these 
rats is damaged. Since the carbachol response is mediated by NO, the diabetic rats 
seem to  be incapable of generating sufficient NO to induce maximum relaxation. In 
diabetic rats fed with erythritol the carbachol response curve was similar to control 
rats, indicating that the loss of endothelium dependent vascular relaxation was 
prevented by erythritol in these rats [30]. 
 
To further investigate the endothelium protective effect a study in endothelial cells 
was performed [36]. The cells were exposed to normal and high glucose 
concentrations and targeted and transcriptomic approaches were used to examine 
the effect of erythritol under these conditions. Overall, it was found that erythritol 
by itself (i.e. under non-diabetic conditions) has no effect on the endothelial cells. 
However, under high glucose conditions, erythritol was able to reverse a number of 
deleterious effects. The most striking observation was that erythritol reversed the 
direction of change of 148 of the 153 transcripts altered by high glucose incubation. 
Another finding was that erythritol did not seem to affect single endpoints, but 
rather had an effect on multiple targets. A mode of action which is not uncommon 
for natural compounds [37,38].  
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Figure 2: Carbachol concentration–response curves recorded with aortic rings from 
normoglycemic rats (N; closed circles). diabetic rats (D; closed squares) normoglycemic rats 
that had consumed erythritol (NE; open circles) and diabetic rats that had consumed 
erythritol (DE; open squares). In diabetic rats the ex vivo carbachol response is smaller and 
requires higher concentrations than in control rats. Erythritol prevents the loss of response 
to carbachol, thus maintaining endothelium dependent vascular relaxation. Adapted from 
den Hartog et al. [30]. 
 
A pilot study on the effects of erythritol in patients with type 2 diabetes also 
revealed protective effects on vascular function [39]. In this study 24 subjects 
consumed 12 g of erythritol three times daily for 4 weeks. Subjects were tested at 
baseline and after 4 weeks. In addition, acute and acute-on-chronic effects before 
and 2 hours after consumption of 24 g erythritol at baseline and follow up visit 
were measured. Acute consumption of erythritol improved small vessel endothelial 
function as measured by fingertip peripheral arterial tonometry (EndoPAT). Chronic 
erythritol consumption showed a decrease in central pulse pressure and a trend 
towards a lower carotid-femoral pulse wave velocity. These findings suggest that 
erythritol can reduce arterial stiffness and improve small vessel endothelial 
function. However, this was a pilot study without a control group and a modest 
sample size. To validate the findings of this study a randomized, placebo-controlled 
study is required [39]. 
 
Conclusion 
Erythritol is a non-caloric bulk sweetener which has been shown in multiple studies 
to reduce the risk of caries development. As erythritol does not influence glucose 
or insulin levels it is a good alternative for sugar in patients with diabetes as well as 
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for people needing or desiring to manage blood sugar levels due to prediabetes or 
compromised carbohydrate metabolism. In addition, diabetes patients could 
benefit from the vascular effects of erythritol described above. It is expected that in 
non-diabetic subjects the endothelium will not be affected by erythritol. However, 
in diabetic subjects, where the endothelium is under diabetic stress, erythritol 
could shift a variety of damage and dysfunction parameters to a safer side as 
observed in the found in vitro, in vivo (rat) studies and in a clinical study with type 2 
diabetes patients. Erythritol can therefore be regarded as a compound that has 
protective effects on the endothelium under high glucose conditions, leading to a 
prevention or delay in onset of diabetic complications.  
 
The characteristic of erythritol to have small effects on multiple targets may also 
prove to be beneficial. A compound with a strong biological effect is less suitable 
for chronic supplementation as is needed in diabetes. The alternative is to use a 
compound with mild protective effects like erythritol. Erythritol can therefore be of 
great importance and considered to be the preferred sugar replacer for a rapidly 
growing population of people with diabetes or prediabetes to reduce their risk of 
developing diabetic complications. 
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Abstract 
Diabetes is characterized by hyperglycemia and development of vascular 
pathology. Endothelial cell dysfunction is a starting point for pathogenesis of 
vascular complications in diabetes. We previously showed the polyol erythritol to 
be a hydroxyl radical scavenger preventing endothelial cell dysfunction onset in 
diabetic rats. To unravel mechanisms, other than scavenging of radicals, by which 
erythritol mediates this protective effect, we evaluated effects of erythritol in 
endothelial cells exposed to normal (7 mM) and high glucose (30 mM) or diabetic 
stressors (e.g. SIN-1) using targeted and transcriptomic approaches. This study 
demonstrates that erythritol (i.e. under non-diabetic conditions) has minimal 
effects on endothelial cells. However, under hyperglycemic conditions erythritol 
protected endothelial cells against cell death induced by diabetic stressors (i.e. high 
glucose and peroxynitrite). Also a number of harmful effects caused by high 
glucose, e.g. increased nitric oxide release, are reversed. Additionally, total 
transcriptome analysis indicated that biological processes which are differentially 
regulated due to high glucose are corrected by erythritol. We conclude that 
erythritol protects endothelial cells during high glucose conditions via effects on 
multiple targets. Overall, these data indicate a therapeutically important 
endothelial protective effect of erythritol under hyperglycemic conditions.  
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Introduction 
Chronic hyperglycemia in diabetes is associated with cardiovascular disease and 
microvascular pathologies in the retina, kidney and peripheral nerves (1; 2). Most 
of these diabetic complications find their origin in damaging of the endothelium, a 
layer of cells lining the cardiovascular system (3-5). The endothelium participates in 
numerous normal physiological functions including control of vasomotor tone, 
maintenance of blood fluidity, regulation of permeability, formation of new blood 
vessels and trafficking of cells. The endothelium also plays an important role in 
several human diseases. During inflammation, genes become activated within the 
endothelium to facilitate recruitment, attachment, and transmigration of 
inflammatory cells. In chronic inflammatory diseases, endothelial cell responses 
become impaired, leading to endothelial dysfunction (ED) (1; 6). 
 
Erythritol (1,2,3,4-butanetetrol; ERT) is a natural C4 polyol that has a sweetness of 
60-80% that of sucrose. More than 90% of ingested ERT is not metabolized by 
humans and excreted unchanged in urine, indicating ERT is efficiently absorbed not 
metabolized for energy and excreted by renal processes (7; 8). It is a suitable bulk 
sweetener because it is not metabolized, does not influence blood glucose or 
insulin levels and does not cause caries (9; 10), consequently it is also safe for 
diabetics. 
 
We have previously shown that ERT is an excellent hydroxyl radical scavenger in 
vitro and that it also delayed radical-induced hemolysis in red blood cells (11). 
Supplementation with ERT reduced lipid peroxidation (8) and prevented loss of 
endothelium-dependent vasorelaxation  in a diabetic rat model (11). Given the 
importance of the endothelium in regulating vascular function and initiation and 
propagation of inflammatory responses to high glucose, herein, we extend our 
previous studies with rats (11) by evaluating effects of ERT in an endothelial cell 
line exposed to normal and high glucose concentrations, using targeted and 
transcriptomic approaches. 
 
 
Material and Methods 
Chemicals 
Erythritol was kindly provided by Cargill (Vilvoorde, Belgium). F12K medium and 
fetal calf serum (FCS) were obtained from ATCC (Wesel, Germany). 
Penicillin/streptomycin, Hank’s Balanced  alt  olution (HB  ) and trypsin were 
purchased from Gibco (Breda, The Netherlands). Glucose, N
G
-nitro-L-arginine 
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methyl ester (L-NAME), 2-thiobarbituric acid (TBA), phosphoric acid, 
Ethylenediaminetetraacetic acid (EDTA), butylated hydroxytoluene (BHT), ethylene 
glycol tetraacetic acid (EGTA), nuclease P1, alkaline phosphatase, calcium ionophor 
A23187 and 4,5-diaminofluorescein diacetate (DAF-2) were obtained from Sigma 
Aldrich (Steinheim, Germany). 3-morpholino sidnonimine (SIN-1) was acquired 
from Alexis Biochemicals (San Diego, CA, USA). Endothelial cell growth supplement 
(ECGS) was obtained from BD Bioscience (Breda, The Netherlands). Heparin was 
purchased from Leo Pharmaceuticals (Amsterdam, The Netherlands). Ethanol, 
methanol and butanol were acquired from Biosolve (Valkenswaard, The 
Netherlands). [
3
H]-arginine was obtained from Perkin Elmer (Waltham, MA, USA). 
 
Cell Culture 
Human umbilical vein endothelial (HUVEC) cell line CRL-1730 was obtained from 
ATCC. HUVECs were cultured in F12K medium with 10% non-heat inactivated FCS, 
1% penicillin/streptomycin, 0.05 mg/ml ECGS and 0.1 mg/ml heparin. Cells were 
maintained in collagen coated T75 flasks (Greiner Bio-one, Alphen a/d Rijn, The 
Netherlands) at 37°C in a 5% CO2 atmosphere. For experiments, cells were seeded 
in 6 well plates/T75 flasks and grown until 80% confluency. Next, medium was 
removed and cells were washed with HBSS. New medium without supplements and 
erythritol (final concentration 5 mM), L-NAME (final concentration 0.1 mM or 0.5 
mM) or vehicle solution (medium) was added to the cells. After 1 hour incubation 
glucose (final concentration 30 mM glucose) or vehicle (medium) was added to the 
cells. Subsequently, cells were incubated for 24 hours. The same protocol was used 
for incubation with SIN-1 (final concentration 0.5 mM). 
 
Cell viability 
HUVEC cells were grown in 6 well plates until 80% confluence. After incubation 
medium was removed, the cells were washed with HBSS and harvested with 
trypsin. All cell material including medium and HBSS was collected and centrifuged 
(5 minutes, 500xg) and used to determine viability of the cells using the trypan blue 
exclusion assay. The percentage of dead cells was calculated with the formula: 
(dead cells / (dead cells + viable cells) * 100%.  
 
Malondialdehyde measurement 
Malondialdehyde (MDA) was measured with HPLC. Briefly, 100 µl of cell lysate or 
MDA standard were mixed with 1 ml of reagent, composed of 10 parts reagent A 
(12 mM TBA, 0.32 M phosphoric acid and 0.01 mM EDTA) and one part of reagent B 
(1.5 mg/ml BHT in ethanol). Samples and standards were heated for 1 hour at 99°C. 
After cooling, 500 µl of butanol was added and samples and standards were 
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centrifuged for 5 minutes at maximum speed to extract the TBA-MDA product. Ten 
µl of the extract was injected on to an Alltima HP C18 column (Grace, Breda, The 
Netherlands) and eluted with 65% water and 35% methanol with 0.1% 
trifluoroacetic acid. Fluorescence was recorded at λex 5   nm/λem 553 nm. MDA 
concentration was determined by calculating the peak height of the TBA-MDA 
product and results were corrected for protein content of the lysates. 
 
Protein carbonyl measurement 
Cell lysates were monitored for their protein carbonyl contents using the protein 
carbonyl assay kit (Cayman Chemical, Ann Arbor, MI, USA). 2,4-
Dinitrophenylhydrazine (DNPH) reacted with protein carbonyls in the lysate. The 
amount of protein-hydrozone produced was then quantified 
spectrophotometrically at an absorbance of 385 nm. The carbonyl content was 
corrected for protein content of the lysates. 
 
8-Hydroxydeoxyguanosine measurement 
DNA was extracted from HUVEC cells using the QIAamp DNA Mini Kit (Qiagen, 
Venlo, The Netherlands) according to the manufacturer’s protocol and quantified 
spectrophotometrically. After extraction, 15 µg DNA was digested into 
deoxyribonucleosides by treatment with nuclease P1 (0.0  U/μl) and alkaline 
phosphatase (0.01  U/μl). To measure oxidative damage of DNA by 8-OHdG the 
Bioxytech 8-OHdG-EIA kit (Oxis Health products, Beverly Hills, CA, USA) was used. 
Digested samples were added to the microtitre plate precoated with 8-OHdG and 
the assay was performed according to the manufacturer’s instructions. 
 
NOS3 activity 
NOS3 activity was determined as described previously (12-14) using the NOS 
activity assay kit from Cayman. NOS3 activity was determined in cell pellets which 
were homogenized in ice-cold 25 mM Tris-HCl buffer containing 1 mM EDTA and 1 
mM EGTA. Next, 22 µM [
3
H]-arginine (specific activity: 43 Ci/mmol) and 1 mM 
calcium chloride, 6 µM tetrahydrobiopterin, 2 µM flavin adenine mononucleotide 
and 1 mM of reduced nicotinamidedinucleotide phosphate as co-factors was added 
to the homogenate. After 60 minutes incubation at room temperature, the 
reaction was stopped by adding a slightly acidic HEPES buffer containing a calcium 
ion chelator. [
3
H]-arginine was separated from [
3
H]-citrulline by DOWEX ion 
exchange resin. Scintilliation fluid was added and samples were counted for 5 
minutes in a Wallac Liquid Scintillation counter. Background counts were 
determined by adding [
3
H]-arginine to the DOWEX resin and determining the 
remaining counts. Total counts were obtained by adding [
3
H]-arginine to the HEPES 
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buffer and determining the counts. NOS3 activity was then determined by 
calculating the conversion percentage by % conversion = ((dpm reaction - dpm 
background)/dpm total) x 100 after which the formed amount of [
3
H]-citrulline 
could be calculated. This value was then transformed into units of NOS3 activity per 
milligram protein (1 unit = 1 micromole of citrulline per minute). 
 
Nitric oxide release 
Quantification of nitric oxide (NO) released by the HUVEC was performed by using 
the DAF-2 fluorescence assay as described by Rathel et al (15). HUVECs were grown 
in 6 well plates until 80% confluence. After incubation, cells were washed twice 
with PBS + Ca
2+
. Subsequently, cells were incubated with PBS + Ca
2+
 containing 100 
µM L-arginine for 10 minutes at 37°C. Afterwards, the calcium ionophor A23187 
and DAF-2 were added into the buffer at final concentrations of respectively 1 µM 
and 0.1 µM. Next, cells were incubated in the dark for another 30 minutes at 37°C. 
Cell supernatants were then transferred into an opaque 96-well plate and 
fluorescence was measured on a spectrofluorometer (Spectra Max M2, Molecular 
Devices) with λex set at  95 nm and λem at 515 nm. The NO release was corrected 
for protein content of the measured wells. 
 
Gene expression analysis 
RNA was isolated from Qiazol suspended cells according to the manufacturer’s 
protocol and quantified spectrophotometrically. Reverse transcription reaction was 
performed using 500 ng of RNA, which was reverse-transcribed into cDNA using 
iScript
TM
 cDNA synthesis kit (Biorad, Veenendaal, The Netherlands). Next, real time 
PCR was performed with a BioRad MyiQ iCycler Single Color RT-PCR detection 
system using Sensimix
TM
Plus SYBR and Fluorescein (Quantace-Bioline, Alphen a/d 
Rijn, The Netherlands), 5 µl diluted (10x) cDNA, and 0.3 µM primers in a total 
volume of 25 µl. PCR was conducted as follows: denaturation at 95ºC for 10 
minutes, followed by 40 cycles of 95ºC for 15 seconds and 60ºC for 45 seconds. 
After PCR a melt curve (60-95ºC) was produced for product identification and 
purity. β-actin was included as internal control. Primer sequences for β-actin were: 
forward 5’-CCTGGCACCCAGCACAAT- ’ and reverse 5’-GCCGATCCACACGGAGTACT-
 ’ and for N    forward 5’-GAGGGGAGCTGTTGTAGGG- ’ and reverse 5’-
GTGGTAACCAGCACATTTGG- ’. Data were analysed using the  y Q software 
system (BioRad) and were expressed as relative gene expression (fold change) 
using the 2
ΔΔCt
 method. 
 
Protein determination 
Protein concentrations were determined spectrophotometrically using the 
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DCprotein assay kit (BioRad) according to the manufacturer’s protocol. 
 
Eicosanoid measurement 
Eicosanoids (or oxylipins) derived from cyclooxygenase-, lipoxygenase- and 
cytochrome P450- enzymes, including those associated with hypertension and ED, 
were measured after published methods (16; 17) in cell pellets (nmol/g protein) 
and culture medium (nM). The 23 eicosanoids measured included 12,13-DiHOME, 
9,10-DiHOME, 14,15-DiHETrE, 11,12-DiHETrE, 8,9-DiHETrE, 5,6-DiHETrE, 9(10)-
EpOME, 12(13)-EpOME, 14(15)-EpETrE, 11(12)-EpETrE, 8(9)-EpETrE, 5(6)-EpETrE, 
TXB2, PGE2, PGD2 4, 5-HETE, 8-HETE, 11-HETE, 12-HETE, and 15-HETE 
[for abbreviations`, see Table S1 in (18)]. 
 
RNA isolation and microarray experiments 
Total RNA was isolated from Qiazol® suspended cells according to the 
manufacturer’s protocol, followed by a clean-up, using a RNAeasy Mini Kit (Qiagen) 
with DNase treatment. RNA quantity and purity were determined 
spectrophotometrically using a Nanodrop. RNA quality was further assessed by 
automated gel electrophoresis on an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Amstelveen, The Netherlands). All samples were found to be pure 
and free of RNA degradation. Sample preparation, hybridization, washing, staining 
and scanning of the Affymetrix Human Genome U133 Plus 2.0 GeneChip arrays 
(Affymetrix,  anta Clara, CA, U A) were conducted according to the manufacturer’s 
manual. Quality controls were within accepted limits.  
 
Data processing and statistical analysis 
Microarray data was processed using R and packages from the Bioconductor 
repository, including affy (19-21). Probe sets and annotations were updated using 
the Entrez Gene based re-annotation by the BrainArray group (22). The RMA 
algorithm was used to obtain background corrected, normalized, and log-
transformed intensities for each probe set (23). Genes that had low intensity 
signals (2log 100) on each array were removed before further processing. 
Determination of differentially expressed genes between relevant experimental 
groups was performed using the R limma package (24). Regression models were 
built correcting for the day of the run and including an interaction term between 
ERT treatment status and glucose level. 
 
Data mining 
Commercial and public domain database tools were used to annotate the changed 
transcripts. These included: the Gene Ontology (GO) database Transcript2GO; 
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GeneSpring  (Agilent Technologies, Inc., Santa Clara, CA, USA) for promoter 
analysis, transport factors and conservative natural language processing on Mesh 
terms and key words; ExPASy for reactions; DAVID for enzyme EC linking; Reactome 
for reactions amongst transcipts; and PhosphoSitePlus and GeneCards for 
annotations and transcript descriptions. The two main effects examined in pathway 
analysis were high glucose (30 mM, HG) vs normal glucose (7 mM, NG) and 
particularly high glucose in combination with pre/coincubation with 5 mM 
erythritol (HGERT) vs HG. Normal glucose in combination with pre/coincubation 
with ERT vs NG was investigated minimally for pathway and network analysis. 
Pathway analysis was performed with PathVisio 2.0.7 (25) (www.pathvisio.org) 
using filtered microarray expression data and pathway collections from KEGG and 
WikiPathways (www.wikipathways.org). GeneSpring was also utilized to identify 
major pathways.  
 
Statistical analysis 
For all analyses, p-values were calculated for the following comparisons: HGERT vs. 
HG (HGERT/HG); NGERT vs. NG (NGERT/NG); and HG vs. NG (HG/NG) (HG, high 
glucose; NG, normal glucose). For targeted analyses, there were 3 replications and 
data were evaluated by AN VA models and student’s t-tests for each of the above 
three comparisons. P-values <0.05 were considered statistically significant. P-values 
<0.1 were considered statistical trends, and are also described, since sample sizes 
were small (typically n=3), and in some cases, assay variation was high.    
 
Results 
Erythritol attenuates glucose induced cell death 
The effect of incubating HUVECs with HG, ERT or a combination of ERT and glucose 
(HGERT) was investigated by evaluating the cell viability using the trypan blue 
exclusion assay.  
 
When HUVECs were incubated with HG for 24 hours the percentage of dead cells 
increased almost 4-fold (p=0.0002) without affecting total cell number (Figure 1). 
Addition of ERT or the nitric oxide synthase (NOS) inhibitor L-NAME (0.1 mM or 0.5 
mM) completely prevented this increase in the percentage of dead cells (p=0.002 
for ERT; p=0.003 and p=0.001 for L-NAME). Longer HG incubation (48 hours) 
resulted in a dramatically lower total cell number (inset figure 1C). Incubation for 
24 hours with the peroxynitrite-generating compound SIN-1 also significantly 
increased cell death which was attenuated by addition of 5 mM ERT (p=0.03 and 
p=0.06). Moreover, under normal glucose conditions incubation with ERT did not 
result in an increased cell death compared to incubation without ERT. 
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Figure 1: Erythritol attenuates cell death induced by diabetic stressors. Effect on viability of 
HUVECs incubated with normal glucose (NG, 7 mM) or high glucose (HG, 30 mM) in the 
presence or absence of erythritol (ERT, 5 mM) for 24 hours (A). Effect on viability of HUVECs 
incubated with HG in the presence of N
G
-nitro-L-arginine methyl ester (L-NAME, 0.1 mM and 
0.5 mM) and 3-morpholino sidnonimine (SIN, 0.5 mM) in the presence or absence of ERT (B) 
Effect of incubations on total cell number after 24 hours (C and D). Inset show data of 48 
hour incubation with ERT, HG or HGERT (n=1). Data are expressed as means ± standard error 
of at least three independent experiments. * = p < 0.05 compared to NG; ** = p<0.05 
compared to HG; *** = p < 0.1 compared to SIN .  
 
Effects on oxidative stress parameters 
Because hyperglycemia is strongly associated with oxidative stress, we investigated 
three parameters of oxidative stress. Firstly, the protein carbonyl content of the 
HUVECs was measured. Protein carbonyls are products of the reaction between 
proteins and reactive oxygen species. Though not significant,  a trend toward 
higher carbonyl content was visible after incubation with HG compared to NG 
incubation for 24 hours (figure 2B). Addition of 5 mM ERT showed a trend toward a 
lower protein carbonyl content (p=0.09). Next, the amount of malondialdehyde 
(MDA) in HUVECs was assessed. MDA is one of the end products of lipid 
peroxidation, a chain reaction in membrane lipids initiated by reactive oxygen 
species. Figure 2A indicates that incubation with 5 mM ERT, HG and HGERT does 
not increase the amount of MDA compared with HUVECs incubated with NG. 
Finally, the amount of oxidized nucleotide, in the form of 8-
hydroxydeoxyguanosine (8-OHdG) was determined. Incubation with HG for 24 
hours did not increase the amount of 8-OHdG (figure 2C). Furthermore, incubation 
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with 5 mM ERT with either NG or HG did not have an effect on the amount of 8-
OHdG in HUVECs. 
 
 
Figure 2: Effect on oxidative stress parameters. Effect of pre/coincubation with 5 mM 
erythritol (ERT) on HUVECS cultured in normal glucose (NG, 7 mM) or high glucose (HG, 30 
mM) for 24 hours on malondialdehyde (A), carbonyl (B) and 8-OHdG (C) content. Data are 
expressed as means ± standard error of three independent experiments. # = p<0.1 compared 
to HG.  
 
Effects on endothelial function 
Production of the vasoactive gaseous radical nitric oxide (NO) by NOS is one of the 
most important functions of the endothelium. In the endothelium this is 
predominantly the NOS3 isoform (3; 26). Therefore, we investigated the production 
of NO by HUVECs, which is shown in Figure 3A. When HUVECs were exposed to HG 
for 24 hours a 3-fold increase in NO release was observed (p=0.04). 
Pre/coincubation with ERT showed a trend toward lower NO production (p=0.06) 
compared to HG alone. Additionally, we looked at the effect of ERT on NOS3 
activity in lysates from HUVECs exposed to HG (figure 3B). No difference between 
the conditions was observed. High variability (either biological or assay specific) 
may have prevented changes from being statistically different. Figure 3C shows an 
increase in gene expression of NOS3 after 24 hours under HG conditions (p=0.03), 
which was attenuated by ERT (p=0.1).  
 
 
Figure 3: Effect on endothelial cell parameters. Effect of pre/coincubation with 5 mM 
erythritol (ERT) on HUVECS cultured in normal glucose (NG, 7 mM) or high glucose (HG, 30 
mM) for 24 hours on NO release (A), NOS3 activity (B) and NOS3 gene expression (C). Data 
are expressed as means ± standard error of at least three independent experiments. * = 
p<0.05 compared to NG; ** = p<0.05 compared to HG; # = p<0.1 compared to HG.  
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Eicosanoid analysis 
Eicosanoids formed from polyunsaturated fatty acids via classical cyclooxygenase 
and lipoxygenase pathways, as well as P450-derived epoxyeicosatreinoic acids 
(EETs) formed via soluble epoxide hydrolase (sEH) were measured in both cell 
pellets and culture medium (Figure 4 and supporting table 1). Thromboxane B2 
(TXB2) was increased in pellets of cells exposed to HGERT compared to HG alone in 
pellets (p=0.03). Both 8-HETE (p=0.05) and 12-HETE (p=0.03) were decreased in 
pellets from cells exposed to HGERT compared to HG alone. In supernatants we 
only found a decrease of excretion of 14,15-dihydroxy-5Z,8Z,11Z-eicosatrienoate 
(14,15-DiHETrE) by cells exposed to HGERT compared to cells exposed to only HG 
(p=0.04). Cells incubated with ERT excreted more 12,13-Dihydroxyoctadecenoic 
acid (12,13-DiHOME; p=0.01) and showed a trend towards less prostaglandin E2 
(PGE2; p=0.06) and prostaglandin D2 (PGD2; p=0.05) excretion compared to cells 
incubated without ERT.  
 
 
Figure 4: Effect on eicosanoid concentrations. Effect of pre/coincubation with 5 mM 
erythritol (ERT) on HUVECS cultured in normal glucose (NG, 7 mM) or high glucose (HG, 30 
mM) for 24 hours on eicosanoid concentrations in cell pellets (A) and culture medium (B). 
Data are expressed as means ± standard error of three independent experiments. * = p<0.05 
compared to NG; ** = p<0.05 compared to HG; # = p<0.1 compared to HG. 
 
Transcriptomic analysis 
The numbers and overlap of transcripts changed in response to three comparisons 
are shown by Venn diagram (Figure 5).  
 
ERT induced small but significant fold changes in many transcripts. Maximum fold 
changes for down regulation were 0.94-0.97; and for up regulation were 1.04-1.13. 
There were 521 transcripts changed in response to HGERT vs. HG (HGERT/HG; 
p<0.05). Numbers of transcripts down- and upregulated was similar (296 down, 225 
up). Comparing NGERT to NG (NGERT/NG), 194 transcripts changed. Only 6 
transcripts changed in common for HGERT/HG and NGERT/NG, often with a 
different directionality, and did not change in response to HG/NG. Without ERT, HG 
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alone (HG/NG) altered 434 transcripts. A striking observation was that under HG 
conditions, ERT reversed direction of change in 148 of the 153 transcripts changing 
in common with HGERT/HG and HG/NG, suggesting potential benefits of using ERT 
to ameliorate pathologies associated with hyperglycemia (figure 6). A subset of 
transcripts (368) were uniquely affected by HGERT/HG but not HG alone (HG/NG). 
 
 
 
Figure 5: Venn diagram of changed transcripts. Venn diagram showing the overlap of 
differentially expressed transcripts after pre/coincubation with or without 5 mM erythritol 
(ERT) of HUVECs cultured in normal glucose (NG, 7 mM) or high glucose (HG, 30 mM) for 24 
hours.  Changed transcripts of the following comparisons are shown: HGERT vs HG 
(HGERT/HG); NGERT vs NG (NGERT/NG) and HG vs NG (HG/NG). 
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Figure 6: Heat map of transcriptomic analysis. Heat map reflecting the mean gene 
expression values in the four different treatment groups: From left to right: high glucose 
(HG, 30 mM), normal glucose and 5 mM erythritol (NGERT), normal glucose (NG), high 
glucose and 5 mM erythritol (HGERT). Cluster analysis shows that the expression profile in 
the HG group differs from the other three treatment group that form a separate cluster. 
 
Discussion 
With this study we want to identify the mechanism(s) by which ERT exerts its 
endothelium-protective effect during diabetic stress, previously demonstrated in a 
diabetic rat model (11). Hydroxyl radical scavenging by ERT alone cannot explain 
the powerful in vivo protective effects. Therefore the potential protective effects of 
ERT were investigated in different areas via targeted (e.g. cell viability, oxidative 
stress parameters, endothelial function parameters) and transcriptomic profiling in 
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HUVECs. This cell line was chosen as a model because it has been used in a number 
of scientific studies into vascular inflammation, endothelial dysfunction and effects 
of hyperglycemia (27-31).  
 
The induction of apoptotic endothelial cell death by HG has often been described 
(32; 33) and is highly implicated in the development of diabetic complications. We 
showed that exposure of HUVECs to HG increased the number of dead cells, which 
could be prevented by ERT. This higher number of death cells under HG conditions 
seems to be caused by an increase in NO, because addition of the NOS inhibitor L-
NAME under HG conditions decreased the amount of dead cells. The involvement 
of NO in glucose toxicity has been described previously (34-36). Another indication 
of the involvement of NO in endothelial cell dead was found when HUVECs were 
incubated with the peroxynitrite generator SIN-1. We showed that SIN-1 induced 
cell death, which was attenuated by ERT. Specifically for endothelial cells during 
diabetes, this is an important finding since peroxynitrite formation is likely to be 
increased during diabetes. Peroxynitrite is generated by the reaction of superoxide 
radicals with nitric oxide (37), the production of these precursors is known to be 
increased during diabetes (38; 39). Peroxynitrite can induce lipid peroxidation and 
protein nitrosylation and thus plays a role in diabetes related tissue damage (40). In 
a previous study, ERT was shown to have peroxynitrite scavenging activity in an in 
vitro system (41). 
 
Subsequently, we looked at the ability of ERT to reduce oxidative damage caused 
by HG in HUVECs. Many studies have demonstrated that hyperglycemia triggers 
oxidative stress and generation of free radicals (1; 33; 42; 43). These radicals cause 
damage to membranes, proteins and DNA resulting in cellular dysfunction and 
death. Radical scavenging by ERT reduces damage which may contribute to its 
endothelial protective effect. In HUVECs exposure to HG resulted in higher protein 
carbonyl levels while MDA and 8OHdG levels were not increased. This indicates 
that oxidative damage in HUVECs due to HG is concentrated in the cytosol. Since 
the majority of the proteins in the cell are located in the cytosol and therefore in 
the vicinity of the source of the high-glucose-induced oxygen radicals, it is likely 
that oxidative damage will probably be noted first as oxidized proteins as we 
observed with these results.  
 
ERT did not affect NOS3 activity in HUVECs. Remarkably, the release of nitric oxide 
and the expression of the NOS3 gene were increased after incubation with high 
glucose only. This is in perfect agreement with the observation of Pandolfi and 
many others, who observed that HUVECs from human and animal origin display 
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increased NO production and NOS3 gene expression (39; 44). How this relates to 
endothelial dysfunction, which is commonly regarded to be the result of impaired 
NO production, is currently unknown, although it has been suggested that the 
increased NO levels influence the transcription of genes that affect adenosine 
uptake by endothelial cells (39). 
 
Eicosanoids are potent inflammatory mediators triggered by oxidative stress 
and/or hyperglycemia. Even small changes in amount of these bioactive molecules 
could be biologically important. Differences in concentration of TXB2, 8-HETE and 
12-HETE were observed in cell pellets. Especially the decrease of 12-HETE in 
presence of ERT is of interest since it is a pro-inflammatory molecule produced 
from arachidonic acid via 12-lipoxygenase (12-LO) (45). Oxidative stress and HG 
incubations of endothelial cells have been shown to increase 12-HETE and diabetic 
pigs with elevated blood glucose have increased 12-HETE (46). In monocytes, HG 
increased 12-HETE and monocyte adhesion to endothelial cells via monocytic 
production of integrins (47). In endothelial cells, 12-HETE induced integrin 
production in a PKC-dependent manner (48). Exposure of endothelial cells to 12-
HETE decreased production of vasodilatory PGI2 (49). In culture medium we found 
differences in 14,15-DiHETrE which is produced from arachidonic acid via Cyp 2C 
and 2J to form EETs, which are in turn converted to DiHETrE via sEH. The decrease 
in 14,15-DiHETrE we found is consistent with HG suppression of sEH (50), resulting 
in increased EETs and EET-induced vasodilation. EETs were not observed to be 
increased in our system. Comparing ERT exposed cells to non-ERT exposed cells we 
also found some differences in the supernatants between molecules involved in 
mitochrondial dysfunction (12,13-DiHOME) and vasodilation and inflammation 
(PGE2 and PGD2) (51). These findings indicate that various biologically important 
eicosanoids may mediate ERT effects under both NG and HG conditions in HUVEC 
cells. 
 
To explore how ERT affected HUVECs on a transcriptional level we performed 
microarray analysis. We found several transcripts related to endothelial function to 
be altered when comparing HG to NG incubations including Bmp4, Vegfc and Ccl2 
(table 1). Bmp4 is a member of the bone morphogenetic protein family, which is a 
part of the TGFβ superfamily of growth and differentiation factors.  n endothelial 
cells, BMP4 produces a pro-inflammatory gene product inducing icam-1 and 
monocyte adhesion via NFκB signaling (52). When overexpressed, BMP4 may 
contribute to endothelial dysfunction,  promoting ROS production and apoptosis 
(53). Vegfc is a PDGF/VEGF family member with roles in angiogenesis and 
endothelial cell growth. Ccl2 transcribes a chemotactic factor attracting monocytes 
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and basophils. Other transcripts are involved in endothelial aggregation (pear1 
(54)) and vasodilation (edn1). Also, HGERT and HG comparisons resulted in altered 
transcripts linked to endothelial function. These transcripts were involved in 
apoptosis (bmp6, highly expressed in HUVECs (55)), focal adhesion (jup, foxc1, 
krit1), differentiation and proliferation (notch1).  
 
Table 1: Altered transcripts with a link to endothelial function. 
Entrez gene name Transcript HGERT/HG HG/NG 
Chemokine (C-C motif) ligand 2 ccl2   1.04 
Endothelin 1 edn1   0.99 
Endoglin eng 1.01 0.98 
Forkhead box C1 foxc1 1.01   
Growth factor receptor-bound protein 10 grb10   0.99 
KRIT1, ankyrin repeat containing krit1 0.99   
Notch 1 notch1 1.02   
Platelet endothelial aggregation receptor 1 pear1   0.99 
Ras homolog gene family, member J rhoj 1.02   
Tumor necrosis factor, alpha-induced protein 1 
(endothelial) 
tnfaip1   0.99 
Vascular endothelial growth factor C vegfc   1.04 
Bone morphogenetic protein 4 bmp4   0.99 
Bone morphogenetic protein 6 bmp6 1.01   
 
Transcripts related to apoptosis are shown in table 2. Under HG, ERT signaled via 
numerous pro- and anti-apoptotic pathways. As ERT protects endothelial cells from 
cell death under HG conditions (figure 1A), it seems that ERT has anti-apoptotic 
effects and that posttranslational modifications of transcribed proteins and 
dimerization events may explain why pro-apoptotic transcriptomic changes seem 
to have occurred (Table 2). 
 
Over-represented canonical pathways included (table 3): tricarboxylic acid cycle 
(TCA) cycle, TGF beta signaling pathway, glutathione metabolism and 
glucuronidation. Non-canonical networks included P K R1, NFκB, HNF, XBP1,    , 
and RELA. These canonical and non-canonical pathways are linked to diabetes 
onset, insulin signaling and production of adhesion molecules/nitric oxide. Of 
particular interest are changes in the TCA cycle and electron transport chain, 
changes of transcripts are shown in table 4. Pyruvate dehydrogenase (PDH) 
complex transfers the acetyl group of pyruvate to coenzyme A prior to the citric 
acid cycle. A very slight up regulation with HG/NG for pyruvate dehydrogenase 
(lipoamide) beta (pdhb), encoding the E1 beta subunit responsible for pyruvate 
dehydrogenase activity was observed. 
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Table 2: Altered transcripts with a link to apoptosis. 
Anti-apoptotic Pro-apoptotic 
Pathway Transcript HGERT/HG HG/NG Pathway Transcript HGERT/HG HG/NG 
AKT /Bad  pik3r1 1.03   Caspase hip1 1.05   
AKT/FRAP1 ddit4l 0.97   Cell cycle maged1 1.01   
BLK elf2 0.99 1.01 Cell 
cycle/CDK 
ccni 1.01   
Caspase hspe1 0.99   Cell 
proliferation 
pdcd7 1.02 0.99 
Caspase ifi6 1.13   Cell 
proliferation 
ubn1 1.02   
Cell 
proliferation 
Furin 1.02   DNA repair rrm2b 0.98   
DNA repair actr5 1.01   FOX foxn3 1.01 0.99 
FOX foxc1 1.01   FOX foxp1 1.01   
Impedes cyt 
c release 
Gsn 1.03   HER-2/NEU casc4 0.99 1.01 
JNK/SAPK Mbip 0.98   JNK/SAPK map4k3 0.98   
p38 MAP 
kinase 
stk39 0.98   JNK/SAPK sos1 1.06 0.94 
P53/XIAP 
inhibition 
notch1 1.02   MYC family mxd4 1.02 0.98 
RAS rsu1 0.99   P53/CDK ccnk 1.01   
RAS rhob 1.02 0.97 P53 rybp 1.01 0.99 
RAS rhoj 1.02   P53 tp53bp2 1.01   
RAS rab3b 1.07   P53 tbrg1 1.02 0.98 
TGFβ acvr2a 0.99   P53 tp53i11 1.02 0.98 
TGFβ bmp6 1.01   RAS rassf2 1.01 1.03 
 eng 1.01 0.98 WNT hbp1 0.99   
 atxn3 0.99     dap 1.01   
 pdcd6 0.99     serinc3 1.01 0.99 
 socs3 1.01     sox4 1.01 0.99 
 txndc5 1.03     lyn 1.02 0.99 
 
Branched-chain alpha-keto acid dehydrogenase complex (BCKD), analogous to the 
PDH complex, is an inner-mitochondrial enzyme complex responsible for the 
degradation of branched-chain amino acids (e.g. isoleucine, leucine, and valine). It 
converts α-keto acids to acyl-CoA + CO2 and requires thiamine pyrophosphate 
(TPP), FAD, NAD
+
, lipoate and coenzyme A as cofactors. BCKD complex contains 24 
core transacylase (E2) subunit and associated decarboxylase (E1), dehydrogenase 
(E3) and regulatory subunits. The lipoamide acyltransferase (or transacylase) E2 
subunit component of BCKD is encoded by dihydrolipoamide branched chain 
transacylase E2 (dbt). DBT was slightly up regulated with HGERT/HG. Succinate CoA 
synthetase converts succinyl CoA and ADP or GDP to succinate and ATP or GTP. 
Succinate-CoA ligase, ADP-forming, beta subunit (sucla2) was down regulated with 
HGERT/HG, and up regulated with HG/NG. Transcripts coding for other subunits 
such as suclg1 (αsubunit) and suclg  (β subunit) were not affected by treatments. 
In the next reaction in the citric acid cycle, succinate dehydrogenase converts 
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succinate to fumarate in an oxidation step. Succinate dehydrogenase is unique 
amongst citric acid enzymes, in that it is a nonheme iron protein located in the 
inner mitochondrial membrane, directly linked to electron transport. Two electrons 
from FADH2 are transferred to FeS clusters on the enzyme which are in turn 
transferred to ubiquinone (coenzyme Q) and then molecular oxygen. Fumurase 
then converts fumurate to malate, which is in turn oxidized to oxaloacetate by 
malate dehydrogenase, using the reduction of NAD
+
 to NADH. Ubiquinone binds in 
a gap between subunits B, C, and D. Succinate dehydrogenase (sdh) consists of 2 
hydrophilic subunits (A, B) and 2 hydrophobic membrane anchor subunits (C, D) 
with phospholipid binding sites for cardiolipin (CL) and phosphatidylethanolamine 
(PE). Transcripts coding for the hydrophilic domains (sdha, sdhb) were not affected. 
Succinate dehydrogenase complex, subunit C and D (sdhc and sdhd) were down 
regulated with HGERT/HG, and up regulated with HG/NG. 
 
Table 3: Top 10 pathways regulated by exposure of HUVECs to high glucose (HG effect) or to 
erythritol during exposure to high glucose (HGERT effect). 
Pathways regulated by exposure to high glucose Z Score 
TGF Beta Signaling Pathway 3.95 
Benzo(a)pyrene metabolism 3.35  
Pentose and glucuronate interconversions 3.26 
Glycosylphosphatidylinositol(GPI)-anchor biosynthe 3.07 
Diurnally regulated genes with circadian orthologs 3.05 
Prostate cancer 2.92 
Sphingolipid metabolism 2.75 
Pathways in cancer 2.58 
Antigen processing and presentation 2.48 
Caffeine metabolism 2.44 
Pathways regulated by erythritol during exposure to high glucose  Z Score 
Chronic myeloid leukemia 4.03 
Citrate cycle (TCA cycle) 3.88 
Delta-Notch Signaling Pathway 3.78 
Prostate cancer 3.24 
Androgen Receptor Signaling Pathway 3.09 
TGF-beta Receptor Signaling Pathway 2.86 
Glutathione metabolism 2.77 
Glucuronidation 2.61 
B cell receptor signaling pathway 2.48 
G13 Signaling Pathway 2.42 
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Electron transport occurs in the inner mitochondrial membrane via enzymatic 
reactions utilizing electron donors and acceptors. It is responsible for generation of 
ATP from products of the TCA cycle, fatty acid oxidation and amino acid oxidation. 
This pathway is tied to oxidative stress (and hyperglycemia via excess glucose 
equivalents entering the mitochondrial machinery) as a small percentage of 
electrons ’leak out’ resulting in superoxide formation. Numerous transcripts 
involved in electron transport (11) had slight down regulation with HGERT/HG, five 
of these were oppositely regulated with HG/NG (Table 2). Transcripts were 
changed in all 5 electron transport chain complexes. In complex I, NADH 
dehydrogenase, the subunits ubiquinone 1 alpha, subcomplexes- 4 (ndufa4) and 12 
(ndufa12) were down regulated with HGERT/HG. Ndufa4 was up regulated with 
HG/NG. Overactivity of the mitochondrial respiratory chains occurs during 
hyperglycemia (56), increasing transcription of complex II. This in turn increases 
electron leaking and production of superoxide radicals. Subunits C and D of 
complex II were down regulated with HGERT/HG, and up regulated with HG/NG 
(see also citric acid cycle). This countering of up regulation by ERT under HG 
conditions probably reduces superoxide production. The ability of ERT to prevent 
HG-induced increases in SDH suggests ERT may protect the mitochondria from 
oxidative damage via this mechanism. The reduction of coenzyme Q in complex III 
(cytochrome bc1 complex) can also contribute to oxidant production as highly 
reactive ubisemiquinone free radicals are formed as intermediaries in the Q cycle, 
leading to electron leakage and superoxide radicals  (57). In complex III, Ubiquinol-
cytochrome c reductase binding protein (uqcrb=qcr7; orthology to subunit 7) and 
ubiquinol-cytochrome c reductase, complex III subunit X (ucrc=uqcr10=qcr9) were 
down regulated with HGERT/HG. uqcrb was up regulated with HG/NG. In complex 
IV, cytochrome c oxidase (COX), subunits VB- (cox5b), VIIa- (cox7a2), VIIIA- (cox8a), 
and 16 (cox16) were down regulated with HGERT/HG (and not affected with 
HG/NG). COX assembly mitochondrial protein homolog (S. cerevisiae) (cmc1) is 
required for mitochondrial COX assembly and respiration. It binds copper, and may 
be involved in copper trafficking and distribution to COX and superoxide dismutase 
1 (SOD1) (58). Cmc1 showed slight up regulation with HG/NG (not changed with 
HGERT/HG). In complex V, ATP synthase, H
+
 transporting, mitochondrial F1 
complex, subunits- epsilon (atp5e) and 0 (atp5o) convert ADP to ATP, pumping 
protons across the proton-motive force. F1 complexes (and their 5 subunits) 
contain extra-membranous catalytic activity. F0 complexes contain the membrane-
spanning component comprising the proton channel, and contain 9 subunits. Atp5e 
was down regulated with HGERT/HG, and up regulated with HG/NG; atp5o was 
very slightly down regulated with HGERT/HG. ATP synthase, H
+
 transporting, 
mitochondrial Fo complex, subunit G (atp5l) was slightly up regulated with HG/NG 
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only.  
 
Table 4: Transcripts changed in citric acid cycle and electron transport system. 
Complex Transcript HGERT/HG HG/NG 
Pyruvate dehydrogenase Pdhb   1.01 
Succinate CoA synthetase sucla2 0.99 1.01 
Succinate dehydrogenase Sdhc 0.96 1.02 
 Sdhd 0.98 1.01 
Complex I NADH dehydrogenase ndufa4 0.99 1.02 
 ndufa12 0.99   
Complex II Succinate dehydrogenase Sdhc 0.96 1.02 
 Sdhd 0.98 1.01 
Complex III Cytochrome bc1 qcr7 (uqcrb) 0.99 1.01 
 qcr9 (ucrc, uqcr10) 0.99   
Complex IV cytochrome c oxidase cox5b 0.98   
 cox7a2 0.99   
 cox8a 0.99   
 cox16 0.99   
 cmc1   1.01 
Complex V ATP synthase atp5e 0.99 1.01 
 atp5o 0.99   
 atp5l   1.01 
 
Although there were considerable changes to electron transport transcripts, there 
was limited evidence from transcriptomic and targeted analyses that ERT acts like 
“classical” antioxidant in decreasing levels of oxidants via effects on glutathione 
peroxidases (gpx), peroxiredoxins (prdx), superoxide dismutases (sod), superoxides 
(alox, cyb, duox, ncf, nos), ROS metabolism and oxidative stress responsive genes. 
Based on transcript annotations, some transcripts are associated with ROS, 
including krit1, bmp4 and sh3pxd2b (increased), the latter with a role in NOX-
dependent ROS production. Also, transcriptomic changes related to the citric acid 
cycle and electron transport chain suggest ERT may reduce mitochondrial 
superoxide production through a novel mechanism. 
 
This study shows that erythritol has a large number of minor, often not reaching 
significance, beneficial effects in endothelial cells during exposure to high glucose. 
It is difficult to pinpoint a specific effect by which erythritol protects the cells during 
diabetic stress, and thus to explain why erythritol was capable of preventing the 
onset of endothelial dysfunction in the diabetic rat. However, it is more than likely, 
that the combination of all the effects displayed by erythritol is ultimately 
responsible for its extraordinary protective effect in vivo. 
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In conclusion, our present data point at a therapeutically important protective 
effect of ERT in endothelial cells. Overall, this study demonstrates that ERT by itself 
(i.e. under non-diabetic conditions) has minimal effects on HUVECs. Viability, 
oxidative damage, endothelial function parameters and the transcriptome do not 
show changes after incubation with ERT. However, when cells are exposed to HG 
following preincubation with ERT, a number of deleterious effects caused by HG 
are reversed. The observation that ERT does not affect single endpoints but has 
multi-targeted effects is not unusual for a natural compound. We have previously 
observed the same mode of action in other studies (59). Therefore, it is expected 
that in non-diabetic subjects ERT will not affect the endothelium which is a 
desirable property, while in diabetic subjects where the endothelium is under 
diabetic stress, ERT could shift a variety of damage and dysfunction parameters to a 
safer side. ERT can therefore be regarded as a compound that has definite 
endothelium protective effects during hyperglycemia.  
 
There is still a considerable need for safe agents that can reduce the risk of 
developing diabetic complications. These diabetic complications in general are the 
consequence of endothelium dysfunction. ERT can therefore be of great 
importance to a rapidly growing population of people with diabetes to reduce their 
risk of developing diabetic complications. 
 
Because diabetes is a chronic disease, supplementation with antioxidants to 
prevent the onset and development of diabetic complications will be chronic as 
well. Compounds with strong and explicit biological activities are probably not 
indicated in long term protection during diabetes. It is therefore important to 
choose a compound that has mild protective effects in small vessel and arteries 
because the endothelial cells are an important target of hyperglycemic damage. 
This study shows that ERT exerts many such beneficial effects on endothelial cells 
during exposure to diabetic stressors.  
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Abstract 
Angiogenesis, the formation of new blood vessels from pre-existing vessels, 
requires a strict balance between pro-angiogenic and anti-angiogenic factors. 
When the balance is disturbed, excessive angiogenesis can occur, a condition which 
has been associated with many diseases including diabetes. In this study we 
extended our previous studies on the endothelial protective diabetic-safe 
sweetener erythritol, to determine the influence of erythritol on high glucose 
induced angiogenesis. We used an endothelial cell model, exposed to normal and 
high glucose concentrations, in the presence or absence of erythritol. We examined 
secretion and expression of angiogenic factors and we determined the ability of the 
endothelial cells to form three-dimensional structures with a tube formation assay. 
We found that incubation with high glucose mainly induced expression and release 
of pro-angiogenic factors and it increased the rate of tube formation. Erythritol 
inhibited tube formation and decreased the expression of anti-angiogenic factors. 
Therefore erythritol could be of interest as a preventive and/or therapeutic target 
in the pathology of diabetic complications like diabetic retinopathy and diabetic 
nephropathy. 
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Introduction 
Angiogenesis is the the formation of new blood vessels from pre-existing vessels. It 
is a tightly controlled process in growth and development. However, in many 
diseases the body loses the control over angiogenesis, which can result in excessive 
or insufficient growth of new blood vessels. Excessive angiogenesis has been 
associated with many diseases including cancer, rheumatoid arthritis, psoriasis and 
diabetes (1).  
Diabetes is characterized by conditions such as chronic inflammation and oxidative 
stress which can stimulate angiogenesis, ultimately contributing to the pathology of 
micro- and macrovascular complications (2). For example, increased levels of 
vascular endothelial growth factor A (VEGFa) is a major cause of irreversible vision 
loss in diabetic retinopathy (3). Abnormal angiogenesis also play a role in diabetic 
nephropathy. High levels of transforming growth factor-β (TGF-β) and VEGFa lead 
to glomular hypertrophy, which in turn increases vascular permeability and cause 
extravasations of plasma proteins (4). Inhibition of pathological angiogenesis may 
benefit patients with these complications. 
Compounds to treat pathological angiogenesis should be selective (i.e. only 
effective against newly forming vessels), non-toxic and reversible when 
angiogenesis is needed (e.g. during wound healing). Research has shown that 
naturally occurring bioactive compounds like phenolics, carbohydrates, vitamins, 
lipids, peptides and proteins show anti-angiogenic capacity mainly by inhibiting 
enzymes involved in the process of angiogenesis (5). In previous studies we found 
that the natural diabetic-safe sweetener erythritol protected endothelial cells 
during exposure to high concentrations of glucose in vitro and prevented loss of 
endothelium dependent vasorelaxation in streptozotocin diabetic rats (6; 7). 
Extending these studies, we investigated the potential of erythritol to protect 
against high glucose induced angiogenesis.  
 
Material and methods 
Chemicals 
All chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) unless 
stated otherwise. F12K medium, Hank’s Balanced  alt  olution (HB  ), trypsin-
EDTA, non-heat inactivated fetal calf serum (FCS), and penicillin/streptomycin were 
obtained from Gibco (Breda, The Netherlands). Endothelial cell growth supplement 
(ECGS) was obtained from BD Bioscience (Breda, The Netherlands). Heparin was 
purchased from Leo Pharmaceuticals (Amsterdam, The Netherlands). 
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Cell culture 
Human umbilical vein endothelial (HUVEC) cell line CRL-1730 was obtained from 
ATCC. HUVECs were cultured in F12K medium with 10% non-heat inactivated FCS, 
1% penicillin/streptomycin, 0.05 mg/ml ECGS and 0,1 mg/ml heparin. Cells were 
maintained in collagen coated T75 flasks (Greiner Bio-one, Alphen a/d Rijn, The 
Netherlands) at 37°C in a 5% CO2 atmosphere. For experiments, cells were seeded 
in 6 well plates / T75 flasks and grown until 80% confluency. Next, medium was 
removed and cells were washed with HBSS. New medium and erythritol (final 
concentration 5 mM) or vehicle solution (medium) was added to the cells. After 1 
hour incubation glucose (final concentration 30 mM glucose) or vehicle (medium) 
was added to the cells. Subsequently, cells were incubated for 24 hours.  
 
Gene expression analysis 
RNA was isolated from Qiazol suspended cells according to manufacturer’s protocol 
and quantified spectrophotometrically with a Nanodrop. Reverse transcriptase 
reaction was performed using 500 ng of RNA, which was reverse transcribed into 
cDNA using iScript
TM
 cDNA synthesis kit (Biorad). Next, real time PCR was 
performed with a Biorad MyIQ iCycler Single Color RT-PCR detection system using 
Sensimix
TM
Plus SYBR and Fluorescein (Quantace-Bioline, Alphen a/d Rijn, The 
Netherlands), 5 µl diluted (10x) cDNA and 0.3 µM primers in a total volume of 25 
µl. PCR was conducted as follows: denaturation at 95°C for 10 minutes, followed by 
40 cycles of 95°C for 15 seconds and 60°C for 45 seconds. After PCR, a melt curve 
(60-95°C) was produced for product identification and purity. β-actin was included 
as internal control. Primer sequences are shown in table 1. Data were analysed 
using the MyIQ software system (BioRad) and were expressed as relative gene 
expression (fold change) using the 2
ΔΔCt
 method. 
 
Table 1: Primer sequences for genes used for gene expression analysis 
Gene Forward (5’ to 3’) Reverse (5’ to 3’) 
Beta-actin (β-actin) CCTGGCACCCAGCACAAT GCCGATCCACACGGAGTACT 
TIMP2 TCCTCTTGATAGGGTTGCCA CGTTTTGCAATGCAGATGTA 
TIMP3 ATGGTGTAGACCAGCGTGC AGGACGCCTTCTGCAACTC 
VEGFA AGCTGCGCTGATAGACATCC CTACCTCCACCATGCCAAGT 
VEGFC TGGACACAGACCGTAACTGC CGGACTCGACCTCTCGG 
ANG2 GCCACTGAGTGTTGTTTTCC CCTACGTGTCCAATGCTGTG 
MMP2 GGAAAGCCAGGATCCATTTT ATGCCGCCTTTAACTGGAG 
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Measurement of MCP-1, IL-6 and IL-8 
Culture medium was collected after incubation. Monocyte chemoattractant 
protein-1 (MCP-1), interleukin-6 (IL-6) and interleukin-8 (IL-8) in the supernatant of 
the cells were measured using the Bio-plex pro assay according to manufacturer’s 
instructions.  This assay uses antibodies coupled to magnetic beads which react 
with 50 µl supernatant. After a series of washes to remove unbound protein, a 
biotinylated detection antibody specific for MCP-1, IL-6 or IL-8 was added to the 
reaction. After 30 minutes incubation and several washes, a streptavidin-
phycoerythrin (streptavidin-PE) reporter complex was added to bind biotinylated 
detection antibodies. The plate was then read using the Luminex system and data 
was analyzed using the Bio-Plex Manager software
TM
. 
 
Tube formation assay 
The assay was performed with the Cultrex In Vitro Angiogenesis Assay Kit Tube 
Formation (Amsbio, Abingdon, UK). In short, we exposed HUVECs to normal (7 mM) 
or high (30 mM) glucose for 24 hours in the presence or absence of ERT. After 23 
hour incubation, 50 µl BME solution was added per well of a 96 well plate. The 
plate was incubated for 60 minutes at 37°C to allow gelatinization. Next, exposed 
cells were added to the well (concentration of 3 * 10
4
 cells). Tube formation was 
monitored by an inverted phase contrast microscope and pictures were taken by 
an attached digital output Olympus camera.  
 
Statistical analysis 
The effect of HG incubation and effects of erythritol were tested using  tudent’s t-
test for independent samples or the Mann-Whitney U test when not normally 
distributed. P-values <0.05 were considered statistically significant and p-values 
<0.1 were considered statistical trends. Statistical analyses were analyzed with SPSS 
for Windows (version 20.0; SPSS Inc., Chicago, IL, USA). 
 
Results  
After exposure of HUVECs to normal and high glucose concentrations for 24 hours, 
angiogenic factors in the culture medium were measured (figure 1). No effects on 
IL-6 concentrations were observed. Incubation with erythritol (under normal 
glucose conditions) and with high glucose showed an increase in IL-8 levels in the 
culture medium. The same effect was seen on MCP-1 levels, although here the 
increase due to incubation with high glucose was much higher (more than 10 
times). Pre/co incubation with erythritol did not reduce the increases in IL-8 and 
MCP-1 caused by high glucose. 
 
Chapter 7 
120 
 
 
Figure 1: Effect on cytokine levels in the supernatant of HUVECs pre/co incubated with 5 mM 
erythritol (ERT) in normal glucose (NG, 7 mM) or high glucose (HG, 30 mM) for 24 hours on 
levels of interleukin-6 (IL-6; A), interleukin-8 (IL-8; B) and monocyte chemotactic protein-1 
(MCP-1; C). Data are expressed as mean ± standard error of the mean (SEM) of at least three 
experiments. * = p<0.05 compared to NG. 
 
The gene expression of several angiogenic factors was also measured (figure 2). No 
effects were observed on the expression of angiopoietin2 (ANG2), matrix 
metalloproteinase 2 (MMP2), and vascular endothelial growth factor A (VEGFa). 
High glucose incubation increased the expression of VEGFC and showed a trend 
towards decreased expression of tissue inhibitor of metalloproteinases 3 (TIMP3). 
Pre/co incubation with erythritol showed a trend toward a lower expression of 
TIMP2, while it increased the expression of TIMP3 compared to high glucose 
incubation alone. 
  
 
Figure 2: Effect of pre/co incubation with 5 mM erythritol (ERT) on HUVECS cultured in 
normal glucose (NG, 7 mM) or high glucose (HG, 30 mM) for 24 hours on gene expression of 
angiopoietin2 (ANG2, A), matrix metalloproteinase 2 (MMP2, B), vascular endothelial growth 
factor A (VEGFA, C), vascular endothelial growth factor C (VEGFC, D), tissue inhibitor of 
metalloproteinases 2 (TIMP2, E) and tissue inhibitor of metalloproteinases 3 (TIMP3, F). Data 
are expressed as mean ± standard error of the mean (SEM) of at least three experiments. * = 
p<0.05 compared to NG; ** = p<0.05 compared to HG; # = p<0.1 compared to HG. 
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The effect of erythritol on angiogenesis was determined using an assay to measure 
the ability of endothelial cells to form three-dimensional structures, the tube 
formation assay. Cells incubated with high glucose before being put on gel showed 
a faster formation of the tubular network. After 4 hours a network is visible in the 
high glucose group, while the other conditions are still in a preliminary stage. After 
6 hours, the other conditions also show tube formation, but less pronounced than 
cells incubated with high glucose (figure 3).  
 
 
 
Figure 3: HUVECS were pre/co incubated with 5 mM erythritol (ERT) in cultured in normal 
glucose (NG, 7 mM) or high glucose (HG, 30 mM) for 24 hours after which cells were put on 
gelled BME to assess the effects on tube formation. Numbers on the left represent hours 
after cells were put on gelled BME. 
 
Discussion 
In this study we measured the effect of high glucose incubation on several steps of 
the angiogenic process. The angiogenic process consists of multiple steps and 
requires a balanced equilibrium between pro-angiogenic and anti-angiogenic 
factors (figure 4). First endothelial cell activation by angiogenic factors (e.g. VEGF) 
takes place. Activated endothelial cells secrete proteases (e.g. MMPs) which are 
capable to degrade the capillary basement membrane. Together with the proteases 
their inhibitors (e.g. TIMPs) are excreted to ensure local proteolytic activity. After 
membrane degradation, the endothelial cells migrate to angiogenic stimuli (e.g. 
released from wound-associated macrophages). Endothelial cell proliferation also 
occurs during this part of the process, which is mediated by cell adhesion 
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molecules. Subsequently, the new outgrowth of endothelial cells needs to 
reorganize into a three-dimensionally tubular structure. The endothelial cells will 
form a lumen and then pericytes and smooth muscle cells are recruited which are 
required for further stabilization (8).  
 
An increase of IL-8 release in the culture medium was observed. This is in line with 
findings in the literature that culturing endothelial cells in high glucose stimulates 
IL-8 production (9). IL-8 is known to be a potent promoter of angiogenesis. 
Biological effects of IL-8 on endothelial cells are concentration dependent, the 
chemotactic properties of IL-8 are lower at higher concentrations (10). Also MCP-1 
was highly induced by high glucose incubation. Stimulation of this chemokine by 
high glucose is in line with findings in different cell and animal models. (11-13). 
MCP-1 is also known to increase angiogenesis, through directly acting on 
endothelial cells but also via monocyte/macrophage recruitment and vessel 
formation (14). Pre/co incubation with erythritol did not lead to a decrease in 
release of IL-8 or MCP-1. However, when cells were incubated with only erythritol 
an increase in both IL-8 and MCP-1 was also observed, but to a lesser extent than 
incubation with high glucose.   
 
When looking into gene expression of angiogenic factors, high glucose induced the 
expression of VEGFc. This gene is a member of the VEGF family of growth factors. 
The main member of this family associated with angiogenesis is VEGFa, of which no 
changes in expression were observed. VEGFc has been associated with the 
development and remodeling of the lymphatic system (i.e. lymphangiogenic 
response). However, in the absence of lymphatic tissue VEGFc also induces 
angiogenesis (15). Pre/co incubation with erythritol did not show differences in 
VEGFc expression compared to high glucose incubation. 
 
Some effects were observed on the expression of the anti-angiogenic factors, 
namely the TIMPs. High glucose decreased the expression of TIMP3, which was 
reversed by pre/co incubation with erythritol. TIMP3 is a member of the TIMP 
family, which show MMP inhibiting capacity. TIMP3 is a potent angiogenesis 
inhibitor by not only inhibiting MMPs but it is also able to block the binding of VEFG 
to its receptor (16). The attenuation of decrease in TIMP3 expression by erythritol 
can therefore be seen as an anti-angiogenic effect.  
 
High glucose also seemed to induce a faster rate of tube formation of the 
endothelial cells. This has also been described in literature (17). Erythritol seemed 
to attenuate this effect, displaying another anti-angiogenic effect. Inhibition of tube 
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formation (and endothelial cell migration) by a dietary product like erythritol has 
also been shown for olive oil and red wine polyphenols. They reduced angiogenesis 
through MMP9 and COX-2 inhibition (18). Although, we did not look to protein 
expression and release of these components, we know that erythritol also 
influences release and expression of eicosanoids, including PGE2 which is involved 
in MMP-9 expression (6; 19). 
 
 
 
 
Figure 4: Effects of incubation with high glucose and erythritol on angiogenesis process 
found in this study. 
 
 
The objective of this study was to study the effects of erythritol on high glucose 
induced angiogenesis (figure 4). We observed some anti-angiogenic effects of 
erythritol, increased expression of TIMP3 and inhibition of tube formation, which 
indicates that erythritol is a potential anti-angiogenic compound. Therefore 
erythritol could be of interest as a preventive and/or therapeutic target in the 
pathology of diabetic complications like diabetic retinopathy and diabetic 
nephropathy. However, additional, more mechanistic, should be done to determine 
whether erythritol is a true anti-angiogenic compound.  
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Abstract 
Hyperglycemia, as occurring during diabetes, has a harmful effect on the function 
and development of beta cells. Consequently, chronic hyperglycemia will result in 
beta cell dysfunction and ultimately cell death. In previous studies erythritol, a 
polyol bulk sweetener, has been shown to prevent loss of ex vivo endothelium 
dependent vasorelaxation in diabetic rats and protect endothelial cells during 
exposure to high concentrations of glucose in vitro. Extending these studies, we 
investigated the potential of erythritol to protect beta cells against glucose induced 
cell death and beta cell dysfunction. The hamster beta cell line HIT-T15 was used as 
a model. After incubation with glucose (with or without erythritol) viability, insulin 
secretory function and expression of genes involved in apoptosis and insulin 
secretion were investigated. Incubation with glucose resulted in a dose-dependent 
decrease in viability of beta cells which was attenuated by erythritol. Additionally, 
erythritol inhibited high glucose induced hypersecretion of insulin. 
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Introduction 
Diabetes mellitus is one of the most prevailing chronic diseases worldwide. 
Generally, 90-95% of diabetes is type 2, which is historically regarded as a disease 
of the elderly, however the age of onset is decreasing (1).  Worldwide, there are 
almost 400 million people with diabetes, and this will only increase in the coming 
years (2). Type 2 diabetes is characterized by hyperglycemia, which is the result of 
deficiencies in insulin action and insulin secretion (3). 
Beta cell function is critical in the etiology of type 2 diabetes (4). Beta cells reside in 
the pancreas in clusters known as the islets of Langerhans. They are adapted to 
sense blood glucose levels and can adjust insulin secretion accordingly (5). Glucose 
is therefore a critical determinant of beta cell function. Prolonged exposure of beta 
cells to elevated levels of glucose is known to contribute to the development of 
beta cell dysfunction and ultimately beta cell apoptosis (6-8).  
Erythritol (1,2,3,4-butanetetrol; ERT) is a simple polyol that occurs naturally in 
some fruits and fermented food (9). It is 60-80% as sweet as sucrose (i.e. table 
sugar). However, unlike other polyols, more than 90% of ingested ERT is efficiently 
absorbed into the bloodstream in the small intestine and excreted unchanged in 
the urine. ERT is well tolerated and has no adverse effects, even after consumption 
of large quantities (10; 11). In addition, oral intake of ERT does not affect plasma 
glucose nor insulin levels, which makes it a useful and safe food component for 
patients with diabetes (12; 13). In previous studies ERT prevented loss of ex vivo 
endothelium dependent vasorelaxation in streptozotocin diabetic rats and 
protected endothelial cells during exposure to high concentrations of glucose in 
vitro (14; 15).  Extending these studies, we investigated the potential of ERT to 
protect beta cells against glucose induced dysfunction and cell death in the 
hamster beta cell line HIT-T15. 
 
Methods and materials 
Chemicals 
All chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) unless 
stated otherwise. Roswell Park  emorial  nstitute (RP  ) 16 0 medium, Hank’s 
Balanced Salt Solution (HBSS), trypsin-EDTA, non-heat inactivated fetal calf serum 
(FCS), and penicillin/streptomycin were obtained from Gibco (Breda, The 
Netherlands). ERT was kindly provided by Cargill (Vilvoorde, Belgium). 
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Cell culture 
HIT-T15 cell line CRL-1777 was obtained from American Type Culture Collection 
(ATCC). Cells were cultured in RPMI 1640 + Glutamax with 10% non-heat 
inactivated fetal calf serum and 1% penicillin/streptomycin (Gibco, Breda, The 
Netherlands). Cells were maintained at 37°C in a 5% CO2 atmosphere. For 
experiments, cells were seeded in 6 or 12 well plates. After overnight attaching, 
medium was removed and cells were washed with HBSS. New medium with ERT 
(final concentration: 5 mM) or vehicle (medium) was added to the cells. After 1 
hour incubation glucose (final concentration 30 or 45 mM) or vehicle (medium) was 
added. Subsequently, cells were incubated for 24 or 48 hours.  
 
Cell Viability 
After incubation, all cell material including medium and HBSS was collected and 
centrifuged (5 minutes, 500xg) and used to determine viability of the cells using the 
trypan blue exclusion assay. Cells suspensions were diluted 1:1 in 0.4% trypan blue 
dye and loaded in a Countess Chamber. Cells were counted and cell size was 
determined using the Countess Cell Counter (Life Technologies, Bleiswijk, The 
Netherlands). Population doubling time (PDT) was calculated with the formula: (t1 
– t0) /3.32 (log Ne – log Nb). Where t0 is the start of the incubation time and t1 is 
the end of the incubation time (in this case 48 hours), Nb is the cell number at the 
beginning of the incubation time and Ne is the cell number at the end of the 
incubation time. 
 
Insulin release assay 
Insulin release in response to glucose was evaluated in HIT-T15 cells preincubated 
to different concentrations of glucose in the presence or absence of ERT. After 24 
or 48 hour incubation, Krebs Ringer Bicarbonate buffer (118.5 mmol/l NaCl, 2.54 
mmol/l CaCl2, 1.19 mmol/l KH2PO4, 4.75 mmol/l KCl, 25 mmol/l NaHCO3, 1.19 
mmol/l MgSO4, 10 mmol/l HEPES, 0.1% BSA, pH 7.4) was added for 1 hour. 
Subsequently, cells were challenged with 16.7 mM glucose in Krebs Ringer 
Bicarbonate buffer for 1 hour. After the incubation, supernatants were collected 
and stored at − 0°C until the insulin determination was performed. Cellular insulin 
content was determined following overnight acid/ethanol extraction. Insulin was 
measured using an enzyme-linked immunosorbent assay using hamster insulin as a 
standard (Crystal Chem, Downers Grove, IL, USA). 
 
Gene expression 
RNA was isolated from Qiazol suspended cells according to the manufacturer’s 
protocol and quantified spectrophotometrically. Reverse transcription reaction was 
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performed using 500 ng of RNA, which was reverse-transcribed into cDNA using 
iScript cDNA synthesis kit (Biorad, Veenendaal, The Netherlands). Next, real time 
PCR was performed with a BioRad MyiQ iCycler Single Color RT-PCR detection 
system using Sensimix
TM
Plus SYBR and Fluorescein (Quantace-Bioline, Alphen a/d 
Rijn, The Netherlands), 5 µl diluted (10x) cDNA, and 0.3 µM primers in a total 
volume of 25 µl. PCR was conducted as follows: denaturation at 95
o
C for 10 
minutes, followed by 40 cycles of 95
o
C for 15 seconds and 60
o
C for 45 seconds. 
After PCR a melt curve (60-95
o
C) was produced for product identification and 
purity. Tubulin and β-actin were included as internal control. Primer sequences are 
shown in table 1. Data were analyzed using the MyIQ software system (BioRad) and 
were expressed as relative gene expression (fold change) using the 2
ΔΔCt
 method. 
 
Table 1: Primer sequences for genes used for gene expression analysis 
Gene Forward (5’ to 3’) Reverse (5’ to 3’) 
Tubulin CTCGCATCCACTTCCCTC ATGCCC TCACCCACGTAC 
β-actin ATGGATGACGATATCGCTGCGC AGTCCATCACAATGCCAGTGGT 
Bax AGAGGCAGCGGCAGTGAT CGATCCTGGATGAAACCCT 
PDX-1 CGCGTCCAGCTCCCTTT TGCCCACTGGCCTTTCC 
Insulin AGGACCCACAAGTGGAACAACT CAACGCCAAGGTCTGAAGGT 
 
Caspase 3/7 activation 
After 48 hour incubation cells were labelled with 5 µM Caspase 3/7 Green 
Detection Reagent (Life Technologies). Fluorescence was measured on a 
spectrofluorometer ( pectra  ax   ,  olecular Devices) with λex set at 502 nm 
and λem at 530. As a positive control, cells were incubated with 500 µM hydrogen 
peroxide (H2O2) for 1 hour.  
 
Statistical analysis 
The effect of high glucose (HG) incubation and effects of ERT were tested using 
 tudent’s t-test for independent samples or the Mann-Whitney U test when not 
normally distributed. P-values <0.05 were considered statistically significant and p-
values <0.1 were considered statistical trends. Statistical analyses were analyzed 
with SPSS for Windows (version 20.0; SPSS Inc., Chicago, IL, USA). 
 
Results 
The effect of incubating HIT-T15 with HG, ERT or a combination was investigated by 
evaluating the cell viability using trypan blue exclusion assay. When cells were 
incubated with HG for 24 hours no differences in viability were observed (figure 
1A). Longer HG incubation (48 hours) resulted in an almost 3-fold increase in the 
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percentage of dead cells, which was attenuated by addition of ERT (figure 1B). 
Moreover, under normal glucose conditions incubation with ERT did not result in 
differences in viability compared to incubation without ERT. Additionally, 
population doubling times (PDT) of the different conditions were determined, with 
an average PDT of 32 hours (figure 1C). No significant differences were found, 
though incubation with 30 mM glucose resulted in a slight non-significant decrease 
in PDT from an average of 32 hours to 29 hours. Also no difference in cell size was 
observed (figure 1D). 
 
Figure 1: Effect on viability of HIT-T15 cells incubated with 10, 30 and 45 mM glucose in the 
presence of absence of erythritol (ERT) for 24 hours (A) and 48 hours (B). For cells incubated 
for 48 hours population doubling time (C) and cell size (D) was determined. Data are 
expressed as mean ± standard error of four independent experiments. * = p< 0.05 compared 
to 10 mM (normal glucose); ** = p<0.05 compared to no ERT. 
 
Insulin release was induced by exposing the cells to 16.7 mM glucose after they had 
been incubated with different glucose concentrations for 24 or 48 hours. Results 
show that incubation with 30 and 45 mM glucose for 24 hours led to a dose 
dependent increase in insulin release (figure 2A). Incubation for 48 hours with 45 
mM glucose resulted in a lower insulin release (figure 2B). Glucose in combination 
with ERT did not result in a change of insulin release compared to normal glucose. 
Additionally, insulin content of the cells was determined after induction of insulin 
release by exposing the cells to 16.7 mM glucose (figure 2C). Average insulin 
content was ~2200 ng insulin per mg protein which is comparable to the reported 
insulin content of the cell line (~2600 ng/mg protein) (16).  
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Figure 2: Insulin secretion induced by exposure to 16.7 mM glucose of HIT-T15 cells cultured 
for 24 (A) or 48 (B) hours with 10, 30 or 45 mM glucose in the presence or absence of 
erythritol (ERT). Figure 2C represents the insulin content after inducing insulin release with 
16.7 mM glucose of HIT-T15 cells cultured for 48 hours with 10, 30 or 45 mM glucose in the 
presence or absence of ERT. Data are expressed as mean ± standard error of three 
independent experiments. * = p< 0.05 compared to 10 mM (normal glucose); ** = p<0.05 
compared to no ERT, ##= p<0.1 compared to no ERT. 
 
To explore mechanisms by which ERT can protect beta cells, we investigated the 
expression of genes related to apoptosis after 24 hour incubation. Incubation with 
45 mM glucose for 24 hours seems to lower the gene expression of insulin, while 
increasing the expression of the pro-apoptotic protein Bcl-2–associated X protein 
(BAX) (figure 3A and 3B). Expression of the anti-apoptotic and cytoprotective gene 
Pancreatic and duodenal homeobox 1 (Pdx1) seems to be induced after 24 hours 
incubation when cells were pre/coincubated with ERT (figure 3C). ERT in 
combination with 30 mM glucose also lowered the expression of insulin.  
 
 
Figure 3: Effect on gene expression of insulin (A), BAX (B) and Pdx1 (C) of HIT-T15 cells 
incubated with 10, 30 and 45 mM glucose in the presence or absence of erythritol (ERT) for 
24 hours. Data are expressed as mean ± standard error of three independent experiments. * 
= p< 0.05 compared to 10 mM (normal glucose); ** = p<0.05 compared to no ERT. 
 
To investigate the possible involvement of caspases in the observed cell death after 
48 hours, cells were labelled with a caspase 3/7 detection reagent. No significant 
changes in caspase 3/7 activation were observed in cells cultured with different 
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glucose concentrations for 48 hours. Incubation with 500 µM H2O2 for 1 hour 
(positive control) increased caspase 3/7 activation (figure 4). 
 
 
Figure 4: Effect on caspase 3/7 activation of HIT-T15 cells incubated with 10, 30 and 45 mM 
glucose in the presence or absence of erythritol (ERT) for 48 hours.  
 
Discussion 
In previous studies ERT has been shown to prevent loss of ex vivo endothelium 
dependent vasorelaxation in streptozotocin diabetic rats and protect endothelial 
cells during exposure to high concentrations of glucose (14; 15). The aim of the 
experiments described in this paper was to investigate the ability of ERT to prevent 
HG induced cell death and cell dysfunction in another cell type that plays an 
important role in diabetes, the pancreatic beta cell. 
 
We observed an increase in the amount of dead cells when the cells were 
incubated with 45 mM glucose for 48 hours. This is in line with other studies which 
observed that chronic exposure to HG results in beta cell death (17; 18). When the 
demand for insulin is high, beta cells compensate to restore glucose homeostasis 
by increasing their number (hyperplasia) and size (hypertrophy) (19). Additionally, 
glucose itself is an important regulator of beta cell proliferation (20-22). We 
determined the cell size of HIT-T15 after 48 hours incubation, but we did not detect 
any changes between the conditions.  Neither did we observe any significant 
changes the rate of proliferation. However we saw a slight decrease in PDT when 
cells were incubated with 30 mM glucose for 48 hours. Although PDT is not the 
best method to measure this, it could indicate a higher rate of proliferation in these 
cells, which is in line with the observation that glucose stimulates proliferation.  
 
It is known that when the need for insulin secretion is higher than normal (e.g. 
during hyperglycemia), an increased beta cell glucose sensitivity occurs as a 
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compensatory mechanism. This leads to hypersecretion of insulin (i.e. more insulin 
is secreted than normally would be expected for the level of glycemia). Continuous 
overstimulation of the beta cells will eventually lead to a depletion of insulin stores, 
subsequently leading to a reduced insulin secretion and a deterioration of beta cell 
function (23; 24). In our in vitro system insulin release was induced by exposing the 
cells to 16.7 mM glucose after they had been incubated with different glucose 
concentrations for 24 or 48 hours. Results show that incubation with 45 mM 
glucose for 24 hours led to a hypersecretion of insulin, which was attenuated by 
pre/coincubation with ERT. This hypersecretion of insulin was not observed when 
cells were incubated for 48 hours, in contrast, cells incubated with 45 mM glucose 
showed a non-significant decrease in insulin release which may be indicative of 
depletion of insulin stores. Pre/coincubation with ERT kept insulin release levels in 
the normal range. On transcriptional level we also found a decrease in expression 
of insulin when cells were incubated with 45 mM for 24 hours, this was not found 
when cells were pre/coincubated with erythritrol. ERT in combination with 30 mM 
glucose also lowered the expression of insulin after 24 hour incubation. However, 
we did not see any effects on the functional insulin release assay in this condition. 
It is possible that this decrease in insulin expression is compensated by expression 
or activity of enzymes involved in insulin biosynthesis. Since hypersecretion of 
insulin can deplete insulin stores, we also determined the insulin content of the 
cells after 48 hour exposure. No significant changes were observed, it might be that 
changes in insulin content will appear after longer incubation times.  
 
The decrease in insulin release after 48 hours occurred at the same time as the 
decrease in cell viability. It might be that beta cell dysfunction plays a role in the 
observed cell death after 48 hours. Beta cell apoptosis is thought to play an 
important role in the progression of type 2 diabetes (17), so we determined the 
expression of several genes involved in apoptosis. BAX is found in the cytosol of all 
living cells. Upon initiation of apoptotic signalling, BAX undergoes a conformation 
shift after which it inserts into mitochondrial membranes. This results in the release 
of cytochrome C and other pro-apoptotic factors into the cytosol, subsequently 
leading to activation of caspases (25; 26). It was found that in isolated human islets 
BAX showed a higher expression compared with Bcl-2 (27). We also found gene 
expression of BAX but hardly any detectable gene expression levels of Bcl-2 (data 
not shown). The expression of BAX was increased in cells incubated with 45 mM for 
24 hours, which also showed a decrease in viability after 48 hours incubation. It is 
possible that 45 mM glucose shifted the balance between pro- and antipoptic 
signals towards apoptosis, which could also explain the observed cell death. The 
expression of BAX was also increased when cells were incubated with ERT alone. 
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Because we do not see any effects of ERT incubation on cell viability or cell 
function, the observed increase did not result in any damaging effects. 
 
The gene Pdx1 encodes a transcription factor which plays a key role in pancreatic 
development, mature beta cell function and insulin signaling (28). Chronic 
hyperglycemia leads to a decrease in Pdx1 expression (29). Downregulation of this 
gene impairs glucose stimulated insulin secretion (28). We observed an increase in 
Pdx1 expression when cells were incubated with 30 mM glucose and ERT compared 
to cells incubated with 30 mM glucose alone. Due to its role in many processes 
concerning maintenance of beta cell neogenesis, differentiation and apoptosis the 
increase in Pdx1 expression can be seen as protective. 
 
Caspase 3 is a key mediator of apoptosis in mammalian cells. Exposure of the beta 
cell line MIN6N8 to HG induced cell death mediated by caspase 3 activation (17). 
Caspase 3 can be activated by Bax (30), so we performed an assay to detect 
caspase 3 and its downstream target caspase 7 activation in our cells. We used a 
detection reagent which does not require wash steps, this helps preserve fragile 
apoptotic cells commonly lost during wash steps. This assay allows live cells 
monitoring of caspase 3/7 activation. No significant differences in caspase 3/7 
activation after 48 hours were observed, however, it is possible that longer 
incubation time will lead to a more pronounced effect on caspase activation. Other 
types of cell death like necrosis and autophagy have also been linked to reduced 
beta cell mass in diabetes (19). It is possible that these types also play a role in the 
increase of death cells in our system, since trypan blue does not distinguish 
between necrotic and apoptotic cells.  
 
In conclusion, this study shows that ERT protects beta cells under HG conditions. 
ERT prevented HG induced cell death. Moreover, cells incubated with ERT did not 
display increased glucose sensitivity and hypersecretion of insulin, which implies 
that ERT prevented beta cell dysfunction. These data extend our previous findings 
that ERT can prevent diabetic complications. As in our previous studies in 
endothelial cells, we observed that ERT was able to attenuate damage and improve 
function. ERT can therefore be regarded as a compound that can have protective 
effects during HG conditions on multiple targets (e.g. endothelium, pancreas). 
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Abstract 
Diabetic complications have been linked to oxidative stress and inflammation. In 
this pilot study we determined the effects of chronic, acute and acute-on-chronic 
effects of consumption of erythritol on plasma levels of oxidative stress and 
inflammatory markers. Twenty four type 2 diabetic subjects consumed 36 grams (3 
x 12 grams) erythritol daily for 4 weeks. In addition, acute and acute-on-chronic 
effects were determined by taking blood samples before and two hours after 
subjects consumed 24 grams of erythritol as a single dose. TEAC, as a marker of 
overall systemic oxidative stress, and malondialdehyde (MDA), as a marker of lipid 
peroxidation, were measured. Chronic consumption of erythritol slightly decreased 
MDA levels in the plasma. Acute consumption lowered TEAC values, which could be 
attributed to a decrease in uric acid levels. Several cytokines were measured as 
markers of inflammation. No chronic effects were observed, but acute 
consumption lowered the concentration of IL-1β,  L-10, IL-5 and IFN-γ.  L-4 and IL-
13 showed a trend towards decreased concentrations. These acute changes are 
promising, but they are not found after chronic consumption, suggesting a limited 
effect of erythritol. The absence of a control group and the variety of diabetic 
treatments taken by the subjects of the study make interpretation of the data 
difficult. Validation of these findings will therefore require a randomized, placebo-
controlled study. 
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Introduction 
Diabetes is a major global health problem. It has almost 400 million patients 
worldwide, and this number will only increase in the coming years, leading to an 
even heavier social and economic burden (1). Diabetic patients are at risk of 
developing a number of disabling and life-threatening health problems, e.g. stroke, 
myocardial infarction and blindness (1; 2). Oxidative stress is linked to these 
complications (3; 4). Oxidative stress can lead to a depletion in antioxidant and 
indeed a reduced antioxidant capacity (lower trolox equivalent antioxidant capacity 
(TEAC)) is observed in type 2 diabetic subjects (5). Lipid peroxidation is one of the 
damaging processes induced by excessive radical formation. Malondialdehyde 
(MDA) is one of the products and has been shown to be related to the severity of 
diabetic complications (6).  Oxidative stress also causes an inflammatory response 
and inflammation has been shown to play a crucial in the pathogenesis of diabetic 
complications (7).  
Erythritol is a simple polyol compound, used as a low-calorie, tooth-friendly bulk 
sweetener. It has no impact on blood glucose or insulin levels, which makes a safe 
food component for diabetic patients (8; 9). Erythritol is an excellent hydroxyl 
radical scavenger in vitro and it delayed radical induced hemolysis in red blood cells 
(10). Furthermore, it protected endothelial cells during exposure to high 
concentration of glucose in vitro (11). Supplementation with erythritol reduced 
lipid peroxidation and prevented loss of endothelium dependent vasorelaxation in 
a rat model (10; 12). Extending these studies, we investigated the effects of 
erythritol consumption by type 2 diabetes patients on oxidative markers (plasma 
TEAC and MDA) and cytokine profile. 
Methods and materials 
Study design 
The pilot study design has been described in Flint et al. (13). Twenty four type 2 
diabetic patients with fasting glucose above 126 mg/dl or treatment with 
hypoglycemic drugs were enrolled. Enrolled subjects underwent testing at baseline 
and after four weeks of consumption of 36 grams a day of erythritol. Erythritol was 
supplied in packets of powder containing 12 grams of erythritol and orange 
flavouring dissolved in 8 oz of water, these packages were taken 3 times a day for 
four weeks. In addition, acute and acute-on-chronic effects were determined by 
taking blood samples before and two hours after subjects consumed 24 grams of 
erythritol as a single dose (figure 1). Blood samples were collected in heparinized 
tubes and centrifuged to obtain blood plasma. 
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Figure 1: Design of the study and coding used in text and tables. V1 t=0 is baseline sample; 
V1 t=2 is sample to study acute effect of consumption of 24 gram erythritol; V2 t=0 is sample 
to study chronic effect after consumption of 36 grams of erythritol per day for four weeks; 
V2 t=1 is sample to study acute-on-chronic effect of consumption of 24 gram erythritol.  
 
Antioxidant capacity measurement 
TEAC was assessed in plasma samples as an index of overall systemic oxidative 
stress. Plasma was deproteinized by the addition of 10% trichloroacetic acid to the 
plasma in a 1:1 ratio. The TEAC was determined in deproteinized plasma according 
to the method described in (14). The concentration of uric acid in deproteinized 
plasma was determined with HPLC using a Hypersil BDS C-18 end-capped column 
(Agilent, Palo Alto, CA) with UV detection at 292 nm. 
 
Malondialdehyde measurement 
MDA was determined in plasma by quantification of the formation of a colored 
TBA-MDA product. A calibration curve with MDA standards (0 – 10 µM) was run 
simultaneously to determine the concentration in the samples. Plasma (100 µl) or 
MDA standard (100 µl) were mixed with 1 ml of reagent, composed of 10 parts 
reagent A (12 mM TBA, 0.32 M phosphoric acid and 0.01 % EDTA) and one part of 
reagent B (1.5 mg/ml BHT in ethanol). Samples and standards were heated for 1 
hour at 99°C in a water bath. After cooling, 500 µl butanol was added and samples 
and standards were centrifuged for 5 minutes at maximum speed to extract the 
TBA-MDA product. The TBA-MDA product (100 µl) was then transferred into an 
opaque 96 well plate and fluorescence was measured on a spectrofluorometer 
(Spectra Max M2, Molecular Devices) with λex set at 5 0 nm and λem at 560 nm.  
 
Cytokine measurement 
Cytokines were determined in plasma using the Cytokine 10-plex panel (IL-1β,  L-2, 
IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IFN-γ and TNFα). This assay  was performed 
according to manufacturer’s instructions. This assay uses antibodies coupled to 
magnetic beads which react with 50 µl plasma. After a series of washes to remove 
unbound protein, a cytokine-specific biotinylated detection antibody was added to 
the reaction. After 30 minutes incubation and several washes, a streptavidin-
phycoerythrin (streptavidin-PE) reporter complex was added to bind biotinylated 
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detection antibodies. The plate was then read using the Luminex system and data 
was analyzed using the Bio-Plex Manager software
TM
. 
 
Statistical analysis 
Subjects with values below detection range (in the cytokine measurements) were 
not included in the analysis. In addition, Grubbs outlier test was performed to 
exclude values that skewed the data. For statistical analysis only subjects with 
measurement on all four time points were included. Chronic, acute and acute-on-
chronic effects were tested using a paired  tudent’s t-test or the Wilcoxon signed 
rank test when not normally distributed. Differences with P-values <0.05 were 
considered statistically significant and those with P-values <0.1 were considered 
trends. Statistical analysis was performed with SPSS for Windows (version 20.0; 
SPSS Inc., Chicago, IL, USA).  
 
Results 
Subjects 
The general characteristics of subjects in the study are depicted in table 1. Twenty-
four subjects completed the study. Average compliance with the study protocol 
was 90 ± 12 % based on count of empty sachets returned at  visit 2. No adverse 
effects were observed.  
 
Table 1: General characteristics of subjects in the study 
Characteristic Number of subjects (total number = 24) 
Age (years) 56 ± 5 
Male / female 11 / 13  
Black race 15 (63%) 
Weight (kg) 90.9 ± 16.8 
Body mass index (kg/m2) 30.3 ± 3.4 
 
TEAC 
One subject was excluded from analysis due to missing values. No effect of chronic 
consumption of erythritol was observed. Acute and acute-on-chronic consumption 
of erythritol led to a decrease in TEAC and uric acid concentration. When TEAC 
values were corrected for uric acid concentration, no differences were observed 
anymore (table 2).  
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Table 2: Plasma TEAC values. Data are expressed as mean ± standard deviation of 23 
subjects. *: P<0.05 
Time point TEAC (µM) Uric acid (µM) Corrected TEAC (µM) 
V1 t=0 463.90 ± 107 289.89 ± 71 174.02 ± 41  
V1 t=1 450.48 ± 99
* 
274.87 ± 67
* 
175.61 ± 40 
V2 t=0 468.52 ± 118 291.64 ± 80 176.88 ± 44 
V2 t=1 453.31 ± 115
* 
279.21 ± 77
* 
174.09 ± 44 
 
MDA levels 
Three subjects were excluded from analysis due to missing values. Consumption of 
erythritol for four weeks significantly lowered MDA levels by 4.7%. No acute effects 
or erythritol consumption were observed. Acute-on-chronic effect showed a trend 
towards higher MDA levels after consumption of erythritol (table 3). 
 
Table 3: Plasma MDA levels. Data are expressed as mean ± standard deviation of 21 subjects. 
*: P<0.05; #: P<0.1 
Time point Plasma MDA levels (µM) 
V1 t=0 1.60 ± 0.22 
V1 t=1 1.63 ± 0.24 
V2 t=0 1.52 ± 0.24
*
 
V2 t=1 1.58 ± 0.16
#
 
 
Cytokine levels 
Subjects with values below detection range of the assay were not included. Some 
subjects had 50-fold higher cytokine concentrations at all four time points, these 
were excluded after outlier testing. Only subjects with values at all four time points 
were included in the analysis (number is shown in table 4). Too few subjects had all 
four IL-6 and TNFα concentrations, so these cytokines were not included in the 
analysis.  No chronic effects on cytokine levels were observed. Acute consumption 
of erythritol significantly decreased the concentration of IL-1β,  L-5 and IL-10, with 
IL-1β and  L-10 also decreasing after acute-on-chronic consumption. IL-13 and IFN-γ 
showed a trend towards lower levels after acute consumption, with IFN-γ 
significantly decreased after acute-on-chronic consumption. IL-4 showed a trend 
towards lower levels after acute-on-chronic consumption.  
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Table 4: Plasma cytokines levels. Data are expressed as mean ± standard deviation. *: 
P<0.05; #: P<0.1 
Cytokine (pg/ml) V1 t=0 V1 t=1 V2 t=0 V2 t=1 
IL-1β (n = 15) 0.35 ± 0.06 0.29 ± 0.03
* 
0.35 ± 0.06 0.28 ± 0.05
* 
IL-2 (n = 9) 5.38 ± 4.73 4.18 ± 3.68 4.64 ± 3.53 4.55 ± 3.56 
IL-4 (n =12) 0.37 ± 0.06 0.34 ± 0.05 0.39 ± 0.07 0.34 ± 0.06
# 
IL-5 (n = 13) 5.42 ± 3.52 4.44 ± 2.49
* 
4.71 ± 2.37 3.85 ± 1.10 
IL-10 (n = 16) 4.04 ± 1.04 3.06 ± 0.66
* 
3.86 ± 0.97 3.30 ± 0.78
* 
IL-12 (n =17) 1.29 ± 0.66 1.25 ± 0.78 1.18 ± 0.48 1.33 ± 1.01 
IL-13 (n = 9) 0.82 ± 0.15 0.70 ± 0.16
# 
0.86 ± 0.22 0.77 ± 0.15 
IFN-γ (n = 13) 2.47 ± 0.78 2.04 ± 0.47
# 
2.66 ± 0.49 1.85 ± 0.53
* 
 
Discussion 
The objective of this study was to determine the effects of chronic, acute and 
acute-on-chronic consumption of erythritol on plasma levels of oxidative stress 
markers and cytokines. Previously, Flint et al. found that erythritol consumption 
reduced arterial stiffness and improved small vessel endothelial function (13).  
 
In this study we measured two markers of oxidative stress. TEAC as a measurement 
of overall systemic oxidative stress and MDA, an end product of lipid peroxidation. 
Consumption of erythritol caused an acute decrease in the TEAC value. However, 
these decreases can be completely attributed to a lowering of uric acid levels. This 
phenomenon has been observed before in food intervention studies (unpublished 
data from our lab). Uric acid is the final oxidation product of purine metabolism in 
humans. High levels of uric acid in serum have been related to type 2 diabetes, 
particularly to impaired glucose regulation (15; 16). These metabolic processes are 
expected to change quite rapidly after consumption of a sweet beverage in 
subjects that have fasted overnight. Since no control group was included in this 
pilot study, no speculations can be done about the effects of erythritol on this 
phenomenon. We did not determine the duration of the lowered uric acid 
concentration, however, there is no reason to assume that it lasts longer than a 
couple of hours. This implies that the TEAC is unchanged when monitored over 
longer time periods, as we observed in the chronic treatment. Erythritol does not 
scavenge ABTS radicals, so its presence in the plasma will not contribute to the 
plasma TEAC value.  
 
MDA is a marker for lipid peroxidation, a chain reaction in membrane lipids 
initiated by reactive oxygen species. We found that chronic consumption of 
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erythritol led to a slight, but significant, decrease in plasma MDA levels. This is in 
line with a previous observation by Yokozawa et al., who also found a decrease in 
lipid peroxidation markers in serum, liver and kidney of rats that received erythritol 
(12). It is known that erythritol can scavenge hydroxyl radicals and that it alters the 
expression of components of the mitochondrial electron transport chain, a major 
site of superoxide production (10; 11). These properties of erythritol might explain 
the decrease in MDA found in this study.  
 
No chronic effects were observed in the plasma concentration of several cytokines. 
At both visits, consumption of erythritol acutely decreased the levels of IL-1β and 
IL-10. IL-1β is a pro-inflammatory cytokine excreted by activated macrophages. 
Recent studies suggest a role for IL-1β in the induction of beta cell death in type   
diabetes. IL-1β release in islets can cause a vicious cycle of inflammation via self-
activation, most likely due to an imbalance with its natural antagonist IL-1Ra (17). 
In type 2 diabetes patients increased expression of IL-1β and decreased expression 
of IL-1Ra has been observed (18; 19). In clinical trials, blockade of IL-1β improved 
beta cell function (17). The observed acute effects of erythritol are promising, 
although we do not see an effect of chronic erythritol consumption on the 
concentration of IL-1β.  L-10 is an anti-inflammatory cytokine that is produced by a 
wide range of cell types involved in the immune response. Experiments with animal 
models suggest it to be a positive regulator of insulin sensitivity (20). We observed 
a decrease in IL-10 levels after acute erythritol consumption, but again no effects of 
chronic consumption of erythritol.  
 
Acute consumption of erythritol also decreased IL-5 concentrations. IL-5 is 
produced by mast cells and Th2 cells. It has a key role in eosinophil proliferation, 
differentiation, maturation, migration as well as in survival as it prevents eosinophil 
apoptosis. It is a prominently elevated cytokine in asthma but its role in diabetes is 
relatively little discussed (21). IFN-γ plasma concentrations were also lowered after 
acute consumption of erythritol. It is predominantly produced by natural killer and 
T effector cells. IFN-γ is critical in innate and adaptive immune responses as an 
important activator of macrophages. It has been implicated in the pathology of 
type 1 diabetes, but not much is known about its involvement in type 2 diabetes 
(22). IL-4 and IL-13 showed a trend toward lower concentrations after erythritol 
consumption. Both of these cytokines have been studied mainly in their 
involvement in type 1 diabetes. However, a recent study suggests that IL-13 
regulates glucose homeostasis, which could provide a new target to control 
hyperglycemia in patients with type 2 diabetes (23). 
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With some cytokines we observed a wide range of concentrations in the different 
subjects. This may be due to the variety of blood sugar lowering drugs taken by the 
subjects (table 5). This diversity renders the interpretation of the data to be 
difficult, as it might be that these drugs also influence the parameters measured in 
this study, especially the cytokines.  
 
Table 5: Clinical characteristics of subjects. ACE = angiotensin converting enzyme; ARB = 
angiotensin receptor blocker. 
Medical characteristic  Number of subjects 
Type 2 diabetes 24 (100%) 
Coronary artery disease  5 (21%) 
Hypertension 20 (83%) 
Cigarette smoking ever 9 (38%) 
Statin treatment 11 (46%) 
ACE inhibitor or ARB treatment 13 (54%) 
Beta blocker treatment 6 (25%) 
Calcium channel blocker treatment 4 (17%) 
Short-acting insulin treatment 1 (4%) 
Other oral diabetes treatment 21 (88%) 
Anti-platelet treatment 7 (29%) 
 
It can be concluded that erythritol consumption for four weeks by diabetic subjects 
reduces oxidative damage but does not change inflammatory status or plasma 
antioxidant capacity. The acute changes in cytokine levels are promising, but they 
are not found after chronic consumption, suggesting a limited effects of erythritol 
on these levels. The absence of a control group and the variety of diabetic 
treatments taken by the subjects of this study make interpretation of the data 
difficult. Validation of these findings will therefore require a randomized, placebo-
controlled study. 
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The major objective of the studies presented in this thesis was to examine the 
potential mechanisms by which natural compounds can help to attenuate or delay 
the onset of diabetic complications caused by high levels of glucose in the blood. 
After presenting an introduction on regulation of glucose homeostasis in chapter 1. 
We focused in chapter 2 and 3 on potential protective mechanisms by polyphenols. 
Chapter 4 was dedicated to potential mechanisms by which glucotoxicity can 
(indirectly) cause damage to beta cells. Chapters 5 to 9 concentrated on the 
various protective mechanisms of the polyol erythritol. 
Below, the most important findings are summarized and discussed. Additionally, 
potential implications and suggestions for future research are presented.  
 
Main Findings 
Polyphenols: compounds with pleiotropic effects 
In chapter 2 we investigated the effect of chronic PARP-1 inhibition on telomere 
stability. As PARP-1 may have a dual role on telomere shortening under conditions 
of chronic oxidative stress, we used the polyphenol fisetin and the antibiotic (and 
known PARP-1 inhibitor) minocycline to inhibit PARP-1 under conditions of chronic 
oxidative stress in an in vitro model using human fibroblasts. These two compounds 
were chosen because they showed a different mode of inhibition. Fisetin, at a 
concentration of 1 µM, showed a mild inhibition while minocycline, at a 
concentration of 100 nM, almost completely inhibited PARP-1. Chronic fisetin and 
minocycline treatment shortened telomeres under normal conditions. Therefore 
precaution should be taken when fisetin and minocycline are used on a regular 
basis, as it could reduce telomere stability and accelerate the rate of biological 
aging. However, under conditions of oxidative stress fisetin and minocycline 
treatment reduced the rate of telomere shortening, indicating that under these 
circumstances PARP-1 inhibition is beneficial.  
 
In chapter 3 we showed that flavonoids are able to protect endothelial cells against 
a drop in NAD
+
 levels caused by high glucose. In this study we used the structurally 
related polyphenols flavone, quercetin and rutin at a concentration of 5 µM. We 
showed that these polyphenols inhibit aldose reductase, the key enzyme of the 
polyol pathway. However, this characteristic appears to be less important in the 
protection of endothelial cells than their ability to prevent PARP-1 overactivation. 
Overall, we concluded that the combination of all these characteristics and other 
known properties (e.g. antioxidant) is most likely the reason why the polyphenols 
showed a protective effect on NAD
+
 levels in endothelial cells.  
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High glucose and the pancreatic beta cell 
In chapter 4 we describe a potential mechanism by which hyperglycemia can 
contribute to diabetic complications. High glucose levels lead to the formation of 
advanced glycation end products (AGEs) which can increase the production of 
reactive oxygen species. It is known that beta cells are particularly vulnerable to 
oxidative stress because of their low defense mechanisms. Therefore we 
investigated the effect of the AGE N
ε
-carboxymethyllysine (CML) on the glutathione 
system in beta cells. As was expected, CML incubation decreased GSH levels and 
affected other components of the glutathione system. Furthermore, it decreased 
viability and increased oxidative stress in the cells. Via this mechanism, 
hyperglycemia (via AGE formation) can accelerate beta cell dysfunction and 
increase beta cell death, thereby accelerating the severity of diabetes. 
 
Erythritol: a small polyol with big health effects 
In chapter 5 an overview of the health effects of the polyol erythritol is given. 
Erythritol is a non-toxic, well tolerated compound which possesses anti-cariogenic 
and antioxidant properties. Previously, it was shown that erythritol prevented loss 
of ex vivo endothelium dependent vasorelaxation in streptozotocin diabetic rats. 
Because its ability to scavenge hydroxyl radicals cannot solely explain this 
protective effect, we examined the effects of erythritol in endothelial cells exposed 
to normal and high glucose levels (chapter 6). We found that erythritol by itself 
showed no effects under normal conditions. However, under high glucose 
conditions erythritol reversed a number of harmful effects. On a transcriptomic 
level it reversed the direction of change of 148 of the 153 transcripts altered by 
high glucose incubation. In chapter 7 we focused on angiogenic effects of erythritol 
in endothelial cells. We found some anti-angiogenic effects of erythritol, which can 
be seen as beneficial as excessive angiogenesis, a condition occurring when the 
balance between pro-angiogenic and anti-angiogenic factors is disturbed, has been 
associated with many diseases including diabetes. In chapter 8 our scope was 
widened by examining the potential of erythritol to protect beta cells against 
glucose induced dysfunction and cell death. Again we showed that erythritol under 
normal conditions had little effect on the cells, while under high glucose conditions 
erythritol attenuated damage and improved function of the cells. Finally, in chapter 
9 we examined the effect of erythritol consumption in an in vivo study with type 2 
diabetes patients. We found that chronic erythritol consumption (for four weeks) 
did not change inflammatory status or oxidative stress markers, although a small 
reduction in malondialdehy (MDA) levels, a marker for lipid peroxidation, was 
observed.  
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Implications and suggestions 
Polyphenols: more is not always better 
Because it is generally assumed that polyphenols are healthy, they are often added 
to nutritional supplements, not seldom in relatively high amounts. As we described 
in chapter 2, exposure of cells to physiological doses of the polyphenol fisetin 
under relatively normal conditions caused an increase in the rate of biological aging 
of cells. Since biological effects of regular consumption of high doses polyphenols 
are not known, thorough safety evaluation is warranted with respect to these 
nutritional supplements. 
 
Some polyphenols have carcinogenic or genotoxic effects at high doses in animal 
studies (1; 2). For example, the isoflavone geneistein has been implicated in the 
development of breast cancer (due to its estrogen-like activity) and infant leukemia 
(due to its ability to inhibit the enzyme topoisomerase) (3; 4). In addition, some 
polyphenols affect thyroid function by inhibition of thyroid peroxidase and 
interference with thyroid biosynthesis (5).  
 
Antinutritional effects of polyphenols are also described. For example, polyphenol 
containing beverages such as tea can reduce non-heme iron absorption by 
formation of insoluble complexes. This will not cause trouble in people with 
adequate iron stores, but may increase risk of iron depletion in individuals with 
marginal iron status (6). Some polyphenols can affect drug bioavailability and 
pharmacokinetics. This has been thoroughly investigated for grapefruit juice. 
Furanocoumarins present in grape juice are metabolized by CYP3A4 to form 
reactive intermediates that subsequently form a covalent bond with the active site 
of CYP3A4, thereby causing irreversible inactivation. This is a serious condition 
because CYP3A4 is responsible for bioinactivation of 50% of all drugs. Currently, 
grape juice is known to interact with over 85 drugs, interactions with 43 drugs is 
known to cause serious adverse effects (7).  
 
Polyphenols present in foods and supplements generally are considered to be 
healthy, however precautions should be taken when polyphenols are consumed at 
high doses for a longer time period.  
 
Food as medicine? 
Supplementation with compounds to prevent or delay the onset of diabetic 
complications is most likely chronic. Therefore compounds with strong biological 
effects are less suitable for chronic supplementation. Alternative compounds with 
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mild protective effects, as those studied in this thesis, can therefore be of 
importance.  
 
The use of dietary compounds for the treatment of disease has become popular in 
recent years. For example, the inhibition of aldose reductase by compounds 
obtained from the diet, as described in chapter 3, has gained attention. Synthetic 
aldose reductase inhibitors showed promising results in vitro, but only a small 
number has reached the stadium of  clinical trials where they eventually failed due 
to hypersensitivity reactions and liver toxicity (8). These unwanted effects could be 
due to a low selectivity for aldose reductase versus the closely related enzyme 
aldehyde reductase. Aldose reductase inhibitors from dietary sources generally 
show a high specificity towards aldose reductase. In addition, they are considered 
to be safe, as most of them are currently used in preparation of food (9).  
 
Also the effects of dietary components on endothelial function have been more 
frequently investigated. Several human intervention studies show beneficial effects 
of polyphenols on endothelium function, in particular intake from food sources rich 
in flavan-3-ols (green tea and cacao) and anthocyanin (berries) (10; 11). The 
evidence for beneficial effects of other foods such as citrus fruit, apples and red 
wine is less consistent (12). The European Food Safety Authority (EFSA) has even 
awarded health claims to walnuts and cocoa flavanols. Consumption of 30 grams or 
more walnuts daily contributes to the improvement of elasticity of blood vessels 
(13). Consumption of 200 mg of cocoa flavanols daily helps maintan endothelium-
dependent vasodilation, which contributes to normal blood flow (14).  
 
Many studies focus on polyphenols with regard to beneficial effects on 
endothelium function. In this thesis we describe the endothelium protective 
capacity of the polyol compound erythritol. To our knowledge, this is the first time 
that a polyol has been linked to improved vascular function. This ability of erythritol 
has been found in vitro (chapter 6), in vivo (rat) studies (15) and in a clinical study 
with type 2 diabetes patients (16).  
 
Beta cells under attack 
Beta cells are important in diabetes as decreased beta cell number and function 
underlies much of the pathology of the disease. Responding to high glucose levels 
in the blood, beta cells increase the production of insulin until their insulin stores 
become depleted which results in inadequate insulin production (17). Genetic 
factors, as well as several pathways, including those related to endoplasmic 
reticulum and oxidative stress, are known to contribute to the ultimate failure of 
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beta cells to produce insulin (18; 19). However, not much is known about the effect 
of AGEs on the glutathione system, a major antioxidant defense system, in the beta 
cell (chapter 4). We provide evidence that hyperglycemia can decrease antioxidant 
systems in beta cells, leading to accelerated beta cell death.  
 
It is known that conventional diabetes treatments such as metformin and 
sulfonylureas do not prevent the progressive decline of beta cell function. As 
oxidative stress plays a major role in beta cell failure, antioxidant treatment, alone 
or in combination with available anti-diabetic drugs is potentially beneficial (19). 
Dietary sources may also prove to be effective in this case, but until now this has 
only been investigated in animal and in vitro models. In our studies we  observed 
that erythritol protected beta cells from high glucose induced cell death and 
dysfunction in vitro (chapter 8). Similar findings were observed for grape seed 
proanthocyanidins and lipoic acid (20; 21) 
 
Something sweet against the bitter effects of sugar? 
Recently, the World Health Organization (WHO) released a draft guideline to 
change its recommendations for sugar intake (22). Currently, the WHO 
recommends that sugars (those added to food, as well as natural sugars) should 
not make up more than 10% of the total energy intake per day, whereas the newly 
proposed guideline reduces this number to 5%. This comes down to about 25 
grams (6 teaspoons) of sugar for an adult with normal body mass index. Since most 
of the sugars consumed today are ‘hidden’ (e.g. a can of sugar-sweetened soda 
contains up to 40 grams of sugar) this seems to be difficult to achieve. The change 
in guidelines is due to scientific evidence that excess sugar consumption increases 
the risk of dental decay and obesity, ultimately leading to diseases like diabetes 
(23; 24). In the USA the consumption of added sugars has decreased between from 
100.1 g/day in 1999-2000 to 76.7 g/d in 2007-2008. This reduction could mainly be 
attributed to a decrease in soda consumption. However, the mean intake (14.6 % 
of daily energy intake) still exceeds the current recommendation (25). 
 
Due to the association of high sugar intake with health risks the intake of sugar 
substitutes has increased in the last decade, as they provide sweetness without 
significantly contributing to caloric intake. Consumption of these sugar substitutes 
in the USA has increased substantially among all age groups since 2000, with 28% 
of the total population reporting intake of sweeteners. The largest observed 
increases were found in beverage consumption among both children and adults 
(26). Sweeteners, specifically artificial sweeteners like aspartame, are often 
associated with health risks. This is a controversial area because there is much 
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conflicting research regarding artificial sweeteners. However, EFSA and the Food 
and Drug Administration (FDA) state that artificial sweeteners are safe at the levels 
currently used in food and drinks (27).   
 
A major part of this thesis focuses on the polyol erythritol. Erythritol is currently 
used as natural sweetener in beverages, chewing gum, chocolate, candies and 
bakery products. In consumer products erythritol is often mixed with Stevia 
extracts, derived from the South American Stevia Rebaudiana plant. Consumption 
of Stevia has been associated with lower postprandial insulin and glucose levels, a 
feature that could be helpful in managing postprandial hyperglycemia, an 
important contributor to the development of insulin resistance (28).  
 
The work described in this thesis and work previously described (15) show that 
erythritol is an excellent sugar substitute for diabetic patients. Not only does it 
reduce the glycemic impact of a snack or beverage, it can also help to reduce the 
onset and progression of diabetic complications by protecting the endothelium and 
pancreatic beta cells against the harmful effects of high glucose concentrations.  
 
Overall conclusion 
The research described in this thesis indicates that natural compounds exert 
multiple effects by which they can attenuate or delay the onset of diabetic 
complications. Although it is often difficult to pinpoint the exact molecular 
mechanism by which these compounds protect the cells in our studies, it appears 
to be a combination of multiple small effects that is ultimately responsible for the 
observed effects. 
 
Although this thesis focused on the deleterious effects of high glucose levels, which 
are linked to the development of diabetes and its complications, many of the 
mechanisms and pathways found to be affected in this thesis are also of 
importance in other diseases. For example, pathways which are transcriptomically 
affected by erythritol also play major roles in diseases like Alzheimer, prostate 
cancer, breast cancer and atherosclerosis. This opens up a wide range of other 
diseases in which long term supplementation with compounds with mild effects, as 
described in this thesis, may be beneficial.  
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In dit proefschrift staan studies beschreven die de mechanismen bestuderen 
waarmee natuurlijke stoffen kunnen helpen om het ontstaan van diabetische 
complicaties te vertragen of voorkomen. Deze diabetische complicaties kunnen 
ontstaan door hoge hoeveelheden glucose in het bloed. 
In hoofdstuk 1 wordt een introductie gegeven over de regulatie van glucose 
homeostase. In hoofdstuk 2 en 3 hebben we potentieel beschermende 
mechanismen van polyfenolen onderzocht. In hoofdstuk 4 hebben we onderzocht 
hoe glucosetoxiciteit (indirect) schade kan toebrengen aan bètacellen. In hoofdstuk 
5 tot en met 9 hebben we ons gericht op de verschillende beschermende effecten 
van het polyol erythritol. 
 
Belangrijkste bevindingen 
 
Polyfenolen: stoffen met pleiotrope effecten 
In hoofdstuk 2 hebben we het effect van chronische inhibitie van PARP-1 op 
telomeer stabiliteit onderzocht. Wij hebben de polyfenol fisetine en het 
antibioticum minocycline gebruikt om PARP-1 the inhiberen onder condities van 
chronische oxidatieve stress in een in vitro model met humane fibroblasten. Deze 
twee stoffen werden gekozen om hun verschil in werking. Fisetine, in een 
concentratie van 1 µM, vertoonde een milde inhibitie van PARP-1, terwijl 
minocycline, in een concentratie van 100 nM een bijna volledige inhibitie van 
PARP-1 vertoonde. We vonden dat chronische behandeling met fisetine en 
minocycline leidde tot kortere telomeren in vergelijking met cellen die gekweekt 
waren onder normale condities. Deze resultaten laten zien dat voorzichtigheid 
geboden is wanneer fisetine en minocycline op een reguliere basis worden 
gebruikt, aangezien ze telomeerstabiliteit kunnen reduceren en daarmee de 
snelheid van biologische veroudering kunnen versnellen. Onder condities van 
chronische oxidatieve stress vonden we echter dat fisetine en minocycline 
telomeerverkorting juist verminderde, wat betekent dat PARP-1 inhibitie onder 
chronisch oxidatieve stress omstandigheden juist voordelig kan zijn.  
 
In hoofdstuk 3 tonen we aan dat polyfenolen endotheelcellen kunnen beschermen 
tegen een verlaging in NAD
+
 concentraties, veroorzaakt door hoog glucose. In de 
studie gebruikten we de polyfenolen flavon, quercetine en rutine in een 
concentratie van 5 µM. We toonden aan dat deze polyfenolen het belangrijkste 
enzym van de polyol pathway, aldose reductase, kunnen remmen. In 
endotheelcellen lijkt dit kenmerk echter minder belangrijk dan de eigenschap van 
polyfenolen om PARP-1 overactivatie te voorkomen. We concludeerden dat de 
combinatie van al deze kenmerken en andere bekende eigenschappen (zoals de 
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werking als antioxidant) waarschijnlijk de reden is dat polyfenolen een 
beschermend effect op NAD
+
 concentraties in endotheelcellen lieten zien. 
 
Hoog glucose en de bètacel van de pancreas 
In hoofdstuk 4 beschrijven we een mogelijk mechanisme waardoor hoge 
glucoseconcentraties kunnen bijdragen aan diabetische complicaties. Hoge 
glucoseconcentraties kunnen leiden tot de vorming van advanced glycation end 
products (AGEs), die vervolgens weer kunnen leiden tot een verhoogde 
hoeveelheid reactieve vormen van zuurstof. Het is bekend dat bètacellen erg 
kwetsbaar zijn voor oxidatieve stress omdat ze weinig verdedigingsmechanismen 
hebben. Daarom onderzochten we het effect van de AGE N
ε
-carboxymethyllysine 
(CML) op het glutathion systeem in bètacellen. Behandeling van de cellen met CML 
leidde tot een verlaging van glutathion (GSH) concentraties en beïnvloedde ook 
andere componenten van het glutathion systeem. Eveneens verlaagde het de 
vitaliteit van de cellen en verhoogde de hoeveelheid oxidatieve stress. Via dit 
mechanisme kunnen hoge glucoseconcentraties (via vorming van AGEs) leiden tot 
een versnelde dysfunctie van de bètacel en een verhoging in dood van bètacellen.  
 
Erythritol: een kleine polyol met grote gezondheidseffecten 
In hoofdstuk 5 hebben we een overzicht gegeven van de gezondheidseffecten van 
erythritol. Het is een niet-toxisch, goed getolereerde stof die anti-cariogene en 
antioxidante eigenschappen heeft. In een vorige studie is aangetoond dat erythritol 
endoltheeldysfunctie in streptozotocine geïnduceerde diabetische ratten kon 
voorkomen. Omdat dit beschermend effect niet alleen kan worden uitgelegd door 
de eigenschap van erythritol om hydroxyl radicalen weg te vangen, hebben we de 
effecten van erythritol verder onderzocht in endotheelcellen die blootgesteld 
werden aan normale en hoge glucoseconcentraties (hoofdstuk 6). We vonden dat 
erythritol zelf geen effect had onder normale omstandigheden. Echter, in de 
situatie met hoge glucoseconcentraties kon erythritol enkele schadelijke effecten 
tegengaan. Op gentranscriptieniveau, veranderde het 148 van de 153 genen terug 
die beïnvloedt waren door hoog glucose. In hoofdstuk 7 hebben we het effect op 
endotheelcellen verder onderzocht, nu gericht op angiogenese, het fysiologische 
proces van nieuwe bloedvatformatie vanuit bestaande vaten. We vonden enkele 
anti-angiogene effecten van erythritol. Dit kan als voordelig worden gezien omdat 
overmatige angiogenese, een conditie waarbij de balans tussen pro-angiogene en 
anti-angiogene factoren verstoord is, geassocieerd wordt met verschillende 
ziektebeelden, inclusief diabetes. In hoofdstuk 8 hebben we onderzocht of 
erythritol bètacellen kan beschermen tegen door hoge concentratie glucose 
geïnduceerde celdood. Ook hier vonden we dat erythritol zelf weinig effect had op 
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de cellen, terwijl in de situatie van hoge glucoseconcentraties erythritol schade en 
celdood kon voorkomen. Tenslotte hebben we in hoofdstuk 9 het effect van 
erythritol consumptie onderzocht in een in vivo studie met type 2 diabetes 
patiënten. Chronische erythritol consumptie (4 weken) leidde niet tot 
veranderingen in markers van inflammatie of oxidatieve stress, hoewel een kleine 
vermindering in malondialdehyde (MDA) concentraties, een marker voor 
vetoxidatie, werd gevonden in het plasma. 
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Relevance 
The focus of this thesis is how natural compounds can influence the toxic effects of 
glucose. These toxic effects can arise during hyperglycemia, i.e. when glucose levels 
in the blood are high. Diabetes, one of the most prevailing chronic diseases has 
hyperglycemia as a hallmark. Diabetes is a global problem with over 380 million 
people worldwide suffering from the disease. For the Netherlands it is known that 
about 1 million people have diabetes (8.5% of the population), making it the most 
common chronic disease of the country. Also more regional in Limburg, the 
province where Maastricht University is located, diabetes has a high prevalence. In 
adults (up to 65 years) the prevalence is 5%, but in the age-group above 65 years 
more than 19% has diabetes. Since the population in Limburg is aging, this number 
will increase in the future.  
Many people with diabetes develop complications like cardiovascular disease, 
kidney and nerve damage. These can impose a large economic burden on 
individuals and families, but also on national health systems and countries. Global 
health spending for treatment of diabetes and management of the complications 
totaled at least 548 billion US Dollars, which is almost 11% of the total health 
expenditure worldwide in 2013. In the Netherlands the costs are at least 1 billion 
euro (in 2007). Complications due to diabetes are major causes of early death. In 
2013, diabetes caused 5.1 million deaths, which means that every six seconds a 
person died of diabetes. In the Netherlands about 2800 people die of diabetes each 
year.  
 
These numbers show that diabetes is a global health and economic problem. 
Reducing the development of complications by natural compounds, as described in 
this thesis, can therefore be of importance to reduce the health burden as well as 
the economic burden.  
 
Target Groups 
People suffering from diabetes are the most important group that can ultimately 
benefit from the research described in this thesis. Diabetic patients can obtain a lot 
of information about their disease and its treatments via their general practitioner, 
brochures or on the internet (figure 1).  Informing them through these channels 
about the potential beneficial effects of natural compounds is a possibility. 
However as also described in the discussion part, many of the pathways and 
mechanisms found to be affected in this thesis are also of importance in other 
diseases. This opens up a wide range of other diseases in which long term 
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supplementation with compounds with mild effects, as described in this thesis, may 
be beneficial.  
 
 
 
Figure 1: A selection of brochures that can be found at the GP practice to inform diabetic 
patients about the disease and its treatments. 
 
Activities/Products 
Compounds described in this thesis are already part of a normal diet. For example, 
consumption of erythritol from its natural occurrence in foods has been estimated 
to be 80 mg per day (~1.3 mg/kg body weight per day) in the United States. 
Erythritol intake from dietary sources in motivated groups (e.g. persons with 
diabetes) can increase to 4 grams per day (67 mg/kg body weight). In addition to 
intake via its natural sources, erythritol can also be consumed via its wide range of 
food applications. As erythritol also has the bulk sweetening properties of sugar, its 
use as a healthy choice for bakery products is also increasing and numerous recipes 
can be found online. The main intake of erythritol will most likely be via its use as 
table top sweetener or via soft drinks. This makes it relatively easy for diabetic 
patients to consume erythritol as a sugar substitute, to reduce the glycemic impact 
of a snack or a beverage but to also help to reduce the onset and progression of 
diabetic complications. 
 
Innovation 
Although the beneficial effects of polyphenolic compounds on endothelial function 
have been described before, this is the first time that a polyol has been linked to 
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improved vascular function. This ability of erythritol has been found in vitro, in vivo 
(rat) studies and in a clinical study with type 2 diabetes patients. 
 
The originality of this find, that a sweetener is able to protect the endothelial cells 
from the damaging effects of high glucose, was shown when the article about this 
research was published in Plos One. After publication, we received several requests 
for interviews about our research and the articles can be found on several Dutch 
websites, magazines and a newspaper (figure 3). The media coverage also showed 
that the public was very interested in this research, as the article in “De Limburger” 
was on the day of publication by far the most popular on the website of the 
newspaper.   
 
 
 
Figure 2: Publication of the endothelial protective effects of erythritol attracted a 
lot of media attention 
 
Schedule and implementation 
The research with erythritol is ongoing. A pilot study into the endothelial protective 
effects has already been finished and is partly described in this thesis. A follow-up 
study in which different  dose-dependent effects of erythritol on endothelial 
function are measured is currently in progress. 
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Bijna is het dan zover: het boekje is bijna af. Maar eerst natuurlijk nog het meest 
gelezen onderdeel van het proefschrift, het dankwoord. Toen ik de bassischool ging 
verlaten schreef de meester voor iedere leerling op een kaart wat hij dacht dat 
diegene later zou worden. Bij mij stond “schrijfster”, hij heeft toch een beetje gelijk 
gekregen, hoewel het denk ik niet is op de manier die hij had gedacht. Ik heb toch 
maar mooi een boekje geschreven! Maar dat boekje was er natuurlijk nooit 
gekomen zonder de hulp van anderen. 
 
Een promovendus is natuurlijk nergens zonder een geweldig promotieteam. 
Daarom wil ik ten eerste Prof. dr. Aalt Bast en dr. Gertjan den Hartog bedanken. 
Bedankt voor al jullie enthousiasme en motiverende begeleiding! Jullie hebben me 
altijd vrij gelaten in mijn experimenten en wanneer ik er dan even niet uitkwam 
hielpen jullie me door de resultaten van een positieve kant te bekijken en advies te 
geven hoe verder te gaan. Ik heb heel veel van jullie geleerd. Gertjan, jij ook nog 
bedankt voor het leuke idee voor de cover! Heren, heel erg bedankt voor de 
aangename samenwerking en voor alle raad en ondersteuning! 
 
Natuurlijk wil ik ook de mensen van Cargill bedanken die betrokken zijn bij dit 
project. Peter de Cock, bedankt voor alle kritische vragen tijdens onze 
vergaderingen, dit heeft geholpen het onderzoek nog beter te maken. Ook heel erg 
bedankt voor de hulp bij het schrijven van met name het review over erythritol. 
Ook de andere mensen van het erythritol team: Alvin Berger, Douwina Bosscher, 
Angela Bonnema en Anne Franck, heel erg bedankt voor alle hulp tijdens mijn 
onderzoek! 
 
Daarnaast wil ik ook graag de leden van de beoordelingscommissie hartelijk 
bedanken voor het beoordelen van mijn proefschrift.  
 
Dan wil ik natuurlijk de rest van de afdeling Toxicologie bedanken voor alle 
gezelligheid en hulp tijdens mijn promotie. Er zijn in die tijd nieuwe mensen 
gekomen maar ook mensen weggegaan, dus ik hoop dat ik niemand ga vergeten. 
Erik, tegelijk begonnen en ook tegelijk klaar! Heel veel succes met jouw eigen 
verdediging, ik verwacht chocoladecake na afloop ;-). Dear Agnieszka, dziękuję! 
Thanks for all the fun times and the great Polish cakes! It was good to have you as a 
neighbor, I could always come in for a chat! Good luck with finishing your thesis!!! 
Alie, ik denk dat het maar goed is dat wij nooit op 1 kamer hebben gezeten, wij 
kletsen te veel ;-). Bedankt voor alle gezelligheid! Matt, I will write this in Dutch, I 
know you understand it! Bedankt voor de gezellige tijd, de zang die door de gang 
galmde vroeg in de ochtend en de leuke nabesprekingen van Game of Thrones en 
Da Vinci’s Demons. Heel veel succes met je postdoc in Vermont! Rianne en  isha, 
jullie zijn begonnen toen ik al zo goed als weg was. Ik wens jullie heel veel succes 
maar vooral ook veel plezier tijdens jullie AIO-periode bij toxicologie.  ok de A  ’s 
die al een tijd weg zijn Jiska, Merel, Max en Nuria, heel erg bedankt voor al jullie 
advies en gezellige babbels.  
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Marie-Claire, dankjewel voor al het regelwerk met betrekking tot mijn promotie! 
Het heeft wat tijd gekost maar na een paar belrondes hebben we dan toch een 
datum gevonden! Geja, heel hartelijk bedankt voor je begeleiding tijdens mijn 
senior stage en de hulp bij het schrijven van het artikel erover. Ik weet niet wat je 
precies tegen Aalt hebt gezegd maar mede dankzij jou heb ik deze promotieplek 
gekregen. Heel erg bedankt daarvoor. Antje, bedankt voor alle gezelligheid, ik zal 
onze whale watching trip in Californië nooit vergeten! Wat was dat toch prachtig! 
Guido, bedankt voor al je advies! Marie-José, jij hebt me heel erg geholpen in mijn 
laatste jaar door nog wat metingen uit te voeren voor me. Heel erg bedankt 
daarvoor! Roger B. heel erg bedankt voor alle leuke uitjes die je hebt 
georganiseerd. Esther, bedankt voor al je hulp met de Luminex en alle gezellige 
babbels. Agnes, heel hartelijk bedankt voor al je advies, het verliezen van die s is 
inderdaad wel fijn! Jan, bedankt voor de mooie vogel die je als cadeau had 
achtergelaten voor Bregje en mij in onze nieuwe kamer, die heeft nog een hoop 
gesprekken opgeleverd omdat iedereen zich afvroeg hoe we daaraan kwamen! 
Marieke, bedankt voor alle hulp en advies bij het afronden en drukken van het 
boekje. Pieter, bedankt voor alle hulp met de computer/laptop! Ook alle andere 
(ex)leden van de afdeling Els, Kimberly, Roger G., Agnieszka S, Frederik-Jan, Joy, 
Leonie, Edwin, Lou, Daniëlle P. heel erg bedankt voor de aangename werksfeer! 
 
Natuurlijk wil ik ook mijn stagiaires Atlanta Elie en Saskia von Ungern-Sternberg 
hartelijk bedanken voor alle inzet tijdens hun stage. Het heeft toch maar mooi twee 
artikelen opgeleverd! Ik wens jullie heel veel succes met jullie eigen carrière. 
Andere stagiaires die hebben rondgelopen bij tox wil ik ook nog graag bedanken 
voor de gezellig tijd, met name Marike (nog een keertje koffie doen?) Nathalie 
(bedankt voor de hulp bij al die celtellingen!) en Mireille (zelfs een paar maanden 
mijn kamergenootje, heel veel succes met jouw PhD!).  
 
Als promovendus is het belangrijk om je kamer te delen met mensen waarmee je 
goed overweg kunt. En dat was voor mij zeker het geval. Hilde en Bregje, jullie 
waren geweldige kamergenootjes! Hilde, ik ben blij dat we elkaar nog regelmatig 
zien voor een gezellige spelletjes of dansavond. Het bezoek aan EB in San Diego 
was toch wel één van de hoogtepunten. Wat hebben we daar een goede tijd 
gehad, misschien moeten we nog maar eens teruggaan naar die Italiaan met de 
toetjeskar op Coronado! Bregje, nadat Hilde weg was bleven we met zijn tweetjes 
over (hoewel we wel nog een paar keer verhuisd zijn). Ook met jou heb ik een 
congres gezocht, in Londen, dat was zeer gezellig samen met Lize en Kristien in de 
family room. Vier meiden, 1 week bij elkaar op de kamer en geen ruzie, dat is toch 
wel erg knap! Ik denk dat we toch nog een keertje met zijn allen een citytrip 
moeten doen (Parijs was het toch?)! Meiden, bedankt dat ik jullie kamergenoot 
mocht zijn, bedankt voor de fijne tijd en alle gesprekjes (van serieus tot helemaal 
niet serieus) en adviezen! Ik hoop dat we elkaar nog vaak zullen zien! 
 
Naast onze eigen afdeling, had ik ook veel contact met de buren. Sandra en Karen, 
heel erg bedankt voor alle adviezen met de celkweek en dat ik altijd even langs 
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mocht komen om te kletsen of vakantiefotoalbums te kijken! Sandra, ook heel erg 
bedankt voor het runnen van de microarrays! Marlon, mijn vrijdagmiddag-trein-
maatje (hoewel dat ook er verminderde in het laatste jaar), altijd gezellig om even 
bij te praten! Dennie, bedankt voor de hulp met de aanvraag voor de reisbeurzen 
van de NVT. Marcel, bedankt voor alle hulp met de celkweek in jullie lab. Lize, ooit 
samen stage gelopen bij neuro en toen liep je ineens bij de buren rond. Leuk om 
jou weer tegen te komen en te kletsen over allerlei reizen die we ooit nog kunnen 
maken.  
 
Zoals in één van mijn stellingen staat is de afdeling behoorlijk internationaal 
georiënteerd. Dat betekent ook dat ik kennis heb mogen maken met een heleboel 
leuke mensen afkomstig van verschillende landen. Maria, you were my roommate 
for a few months when I was still working at GRAT. I will always remember your 
baklava (and the clove!). σας ευχαριστώ! Ariane, you are someone who is always 
positive and happy. I always enjoyed our ABC dinners! Thank you so much for 
showing me and Leen around in your beautiful city San Sebastian and of course 
thank you for the opportunity to experience a Spanish/Italian wedding! That was 
wonderful. I really hope we keep up with our annual ABC dinners, somewhere in 
Europe! Gracias!! Thalita, you crazy Brazilian girl! We had some good times on the 
lab (with your invisible hair dye) and during coffee breaks. I hope I can visit you one 
day in São Paulo or maybe we see each other again in the Netherlands. Obrigada! 
Gesiele, although you started when I was gone, we had some fun times during AIO-
dinners and during my visits to Maastricht. I hope you have a lot of fun during your 
time at Toxicology (and that you will also get some good results out of it!).  
 
En dan natuurlijk mijn paranimfen. Kristien en Leen, mijn twee rustige Belgische 
steunpunten tijdens de verdediging. Kristien, wij kennen elkaar sinds mijn stagetijd 
bij GRAT. Ik ben blij dat je daarna ook bij toxicologie bent komen promoveren, 
daardoor hebben we beter contact gekregen. Zoals ik bij Bregje al schreef hebben 
we goede tijd gehad in LONDON baby! Wat hebben gelachen met die Jack the 
Ripper tour of die vrouw die het had over “this is a restaurant, you have to eat 
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erg bedankt dat je mijn paranimf wilt zijn. Ik heb eigenlijk ook een derde paranimf, 
en dat is Joyce. Joyce, ook jij was mijn begeleidster tijdens mijn senior stage, en 
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meegemaakt. Ik wil je bedanken voor alle steun tijdens de promotieperiode! Ich 
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